Nuclear transport modulators and uses thereof

CN119053594APending Publication Date: 2024-11-29SHANGHAI HAIYAN PHARMA TECH +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380016820.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-12
Filing Date
2023-01-09
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

It is difficult to effectively treat proliferative diseases, autoimmune diseases, and inflammatory diseases caused by abnormal Crm1 localization with existing technology, especially cancers caused by excessive output of tumor suppressor proteins.

Method used

A new class of compounds has been developed as Crm1 inhibitors. By inhibiting the function of Crm1, it can be used to treat a variety of diseases related to abnormal cellular responses triggered by improper nuclear transport, including proliferative diseases, autoimmune diseases and inflammatory diseases. The specific compound structure It is represented by formula (I) to formula (VIII) and has good pharmacological activity and ADME properties.

Benefits of technology

The compound shows significant Crm1 inhibitory activity, especially in the treatment of colon cancer and prostate cancer, with better therapeutic effects, providing better clinical application prospects and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119053594A_ABST
    Figure CN119053594A_ABST
Patent Text Reader

Abstract

The invention relates to the field of medicines, in particular to a compound as shown in formula (I) or stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug thereof of the compound as shown in formula (I), # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Nuclear transport regulators and uses thereof Technical Field

[0001] This disclosure claims priority to and benefits of patent application No. 202210032243.8 filed with the State Intellectual Property Office of China on January 12, 2022, and incorporates the entire text of the patent application herein by cross-reference.

[0002] Technical Field

[0003] The present disclosure relates to the field of medicine, and in particular, to a class of novel compounds as nuclear transport regulators, methods for preparing the same, pharmaceutical compositions containing the compounds, and applications of the compounds and pharmaceutical compositions thereof in treating a variety of different diseases. Background Art

[0004] Studies have found that most cells of human hematological malignancies exhibit abnormal cellular localization of various oncogenic proteins, tumor suppressor proteins, and cell cycle regulators. For example, certain p53 mutations can lead to cytosolic localization rather than nuclear localization. This results in the loss of normal growth regulation, although the tumor suppressor function is intact. Restoring the correct nuclear localization of functional p53 protein can normalize certain characteristics of tumor cells, thereby restoring the sensitivity of cancer cells to DNA damaging agents and leading to tumor regression. The abnormal localization of some tumor suppressors and growth regulatory proteins may be related to the pathogenesis of autoimmune diseases. In familial cancer syndromes (e.g., Li-Fraumeni syndrome caused by p53 allele deletion, BRCA1 or BRCA2 cancer syndrome), inhibition of chromosome region stabilization protein 1 (Crm1) can cause specific tumor suppressor proteins (TSPs) to be eliminated or rendered dysfunctional.

[0005] Crm1 is a major exporter that exports specific proteins and RNAs from the cell nucleus via specialized transport molecules. These exported nuclear proteins contain nuclear export (NES) sequences, enabling them to interact with relevant transport factors. Studies have shown that Crm1 is overexpressed in several tumor types, including human ovarian, cervical, pancreatic, hepatocellular, and osteosarcoma cancers. Inhibition of Crm1 can block tumor suppressor proteins and / or growth regulators. Crm1 inhibitors have been shown to induce apoptosis in cancer cells even in the presence of oncogenic activation signals or growth triggers, without affecting normal (non-transformed) cells. Therefore, the development of suitable small-scale drug-like nuclear export inhibitors holds promise for the treatment of various neoplastic and other proliferative diseases. In addition to tumor suppressor proteins, Crm1 also exports several key proteins involved in numerous inflammatory processes, mediates the transport of retinoid X receptor α (RXRa), mediates the transport of key neuroprotective proteins, and inhibits the activation of a range of transcription factors, including Icp27 and E2F4, thereby affecting gene expression. The complete maturation of many viruses also requires complete nuclear export, primarily mediated by Crm1.

[0006] In view of this, it is desirable to develop a novel nuclear transport regulator that acts as a Crm1 protein inhibitor for the treatment of various diseases, disorders or conditions associated with abnormal cellular responses triggered by improper nuclear transport.

[0007] Summary of the Invention

[0008] The present disclosure is intended to solve one of the technical problems in the related art to at least a certain extent. To this end, an object of the present disclosure is to provide a class of compounds that inhibit, regulate and / or control Crm1 for treating a variety of abnormal cell response-related diseases, disorders or conditions triggered by improper nuclear transport, including: proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection and their complications. The present disclosure also provides methods for preparing these compounds, methods for using these compounds to treat mammals, especially the above-mentioned diseases of humans, and pharmaceutical compositions comprising these compounds. The compounds of the present disclosure and their compositions have good clinical application prospects. Compared with existing similar compounds, the compounds of the present disclosure have better pharmacological activity, ADME characteristics (absorption, distribution, metabolism and excretion), pharmacokinetic properties, physicochemical properties and / or toxicological properties. Specifically, the compounds of the present disclosure show good inhibitory activity against Crm1. The inventors have found that the compounds of the present disclosure have better therapeutic effects on colon cancer or prostate cancer.

[0009] Specifically:

[0010] In one aspect, the present disclosure provides a compound represented by formula (I) or a stereoisomer, tautomer, deuterated product, metabolite, pharmaceutically acceptable salt or prodrug thereof,

[0011]

[0012] wherein A1, A2, and A3 are each independently C or N;

[0013] Ring B is C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl consisting of 5-12 atoms, wherein the ring B is optionally substituted by m Bn;

[0014] m is 0, 1, 2 or 3. When m is 1, 2 or 3, Bn are the same or different;

[0015] R1, R2, R3, R4, R5, Bn are each independently selected from hydrogen, deuterium, F, Cl, Br, I, -NO2, =O, N3, CN, -OH, -NH2, -C(=O)CH2CN, -NHC(=O)CH2CN, -N(CH3)C(=O)CH2CN, Cl-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl composed of 5-12 atoms, -NR 10a R 10b 、-O-(C0-C4 alkylene)-R 10c 、-O-(C1-C4 alkylene)-OR 10c 、-O-(C1-C4 alkylene)-NR 10a R 10b 、-C(=O)R 10d 、-N(R 10e )C(=O)R 10d 、-C(=O)NR 10a R 10b 、-N(R 10e )C(=O)NR 10a R 10b 、-N(R 10e )C(=O)OR 10a 、-C(=O)N(R 10e )C(=O)R 10d 、-S(=O)2R 10f、-N(R 10e )S(=O)2R 10f or -S(=O)2NR 10a R 10b , or, R1 and R5 together with the atoms to which they are attached, or R1 and R2 together with the atoms to which they are attached, or R2 and R3 together with the atoms to which they are attached, or R3 and R4 together with the atoms to which they are attached, or R4 and Bn together with the atoms to which they are attached, or R5 and Bn together with the atoms to which they are attached, form C3-C 12 Cycloalkyl or heterocycloalkyl group composed of 3-12 atoms; wherein each C1-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms and heterocycloalkyl consisting of 3-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 11 substituted by a group;

[0016] R8 is C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 10 substituted by a group;

[0017] R9 is -C(=O)NR 10a R 10b 、C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 10 substituted by a group;

[0018] R 10 is selected from hydrogen, deuterium, F, Cl, Br or I;

[0019] R10a 、R 10b 、R 10c 、R 10d 、R 10e 、R 10f are independently H, C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-12 atoms), -(C0-C4 alkylene)-(C6-C 12 aryl) or -(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms), or R 10a and R 10b Together with the nitrogen atom to which they are attached, they form a heterocyclic group consisting of 3 to 12 atoms, wherein each of the C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-12 atoms), -(C0-C4 alkylene)-(C6-C 12 -(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms) and heterocyclyl groups consisting of 3-12 atoms are optionally substituted with 1, 2, 3 or 4 substituents independently selected from F, Cl, Br, CN, N3, -NO2, -OH, -NH2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 alkylamino;

[0020] Each R 11 are independently hydrogen, deuterium, F, Cl, Br, I, CN, -NO2, =O, N3, -OH, -NH2, C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Halogenated alkyl, C3-C 12 Cycloalkyl, C6-C 12 Aryl, heterocyclic group composed of 3-12 atoms, heteroaryl composed of 5-12 atoms, C1-C 12 Aminoalkyl, C1-C12 Alkylamino, C1-C 12 Alkoxy, C1-C 12 Hydroxyalkyl, -NH(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -NH(C0-C4 alkylene)-(C6-C 12 aryl), -NH(C0-C4 alkylene)-(heterocyclic group composed of 3-12 atoms), -NH(C0-C4 alkylene)-(heteroaryl composed of 5-12 atoms), -N[(C0-C4 alkylene)-(C3-C 12 Cycloalkyl)]2, -N[(C0-C4 alkylene)-(C6-C 12 -N[(C0-C4 alkylene)-(heterocyclic group composed of 3-12 atoms)]2, -N[(C0-C4 alkylene)-(heteroaryl composed of 5-12 atoms)]2, -O-(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -O-(C0-C4 alkylene)-(C6-C 12 -O-(C0-C4 alkylene)-(heterocyclyl consisting of 3-12 atoms) or -O-(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms); and

[0021] The condition is that when R9 is -C(=O)NH2, Bn is not hydrogen at the same time or R1 and R3 are not C1-C 12 Halogenated alkyl or A1, A2, A3 are not C or R at the same time 10 Not hydrogen.

[0022] According to the embodiment of the present disclosure, its structural formula is shown in formula (II),

[0023]

[0024] Wherein, B1, B2, B3, B4 are each independently C or N, B5 is C, N or empty, and when B5 is C or N, said B5 is optionally replaced by R 11 replaced by;

[0025] n is 1 or 2, and when n is 2, B2 are the same or different;

[0026] B2 is optionally replaced by R 11 replaced by;

[0027] R1, R2, R3, R4, R5, R6, and R7 are each independently selected from hydrogen, deuterium, F, Cl, Br, I, -NO2, =O, N3, CN, -OH, -NH2, -C(=O)CH2CN, -NHC(=O)CH2CN, -N(CH3)C(=O)CH2CN, Cl-C12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl composed of 5-12 atoms, -NR 10a R 10b 、-O-(C0-C4 alkylene)-R 10c 、-O-(C1-C4 alkylene)-OR 10c 、-O-(C1-C4 alkylene)-NR 10a R 10b 、-C(=O)R 10d 、-N(R 10e )C(=O)R 10d 、-C(=O)NR 10a R 10b 、-N(R 10e )C(=O)NR 10a R 10b 、-N(R 10e )C(=O)OR 10a 、-C(=O)N(R 10e )C(=O)R 10d 、-S(=O)2R 10f 、-N(R 10e )S(=O)2R 10f or -S(=O)2NR 10a R 10b , or, R1 and R5 together with the atoms to which they are attached or R1 and R2 together with the atoms to which they are attached or R2 and R3 together with the atoms to which they are attached or R3 and R4 together with the atoms to which they are attached or R4 and R6 together with the atoms to which they are attached or R5 and optionally a substituent R of B5 11 Together with the atoms to which they are attached, or together with R5 and R7 and the atoms to which they are attached, form C3-C 12 Cycloalkyl or heterocycloalkyl group composed of 3-12 atoms, wherein each C1-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12Aryl, heteroaryl consisting of 5-12 atoms and heterocycloalkyl consisting of 3-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 11 group substituted.

[0028] According to the embodiment of the present disclosure, its structure is shown in formula (III),

[0029]

[0030] Among them, A is C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 11 group substituted.

[0031] According to the embodiment of the present disclosure, its structure is shown in formula (IV),

[0032]

[0033] According to an embodiment of the present disclosure, wherein A1 and A3 are C;

[0034] R1 and R3 are each independently selected from C1-C6 haloalkyl, C3-C6 cycloalkyl;

[0035] R2, R4, and R5 are H;

[0036] B1, B2, B3, and B4 are each independently C or N, B5 is empty, and n is 1;

[0037] R6 and R7 are each independently selected from hydrogen, deuterium, C1-C6 alkyl, and the C1-C6 alkyl is independently optionally substituted by 1, 2, 3, 4 or 5 R 11 Group substituted, each R 11 are independently hydrogen, deuterium, F, Cl, Br, I;

[0038] R8 is selected from a heteroaryl group consisting of 5 to 12 atoms, wherein the heteroaryl group consisting of 5 to 12 atoms is optionally replaced by 1, 2, 3, 4 or 5 R 10 substituted by a group;

[0039] R 10 selected from hydrogen and deuterium;

[0040] R 10a 、R 10b are independently H, or R10a and R 10b Together with the nitrogen atom to which they are attached, they form a heterocyclyl group consisting of 3 to 6 atoms, and the heterocyclyl group consisting of 3 to 6 atoms is optionally substituted by 1, 2, 3 or 4 substituents independently selected from F, Cl, Br, and -OH.

[0041] According to an embodiment of the present disclosure, wherein A1, A2, and A3 are C;

[0042] R1 and R3 are each independently selected from C1-C3 haloalkyl;

[0043] R2, R4, and R5 are H;

[0044] B1, B2, B3, and B4 are each independently C or N, B5 is empty, and n is 1;

[0045] R6 and R7 are each independently selected from hydrogen, C1-C3 alkyl;

[0046] R8 is selected from a 5-6 atom N-containing heteroaryl group;

[0047] R 10 is hydrogen;

[0048] R 10a 、R 10b are independently H, or R 10a and R 10b Together with the nitrogen atom to which they are attached, they form a 3-6 atom heterocyclyl group, which is substituted by 1, 2, 3 or 4 -OH substituents.

[0049] Another aspect of the present disclosure provides a compound represented by formula (I) or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs,

[0050]

[0051] wherein A1, A2, and A3 are each independently C or N;

[0052] Ring B is C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl consisting of 5-12 atoms, wherein the ring B is optionally substituted by m Bn;

[0053] m is 0, 1, 2 or 3. When m is 1, 2 or 3, Bn are the same or different;

[0054] R1, R2, R3, R4, R5, and Bn are each independently selected from hydrogen, deuterium, halogen, -NO2, =O, N3, CN, -OH, -NH2, -C(=O)CH2CN, -NHC(=O)CH2CN, -N(CH3)C(=O)CH2CN, -C(C 1-3 Alkyl)3, C1-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl composed of 5-12 atoms, -C(C 1-3 alkyl)2-OH, -CH(C 1-3 Alkyl)OH, -NR 10a R 10b 、-O-CH(C 1-3 alkyl)2, -O-(C0-C4 alkylene)-R 10c 、-O-(C1-C4 alkylene)-OR 10c 、-O-(C1-C4 alkylene)-NR 10a R 10b 、-O-(C3-C 12 Cycloalkyl), -O-(heterocyclic group consisting of 3-12 atoms), -C(=O)R 10d 、-N(R 10e )C(=O)R 10d 、-C(=O)NR 10a R 10b 、-N(R 10e )C(=O)NR 10a R 10b 、-N(R 10e )C(=O)OR 10a 、-C(=O)N(R 10e )C(=O)R 10d 、-S(=O)2R 10f 、-N(R 10e )S(=O)2R 10f 、-S(=O)(C 1-3 alkyl)(=N)R 10f or -S(=O)2NR 10a R 10b, or, R1 and R5 together with the atoms to which they are attached, or R1 and R2 together with the atoms to which they are attached, or R2 and R3 together with the atoms to which they are attached, or R3 and R4 together with the atoms to which they are attached, or R4 and Bn together with the atoms to which they are attached, or R5 and Bn together with the atoms to which they are attached, form C3-C 12 Cycloalkyl or heterocyclic group composed of 3-12 atoms; wherein each C1-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl of 5-12 atoms and heterocyclyl of 3-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 11 substituted by a group;

[0055] R8 is optionally substituted C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms; wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 16 substituted by a group;

[0056] R9 is hydrogen, -C(=O)NR 10a R 10b 、-COR 13 、C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 17 substituted by a group;

[0057] Or R9 does not exist, the group for Wherein, X1 and X2 are each independently selected from C, N, O or S;

[0058] R 10 is selected from hydrogen, deuterium, F, Cl, Br or I;

[0059] R 16 、R 17 Each is independently selected from hydrogen, deuterium, halogen, =O, -CN, -OH, -NH2, -COOH, C1-C6 alkyl, C1-C6 alkoxy, C 3-6 Cycloalkyl, -(C1-C4 alkylene)COOH, -(C1-C4 alkylene)N(C 1-3 alkyl)2, -(C1-C4 alkylene)NH(C 1-3 alkyl), -(C1-C4 alkylene)OH, -(C1-C4 alkylene)NH2, -CH(C1-C6 alkyl)OH, -(C1-C4 alkylene)OH, -(C1-C4 alkylene)CH(C 1-3 alkyl) OH, -(C0-C4 alkylene) CONH2, -(C0-C4 alkylene) CF3, -O(C 1-3 -(C0-C4 alkylene)O(C1-C4 alkylene)O(C1-C4 alkylene)OH, -(C0-C4 alkylene)O(C1-C4 alkylene)O(C1-C4 alkylene)COOH, -(C0-C4 alkylene)O(C1-C4 alkylene)OH, -(C0-C4 alkylene)CN, -(C0-C4 alkylene)CONH(C0-C4 alkylene)CN, -(C0-C4 alkylene)SO2(C 1-3 Alkyl), -SO2(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)O(C 1-3 alkyl), -(C1-C4 alkylene)CHOH(C1-C4 alkylene)OH, -(C0-C4 alkylene)CH(NH2)COOH, -(C0-C4 alkylene)CH(OH)COOH, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-6 atoms), -(C0-C4 alkylene)-(C6-C 12 -(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms), wherein the alkylene, alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl may be further substituted with one or more of the following substituents: hydrogen, deuterium, halogen, -OCH3, -OH, -COOH, -NH2, -CN, -CH(CH3)OH;

[0060] R 10a 、R 10b 、R 10c 、R 10d 、R 10e 、R 10f are independently selected from hydrogen, deuterium, halogen, C1-C12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-12 atoms), -(C0-C4 alkylene)-(C6-C 12 aryl) or -(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms), or R 10a and R 10b Together with the nitrogen atoms to which they are connected, they form a heterocyclic group consisting of 3 to 12 atoms or a heteroaryl group consisting of 5 to 12 atoms, wherein each of the C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-12 atoms), -(C0-C4 alkylene)-(C6-C 12 -(C1-C4 alkylene)NH2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyC1-C6 alkyl, aminoC1-C6 alkyl or C1-C6 alkylamino substituents;

[0061] Each R 11 are independently hydrogen, deuterium, halogen, CN, -NO2, =O, N3, -OH, -NH2, C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Halogenated alkyl, C3-C 12 Cycloalkyl, C6-C 12 Aryl, heterocyclic group composed of 3-12 atoms, heteroaryl composed of 5-12 atoms, C1-C 12 Aminoalkyl, C1-C 12 Alkylamino, C1-C 12 Alkoxy, C1-C12 Hydroxyalkyl, -NH(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -NH(C0-C4 alkylene)-(C6-C 12 aryl), -NH(C0-C4 alkylene)-(heterocyclic group composed of 3-12 atoms), -NH(C0-C4 alkylene)-(heteroaryl composed of 5-12 atoms), -N[(C0-C4 alkylene)-(C3-C 12 Cycloalkyl)]2, -N[(C0-C4 alkylene)-(C6-C 12 -N[(C0-C4 alkylene)-(heterocyclic group composed of 3-12 atoms)]2, -N[(C0-C4 alkylene)-(heteroaryl composed of 5-12 atoms)]2, -O-(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -O-(C0-C4 alkylene)-(C6-C 12 -O-(C0-C4 alkylene)-(heterocyclic group consisting of 3-12 atoms) or -O-(C0-C4 alkylene)-(heteroaryl group consisting of 5-12 atoms);

[0062] R 13 Selected from C 3-6 Cycloalkyl, -NH(C0-C4alkylene)CN, -NH(C0-C4alkylene)CF3;

[0063] R 14 、R 15 Each is independently selected from hydrogen, deuterium, halogen, =O, -CN, -OH, -NH2, -COOH, C1-C6 alkyl, C 3-6 Cycloalkyl, -(C1-C4 alkylene)COOH, -(C1-C4 alkylene)N(C 1-3 alkyl)2, -(C1-C4 alkylene)NH(C 1-3 alkyl), -(C1-C4 alkylene)NH2, -(C1-C4 alkylene)OH, -(C1-C4 alkylene)CH(C 1-3 alkyl) OH, -(C0-C4 alkylene) CONH2, -(C0-C4 alkylene) CF3, -O(C 1-3 -(C0-C4 alkylene)O(C1-C4 alkylene)O(C1-C4 alkylene)OH, -(C0-C4 alkylene)O(C1-C4 alkylene)O(C1-C4 alkylene)COOH, -(C0-C4 alkylene)O(C1-C4 alkylene)OH, -(C0-C4 alkylene)CN, -(C0-C4 alkylene)CONH(C0-C4 alkylene)CN, -(C0-C4 alkylene)SO2(C 1-3Alkyl), -SO2(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)O(C 1-3 alkyl), -(C1-C4 alkylene)CHOH(C1-C4 alkylene)OH, -(C0-C4 alkylene)CH(NH2)COOH, -(C0-C4 alkylene)CH(OH)COOH, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-6 atoms), -(C0-C4 alkylene)-(C6-C 12 -(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms) or -(C1-C4 alkylene)C(=O)-(heterocyclyl consisting of 3-6 atoms), wherein the alkylene, alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl may be further substituted with one or more of the following substituents: hydrogen, deuterium, halogen, -OCH3, -OH, -COOH, -NH2, -CN, -CH(CH3)OH; and

[0064] The condition is that when R9 is -C(=O)NH2, Bn is not hydrogen at the same time or R1 and R3 are not C1-C 12 Halogenated alkyl or A1, A2, A3 are not C or R at the same time 10 Not hydrogen.

[0065] According to an embodiment of the present disclosure, the structural formula thereof is a compound of formula (V):

[0066]

[0067] wherein B1, B2, B3, and B4 are each independently C or N;

[0068] Among them, the group Select one of the following formulae:

[0069]

[0070] wherein ring A is selected from C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 16 substituted by a group;

[0071] Ring C is selected from C3-C 12Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 17 substituted by a group;

[0072] R7 is selected from hydrogen, deuterium, halogen, C1-C6 alkyl, -NO2, =O, -CN, -OH or -C(=O)NH2;

[0073] Each R 11 Independently selected from hydrogen, deuterium, F, Cl, Br, I, , -CN, -NO2, =O, N3, -OH, -NH2 or C1-C6 alkyl;

[0074] Among them, when R 10a 、R 10b When both are hydrogen, R7 is not hydrogen or A2 is N.

[0075] According to an embodiment of the present disclosure, the group Select one of the following structures:

[0076]

[0077] According to the embodiment of the present disclosure, its structural formula is shown in the following formula (VI):

[0078]

[0079] wherein R1 and R3 are each independently selected from halogen, -CF3, C3-C6 cycloalkyl, a heterocyclic group consisting of 3-6 atoms or a heteroaryl group consisting of 5-6 atoms, -C(CH3)2OH, -S(=O)(=NH)CH3, -S(=O)(=N)CH3Cl, -CF2CH3, -CF(CH3)2, -CONH2, -C(C 1-3 Alkyl)3, -O-CH(C 1-3 wherein the cycloalkyl, heteroaryl, and heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, =O, -OCH3, -OH, -COOH, -NH2, -CN, or -CH(CH3)OH;

[0080] R2, R4, and R5 are all hydrogen.

[0081] According to an embodiment of the present disclosure, A1 is C;

[0082] R1 and R3 are each independently selected from -CF3, C3-C6 cycloalkyl;

[0083] R4 and R5 are H;

[0084] R7 is selected from hydrogen, deuterium, C1-C6 alkyl;

[0085] R8 is selected from C6-C 12 Aryl, heteroaryl composed of 5-12 atoms, wherein the C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1 or 2 R 16 substituted by a group;

[0086] R9 is -C(=O)NR 10a R 10b ;

[0087] R 16 Selected from hydrogen, deuterium, C1-C6 alkoxy, -S(=O)2(C3-C 12 cycloalkyl);

[0088] R 10a 、R 10b are each independently selected from hydrogen or R 10a and R 10b Together with the nitrogen atom to which they are attached, they form a heterocyclic group consisting of 3 to 12 atoms, wherein the heterocyclic group consisting of 3 to 12 atoms is optionally substituted by 1 or 2 -OH groups.

[0089] According to an embodiment of the present disclosure, R7 is selected from hydrogen, C1-C3 alkyl;

[0090] R8 is selected from C6-C 10 Aryl, heteroaryl composed of 6-10 atoms, wherein the C6-C 10 Aryl, heteroaryl consisting of 6-10 atoms are independently optionally replaced by 1 R 16 substituted by a group;

[0091] R9 is selected from -C(=O)NR 10a R 10b ;

[0092] R 16 Selected from hydrogen, C1-C6 alkoxy, -S(=O)2(C3-C6 cycloalkyl);

[0093] R 10a 、R 10b are each independently selected from hydrogen or R 10a and R 10bTogether with the nitrogen atom to which they are attached, they form a heterocyclic group consisting of 4 to 10 atoms, wherein the heterocyclic group consisting of 4 to 10 atoms is optionally substituted by 1 -OH.

[0094] According to an embodiment of the present disclosure, when A2 is N, the group for

[0095] Among them, R 14 、R 15 Each independently selected from hydrogen, C1-C3 alkyl, -(C1-C4 alkylene)COOH, -(C1-C4 alkylene)N(C 1-3 -(C1-C4 alkylene) OH, -(C0-C4 alkylene) CONH2, -(C0-C4 alkylene) CF3, -(C0-C4 alkylene) O(C1-C4 alkylene) OH, -(C0-C4 alkylene) O(C1-C4 alkylene) O(C1-C4 alkylene) OH, -(C0-C4 alkylene) O(C1-C4 alkylene) O(C1-C4 alkylene) COOH, -(C1-C4 alkylene) CN, -(C1-C4 alkylene) CH(C 1-3 alkyl)OH, -(C0-C4 alkylene)SO2(C 1-3 alkyl), -(C0-C4 alkylene)O(C 1-3 alkyl), -(C1-C4 alkylene)CHOH(C1-C4 alkylene)OH, -(C0-C4 alkylene)CH(NH2)COOH, -CH2CONHCH2CN,

[0096] According to the embodiment of the present disclosure, the structural formula is shown in the following formula (VII):

[0097]

[0098] Wherein, R1 and R3 are each independently selected from -CF3, C3-C6 cycloalkyl, heterocyclic group consisting of 3-6 atoms or heteroaryl consisting of 5-6 atoms, -C(C 1-3 Alkyl)3, -O-CH(C 1-3 wherein the cycloalkyl, heteroaryl, and heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, -OCH3, -OH, -COOH, -NH2, -CN, and -CH(CH3)OH.

[0099] According to an embodiment of the present disclosure, when R7 is not hydrogen, its structural formula is shown in the following formula (VIII):

[0100]

[0101] Wherein, R1 and R3 are each independently selected from -CF3, C3-C6 cycloalkyl, heterocyclic group consisting of 3-6 atoms or heteroaryl consisting of 5-6 atoms, -C(C 1-3 Alkyl)3, -O-CH(C 1-3 wherein the cycloalkyl, heteroaryl, and heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, -OCH3, -OH, -COOH, -NH2, -CN, and -CH(CH3)OH.

[0102] According to an embodiment of the present disclosure, the group for

[0103] Where X1 and X2 are both N, R 14 、R 15 Each independently selected from hydrogen, C1-C3 alkyl, -(C1-C4 alkylene)COOH, -(C1-C4 alkylene)N(C 1-3 -(C1-C4 alkylene) OH, -(C0-C4 alkylene) CONH2, -(C0-C4 alkylene) CF3, -(C0-C4 alkylene) O(C1-C4 alkylene) OH, -(C0-C4 alkylene) O(C1-C4 alkylene) O(C1-C4 alkylene) OH, -(C0-C4 alkylene) O(C1-C4 alkylene) O(C1-C4 alkylene) COOH, -(C1-C4 alkylene) CN, -(C1-C4 alkylene) CH(C 1-3 alkyl)OH, -(C0-C4 alkylene)SO2(C 1-3 alkyl), -(C0-C4 alkylene)O(C 1-3 alkyl), -(C1-C4 alkylene)CHOH(C1-C4 alkylene)OH, -(C0-C4 alkylene)CH(NH2)COOH, -CH2CONHCH2CN,

[0104] According to an embodiment of the present disclosure, -NR 10a R 10b One selected from the following formulas: -NH2,

[0105] According to an embodiment of the present disclosure, R1 and R3 are each independently selected from -CF3 or C3-C6 cycloalkyl.

[0106] According to an embodiment of the present disclosure, Ring A and Ring C are each independently selected from

[0107]

[0108] According to an embodiment of the present disclosure, the group Has the following structure:

[0109]

[0110] According to an embodiment of the present disclosure, the compound has one of the following structures:

[0111]

[0112]

[0113]

[0114]

[0115]

[0116]

[0117]

[0118]

[0119]

[0120]

[0121]

[0122]

[0123]

[0124]

[0125]

[0126]

[0127]

[0128] Preferably, the compound has one of the following structures:

[0129]

[0130]

[0131] Another aspect of the present disclosure provides a pharmaceutical composition comprising the aforementioned compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts, or prodrugs.

[0132] According to an embodiment of the present disclosure, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, vehicle, carrier, solvent or a combination thereof.

[0133] Another aspect of the present disclosure relates to the use of the aforementioned compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs, or pharmaceutical compositions in the preparation of a medicament for preventing, treating, curing or alleviating a CRM1 disorder-related disease in a mammal.

[0134] According to an embodiment of the present disclosure, the mammal is a human.

[0135] According to an embodiment of the present disclosure, the CRM1 disorder-related diseases include proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, polycythemia vera, essential thrombocythemia, myelofibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic obstructive pulmonary disease, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type II diabetes, gout, post-traumatic stress disorder, respiratory allergic diseases, sinusitis, eczema, measles, food allergies, insect venom allergies, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, organ transplant rejection, tissue transplant rejection, cell transplant rejection, viral infections, ophthalmic disorders, neurodegenerative disorders, abnormal tissue growth disorders or new coronavirus pneumonia.

[0136] According to an embodiment of the present disclosure, the cancer includes at least one of prostate cancer, colon cancer, lymphoma, myeloma, gastric cancer, lung cancer, breast cancer, pancreatic cancer, liver cancer, and kidney cancer.

[0137] Another aspect of the present disclosure relates to use of the aforementioned compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs, or pharmaceutical compositions in the preparation of a medicament for selectively antagonizing Crm1.

[0138] In another aspect, the present disclosure provides methods for preparing, separating and purifying compounds represented by formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII) and formula (VIII).

[0139] According to the embodiments of the present disclosure, the inventors found through biological experiments that the compounds provided by the present disclosure have Crm1 inhibitory activity and can be used as better Crm1 inhibitors.

[0140] It should be noted that any embodiments of any aspect of the present disclosure may be combined with other embodiments as long as they do not conflict. In addition, in any embodiments of any aspect of the present disclosure, any technical feature may be applicable to the technical feature in other embodiments as long as they do not conflict.

[0141] In addition, it should be noted that the above description only summarizes certain aspects of the present invention, but is not limited to these aspects. These and other aspects will be described in more detail and fully below. BRIEF DESCRIPTION OF THE DRAWINGS

[0142] The above and / or additional aspects and advantages of the present disclosure will become apparent and readily understood from the description of the embodiments in conjunction with the following drawings, in which:

[0143] Figure 1 shows the anti-tumor activity results of compounds 15, 61, and 199 in mice;

[0144] FIG2 shows the effects of compounds 15, 61, and 199 on the body weight of mice.

[0145] Detailed Description of the Invention

[0146] The embodiments of the present disclosure are described in detail below. The embodiments described below are exemplary and are only used to explain the present disclosure, and should not be understood as limiting the present disclosure.

[0147] Detailed description of the present disclosure

[0148] Definitions and General Terms

[0149] Certain embodiments of the present disclosure are now described in detail, examples of which are illustrated by the accompanying structural formulas and chemical formulae. The present disclosure is intended to cover all alternatives, modifications, and equivalent technical solutions, which are all included within the scope of the present disclosure as defined in the claims. Those skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used to practice the present disclosure. The present disclosure is in no way limited to the methods and materials described herein. In the event that one or more of the incorporated literature, patents, and similar materials differ from or contradict the present disclosure (including but not limited to defined terms, term applications, described techniques, etc.), the present disclosure shall prevail.

[0150] It will be further appreciated that certain features of the present disclosure, which for clarity are described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the present disclosure, which for brevity are described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

[0151] Unless otherwise specified, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. All patents and publications related to this disclosure are incorporated herein by reference in their entirety.

[0152] Unless otherwise indicated, the following definitions used herein shall apply. For the purposes of this disclosure, the chemical elements are referred to in accordance with the Periodic Table of the Elements, CAS version, and Handbook of Chemistry and Physics, 75th edition, 1994. In addition, general principles of organic chemistry may be found in "Organic Chemistry," Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry" by Michael B. Smith and Jerry March, John Wiley & Sons, New York: 2007, the entire contents of which are incorporated herein by reference.

[0153] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present disclosure. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and features of different embodiments or examples, unless they are mutually inconsistent.

[0154] Unless otherwise specified or clearly contradicted by context, the articles "a," "an," and "the" as used herein are intended to include "at least one" or "one or more." Thus, as used herein, these articles refer to one or more than one (i.e., at least one) of the objects. For example, "a component" refers to one or more components, i.e., more than one component may be contemplated for use or use in implementing the described embodiments.

[0155] The term "subject" as used in this disclosure refers to an animal. Typically, the animal is a mammal. A subject also refers to, for example, a primate (e.g., human, male or female), cattle, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, etc. In certain embodiments, the subject is a primate. In other embodiments, the subject is a human.

[0156] The term "patient" as used in this disclosure refers to humans (including adults and children) or other animals. In some embodiments, "patient" refers to humans.

[0157] The term "comprising" is an open expression, that is, including the contents specified in the present disclosure, but not excluding other contents.

[0158] "Stereoisomers" are compounds that have identical chemical constitutions but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric (cis / trans) isomers, atropisomers, and the like.

[0159] "Chiral" refers to a molecule that is non-superimposable on its mirror image; "achiral" refers to a molecule that is superimposable on its mirror image.

[0160] "Enantiomers" refer to two non-superimposable isomers of a compound that are mirror images of each other.

[0161] "Diastereoisomers" refers to stereoisomers that have two or more chiral neutral groups whose molecules are not mirror images of each other. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivities. Diastereomeric mixtures can be separated by high-resolution analytical procedures such as electrophoresis and chromatography, for example, HPLC.

[0162] Stereochemical definitions and conventions used in this disclosure generally follow SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994.

[0163] Many organic compounds exist in optically active forms, meaning they have the ability to rotate the plane of plane-polarized light. When describing an optically active compound, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are the symbols used to designate the rotation of plane-polarized light caused by the compound, where (-) or l indicates that the compound is left-handed. A compound prefixed with (+) or d is right-handed. A specific stereoisomer is an enantiomer, and a mixture of such isomers is called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which can occur when there is no stereoselectivity or stereospecificity in a chemical reaction or process.

[0164] Any asymmetric atom (e.g., carbon, etc.) of the compounds disclosed herein can exist in a racemic or enantiomerically enriched form, such as in the (R)-, (S)-, or (R,S)-configuration. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in terms of the (R)- or (S)-configuration.

[0165] Depending on the choice of starting materials and process, the compounds of the present disclosure may exist as one of the possible isomers or as a mixture thereof, such as a racemate or a mixture of diastereoisomers (depending on the number of asymmetric carbon atoms). Optically active (R)- or (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituents may be in the E or Z configuration; if the compound contains a disubstituted cycloalkyl group, the cycloalkyl substituents may be in the cis or trans configuration.

[0166] Any resulting mixture of stereoisomers can be separated into the pure or substantially pure geometric isomers, enantiomers, and diastereomers on the basis of the differences in the constituent physicochemical properties, for example, by chromatography and / or fractional crystallization.

[0167] Any racemate of the resulting final product or intermediate can be resolved into its optical antipodes by methods familiar to those skilled in the art using known methods, such as by separation of its diastereomeric salts obtained. Racemic products can also be separated by chiral chromatography, such as high performance liquid chromatography (HPLC) using a chiral adsorbent. In particular, enantiomers can be prepared by asymmetric synthesis, for example, see Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Principles of Asymmetric Synthesis (2nd Ed. Robert E. Gawley, Jeffrey Aubé, Elsevier, Oxford, UK, 2012); Eliel, EL Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SH Tables of Resolving Agents and Optical Resolutions p. 268 (EL Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972); Chiral Separation Techniques: A Practical Approach (Subramanian, G. Ed., Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2007).

[0168] The term "tautomer" or "tautomeric form" refers to structural isomers with different energies that can be converted into each other through a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of the tautomers can be reached. For example, proton tautomers (also known as prototropic tautomers) include interconversions performed by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions performed by the reorganization of some bonding electrons. A specific example of keto-enol tautomerism is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-ene-2-one tautomers. Another example of tautomerism is phenol-keto tautomerism. A specific example of phenol-keto tautomerism is the interconversion of pyridine-4-ol and pyridine-4(1H)-one tautomers. Unless otherwise indicated, all tautomeric forms of the disclosed compounds are within the scope of the disclosure.

[0169] As described herein, the compounds of the present disclosure may be optionally substituted with one or more substituents, such as the compounds of the general formula above, or as described in the specific examples, subclasses, and classes of compounds encompassed by the present disclosure.

[0170] In general, the term "substituted" means that one or more substitutable hydrogen atoms in a given structure are replaced with a specified substituent. Unless otherwise indicated, a substituted group may have a substituent at each substitutable position of the group. When more than one position in a given structure is substitutable with one or more substituents selected from a specified group, the substituents may be the same or different at each position.

[0171] The term "unsubstituted" means that the designated group bears no substituents.

[0172] The term "optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, "a heterocyclic group optionally substituted with an alkyl group" means that the alkyl group may but need not be present, and that the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.

[0173] The term "optionally substituted with..." can be used interchangeably with the term "unsubstituted or substituted with...", i.e., the structure is unsubstituted or substituted with one or more substituents disclosed herein, including, but not limited to, deuterium (D), F, Cl, Br, I, CN, N3, -NO2, -OH, -SH, -NH2, -C(=O)CH2CN, -NHC(=O)CH2CN, -N(CH3)C(=O)CH2CN, -NR 10a R 10b 、-C(=O)R 10d 、-OC(=O)R 10d 、-C(=O)OR 10c 、-N(R 10e )C(=O)R 10d 、-C(=O)NR 10a R 10b 、-N(R 10e )C(=O)NR 10a R 10b 、-C(=O)N(R 10e )C(=O)R 10d 、-S(=O)2R 10f 、-N(R 10e )S(=O)2R 10f 、-S(=O)2NR 10a R 10b , alkyl, haloalkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, alkylthio, alkylamino, aminoalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl, etc., wherein R 10a 、R 10b 、R 10c 、R 10d 、R 10e and R 10f has the definition as described in this disclosure.

[0174] In addition, it should be noted that, unless otherwise explicitly stated, the description methods used in this disclosure, "each...independently is" and "...each independently is" and "...independently is" can be interchanged and should be understood in a broad sense. They can mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other.

[0175] In this specification, the structural formulas (I) to (IV) are It is a single bond or a double bond.

[0176] In this specification, the configuration of the olefinic bond in the structural formulas (I) to (IV) is not particularly limited and can be cis or trans. R8, R9 and R 10 The relative positions of may vary depending on the configuration of the olefinic bond of the compound.

[0177] Throughout this specification, substituents of compounds disclosed herein are disclosed by group class or range. It is specifically noted that the disclosure includes every independent subcombination of the individual members of these group classes and ranges. For example, the term "C1-C6 alkyl" specifically refers to the independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl groups.

[0178] In various parts of this disclosure, linking substituents are described. When the structure clearly requires a linking group, the Markush variable listed for that group should be understood to be a linking group. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl", it should be understood that the "alkyl" or "aryl" represents a linking alkylene group or arylene group, respectively.

[0179] The term "alkyl" or "alkyl group" as used herein refers to a saturated, straight-chain or branched monovalent hydrocarbon group containing 1 to 20 carbon atoms, wherein the alkyl group may be optionally substituted with one or more substituents described herein. Unless otherwise specified, an alkyl group contains 1-20 carbon atoms. In some embodiments, the alkyl group contains 1-12 carbon atoms; in other embodiments, the alkyl group contains 1-6 carbon atoms; in yet other embodiments, the alkyl group contains 1-4 carbon atoms; and in still other embodiments, the alkyl group contains 1-3 carbon atoms. The alkyl group may be optionally substituted with one or more substituents described herein.

[0180] Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), isobutyl (i-Bu, -CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert-butyl (t-Bu, -CH(CH3)CH2CH3), u, -C(CH3)3), n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1 -butyl (-CH2CH(CH3)CH2CH3), n-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH 3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), n-heptyl, n-octyl, etc.

[0181] The term "alkylene" refers to a saturated divalent or polyvalent hydrocarbon radical derived by removing two or more hydrogen atoms from a saturated straight-chain or branched hydrocarbon radical. Unless otherwise specified, an alkylene group contains 1-12 carbon atoms. In some embodiments, an alkylene group contains 1-6 carbon atoms; in other embodiments, an alkylene group contains 1-4 carbon atoms; in other embodiments, an alkylene group contains 0-4 carbon atoms; in still other embodiments, an alkylene group contains 0-3 carbon atoms; and in still other embodiments, an alkylene group contains 1-3 carbon atoms. An alkylene group containing 0 carbon atoms means that the alkylene group is absent and is directly a single bond. Examples of alkylene groups include methylene (-CH2-), ethylene (-CH2CH2-), isopropylene (-CH(CH3)CH2-), and the like.

[0182] The term "alkenyl" refers to a straight or branched chain monovalent hydrocarbon radical containing 2 to 12 carbon atoms, wherein there is at least one site of unsaturation, i.e., a carbon-carbon sp 2 Double bond, wherein the alkenyl group may be optionally substituted with one or more substituents described herein, including "cis" and "tans" positioning, or "E" and "Z" positioning. In some embodiments, the alkenyl group contains 2-8 carbon atoms; in other embodiments, the alkenyl group contains 2-6 carbon atoms; in yet other embodiments, the alkenyl group contains 2-4 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl (-CH=CH2), allyl (-CH2CH=CH2), and the like. The alkenyl group may be optionally substituted with one or more substituents described herein.

[0183] The term "alkynyl" refers to a straight or branched monovalent hydrocarbon radical containing 2 to 12 carbon atoms, wherein there is at least one site of unsaturation, i.e., a carbon-carbon sp triple bond, wherein the alkynyl group may be optionally substituted with one or more substituents described herein. In some embodiments, the alkynyl group contains 2 to 8 carbon atoms; in other embodiments, the alkynyl group contains 2 to 6 carbon atoms; in yet other embodiments, the alkynyl group contains 2 to 4 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl (-C≡CH), propargyl (-CH2C≡CH), 1-propynyl (-C≡C-CH3), and the like.

[0184] The term "alkoxy" refers to an alkyl group attached to the remainder of a molecule through an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In some embodiments, the alkoxy group contains 1-6 carbon atoms; in other embodiments, the alkoxy group contains 1-4 carbon atoms; in yet other embodiments, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents described herein.

[0185] Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-1-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH3)CH2CH3), 2-methyl-2- Propoxy (t-BuO, t-butoxy, -OC(CH3)3), 1-pentyloxy (n-pentyloxy, -OCH2CH2CH2CH2CH3), 2-pentyloxy (-OCH(CH3)CH2CH2CH3), 3-pentyloxy (-OCH(CH2CH3)2), 2-methyl-2-butoxy (-OC(CH3)2CH2CH3), 3-methyl-2-butoxy (-OCH(CH3)CH(CH3)2), 3-methyl-l-butoxy (-OCH2CH2CH(CH3)2), 2-methyl-l-butoxy (-OCH2CH(CH3)CH2CH3), and the like.

[0186] The term "haloalkyl", "haloalkenyl" or "haloalkoxy" means an alkyl, alkenyl or alkoxy group substituted with one or more halogen atoms, examples of which include, but are not limited to, difluoroethyl (-CH2CHF2, -CF2CH3, -CHFCH2F), trifluoroethyl (-CH2CF3, -CF2CH2F, -CFHCHF2), trifluoromethyl (-CF3), trifluoromethoxy (-OCF3), etc.

[0187] The terms "hydroxyalkyl" and "hydroxyalkoxy" refer to an alkyl or alkoxy group, as the case may be, substituted with one or more hydroxy groups, wherein "hydroxyalkyl" and "hydroxyalkyl" are used interchangeably, such examples include, but are not limited to, hydroxymethyl (-CH2OH), hydroxyethyl (-CH2CH2OH, -CH(OH)CH3), hydroxymethoxy (-OCH2OH), and the like.

[0188] The term "cycloalkyl" refers to a monovalent or multivalent saturated monocyclic, bicyclic, or tricyclic ring system containing 3 to 12 carbon atoms. In some embodiments, the cycloalkyl group contains 3 to 12 carbon atoms; in other embodiments, the cycloalkyl group contains 3 to 8 carbon atoms; in other embodiments, the cycloalkyl group contains 3 to 6 carbon atoms. In some embodiments, the cycloalkyl group is a C7-C12 group containing 7 to 12 carbon atoms. 12 Cycloalkyl further comprising C7-C 12Spirobicycloalkyl, C7-C 12 Fused bicycloalkyl and C7-C 12 In other embodiments, the cycloalkyl group is a C8-C 11 Cycloalkyl further comprising C8-C 11 Spirobicycloalkyl, C8-C 11 Fused bicycloalkyl and C8-C 11 Bridged bicycloalkyl. Examples of cycloalkyl include, but are not limited to, C3-C6 cycloalkyl, specifically cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The cycloalkyl groups may independently be unsubstituted or substituted with one or more substituents described herein.

[0189] The terms "heterocyclyl" and "heterocycle" are used interchangeably herein and refer to a monocyclic, bicyclic or tricyclic ring system containing 3-12 ring atoms, which is monovalent or polyvalent, saturated or partially unsaturated, and non-aromatic, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. The "heterocyclyl" or "heterocycle" is optionally linked to other groups by a single bond, or any two or more atoms on the ring are further linked to other cycloalkyl, heterocyclyl, aryl or heteroaryl groups in a ring. Unless otherwise specified, the heterocyclyl group can be a carbon group or a nitrogen group, and the -CH2- group can be optionally replaced by -C(=O)-. The sulfur atom of the ring can be optionally oxidized to an S-oxide. The nitrogen atom of the ring can be optionally oxidized to an N-oxide. Heterocyclyl includes saturated heterocyclyls (i.e., heterocycloalkyls) and partially unsaturated heterocyclyls. Examples of heterocyclic groups include, but are not limited to, oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolane, dithiolanyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepine Base (eg, 1,4-oxazepine 1,2-oxazepine yl), diazepine Base (eg, 1,4-diazepine 1,2-diazepine yl), dioxa Base (eg, 1,4-dioxa 1,2-dioxazoline yl), thiazolin Base (such as 1,4-thiazepine 1,2-thiazepine 1-H-isoindolyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,3-benzodioxolyl, 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, 2-azaspiro[4.4]nonanyl, 1,6-dioxaspiro[4.4]nonanyl, 2-azaspiro[4.5]decanyl, 8-azaspiro[4.5]decanyl, 7-azaspiro[4.5]decanyl, 3-azaspiro[5.5]undecyl, 2-azaspiro[5.5]undecyl, octahydro-1H-isoindolyl, octahydrocyclopenta[c]pyrrolyl, hexahydrofuro[3,2-b]furanyl and dodecahydroisoquinolinyl, and the like. Examples of heterocyclic groups in which the -CH2- group is replaced by -C(=O)- include, but are not limited to, 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, 2-piperidonyl, and 3,5-dioxopiperidinyl. Examples of heterocyclic groups in which the sulfur atom is oxidized include, but are not limited to, sulfolane, 1,1-dioxothiomorpholinyl, 1,1-dioxotetrahydrothiophenyl, and 1,1-dioxotetrahydro-2H-thiopyranyl. The heterocyclic group may be optionally substituted with one or more substituents described herein.

[0190] In some embodiments, the heterocyclic group is a heterocyclic group consisting of 3-8 atoms, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 3-8 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. Unless otherwise specified, the heterocyclic group consisting of 3-8 atoms can be a carbon group or a nitrogen group, and the -CH2- group can be optionally replaced by -C(=O)-. The sulfur atom of the ring can be optionally oxidized to S-oxide. The nitrogen atom of the ring can be optionally oxidized to N-oxide. Examples of heterocyclic groups of 3-8 atoms include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolane, dithiolanyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepanyl, Base, diazepine thiazolinone Examples of heterocyclic groups in which the -CH2- group is replaced by -C(=O)- include, but are not limited to, 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, 2-piperidonyl, and 3,5-dioxopiperidinyl. Examples of heterocyclic groups in which the sulfur atom is oxidized include, but are not limited to, sulfolane and 1,1-dioxothiomorpholinyl. The 3-8-atom heterocyclic group may be optionally substituted with one or more substituents described herein.

[0191] In other embodiments, the heterocyclic group is a 4-7 atom heterocyclic group, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 4-7 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. Unless otherwise specified, the 4-7 atom heterocyclic group can be a carbon group or a nitrogen group, and the -CH2- group can be optionally replaced by -C(=O)-. The sulfur atom of the ring can be optionally oxidized to an S-oxide. The nitrogen atom of the ring can be optionally oxidized to an N-oxide. Examples of heterocyclic groups of 4 to 7 atoms include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolane, dithiolanyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepanyl, Base, diazepine thiazolinone The heterocyclyl group composed of 4 to 7 atoms may be optionally substituted with one or more substituents described in the present disclosure.

[0192] In other embodiments, the heterocyclic group is a heterocyclic group consisting of 7-12 atoms, which refers to a spiro heterobicyclic group, a fused heterobicyclic group, or a bridged heterobicyclic group containing 7-12 ring atoms, which is monovalent or polyvalent, saturated or partially unsaturated, wherein at least one ring atom is selected from nitrogen, sulfur, and oxygen atoms. Unless otherwise specified, the heterocyclic group consisting of 7-12 atoms can be a carbon group or a nitrogen group, and the -CH2- group can be optionally replaced by -C(=O)-. The sulfur atom of the ring can be optionally oxidized to an S-oxide. The nitrogen atom of the ring can be optionally oxidized to an N-oxide. Examples of heterocyclic groups of 7 to 12 atoms include, but are not limited to, indolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,3-benzodioxolyl, 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, 2-azaspiro[4.4]nonanyl (e.g., 2-azaspiro[4.4]nonan-4-yl, 2-azaspiro[4.4]nonan-2-yl), 1,6- dioxaspiro[4.4]nonanyl (e.g., 1,6-dioxaspiro[4.4]nonan-9-yl, 1,6-dioxaspiro[4.4]nonan-4-yl), 2-azaspiro[4.5]decanyl (e.g., 2-azaspiro[4.5]decan-8-yl, 2-azaspiro[4.5]decan-2-yl), 7-azaspiro[4.5]decanyl (e.g., 7-azaspiro[4.5]decan- 2-yl, 7-azaspiro[4.5]decane-8-yl), 3-azaspiro[5.5]undecane (e.g., 3-azaspiro[5.5]undecane-3-yl, 3-azaspiro[5.5]undecane-9-yl), 2-azaspiro[5.5]undecane, 8-azaspiro[4.5]decane, decahydroisoquinolinyl, octahydro-1H-isoindolyl (e.g., octahydro-1H-isoindolyl), The heterocyclyl groups of 7 to 12 atoms may be optionally substituted with one or more substituents described herein.

[0193] In some other embodiments, the heterocyclic group is a spiro heterobicyclic group consisting of 7-12 atoms, which refers to a spiro heterobicyclic group comprising 7-12 ring atoms, which is monovalent or polyvalent, saturated or partially unsaturated, non-aromatic, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. Unless otherwise indicated, the spiro heterobicyclic group consisting of 7-12 atoms can be a carbon group or a nitrogen group, and the -CH2- group can be optionally substituted by -C(=O)-. The sulfur atom of the ring can optionally be oxidized to an S-oxide. The nitrogen atom of the ring can optionally be oxidized to an N-oxygen compound. The spiro heterobicyclic group consisting of 7-12 atoms includes a saturated spiro heterobicyclic group (i.e., a spiro heterobicycloalkyl group consisting of 7-12 atoms) and a partially unsaturated spiro heterobicyclic group consisting of 7-12 atoms. Examples of spiroheterobicyclic groups of 7 to 12 atoms include, but are not limited to, 2-azaspiro[4.4]nonanyl (e.g., 2-azaspiro[4.4]nonan-4-yl, 2-azaspiro[4.4]nonan-2-yl), 1,6-dioxaspiro[4.4]nonanyl (e.g., 1,6-dioxaspiro[4.4]nonan-9-yl, 1,6-dioxaspiro[4.4]nonan-4-yl), 2-azaspiro[4.5]decyl (e.g., 2-azaspiro[4.5]decyl), [4.5]decane-8-yl, 2-azaspiro [4.5]decane-2-yl), 7-azaspiro [4.5]decane (e.g., 7-azaspiro [4.5]decane-2-yl, 7-azaspiro [4.5]decane-8-yl), 3-azaspiro [5.5]undecane (e.g., 3-azaspiro [5.5]undecane-3-yl, 3-azaspiro [5.5]undecane-9-yl), 2-azaspiro [5.5]undecane, 8-azaspiro [4.5]decane, and the like. The spiroheterobicyclic group of 7 to 12 atoms may be optionally substituted with one or more substituents described herein.

[0194] In other embodiments, the heterocyclic group is a spiro heterobicyclic group consisting of 8-11 atoms, which refers to a spiro heterobicyclic group consisting of 8-11 ring atoms, monovalent or polyvalent, saturated or partially unsaturated, non-aromatic, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. Unless otherwise indicated, the spiro heterobicyclic group consisting of 8-11 atoms can be a carbon group or a nitrogen group, and the -CH2- group can be optionally replaced by -C(=O)-. The sulfur atom of the ring can be optionally oxidized to an S-oxide. The nitrogen atom of the ring can be optionally oxidized to an N-oxygen compound. The spiro heterobicyclic group consisting of 8-11 atoms includes a saturated spiro heterobicyclic group (spiro heterobicycloalkyl consisting of 8-11 atoms) and a partially unsaturated spiro heterobicyclic group consisting of 8-11 atoms. Examples of spiroheterobicyclic groups consisting of 8 to 11 atoms include, but are not limited to, 2-azaspiro[4.4]nonanyl (e.g., 2-azaspiro[4.4]nonan-4-yl, 2-azaspiro[4.4]nonan-2-yl), 1,6-dioxaspiro[4.4]nonanyl (e.g., 1,6-dioxaspiro[4.4]nonan-9-yl, 1,6-dioxaspiro[4.4]nonan-4-yl), 2-azaspiro[4.5]decyl (e.g., 2-azaspiro[4.5]decyl), [4.5]decane-8-yl, 2-azaspiro [4.5]decane-2-yl), 7-azaspiro [4.5]decane (e.g., 7-azaspiro [4.5]decane-2-yl, 7-azaspiro [4.5]decane-8-yl), 3-azaspiro [5.5]undecane (e.g., 3-azaspiro [5.5]undecane-3-yl, 3-azaspiro [5.5]undecane-9-yl), 2-azaspiro [5.5]undecane, 8-azaspiro [4.5]decane, and the like. The spiroheterobicyclic group consisting of 8 to 11 atoms can be optionally substituted with one or more substituents described herein.

[0195] In some other embodiments, the heterocyclic group is a fused heterobicyclic group consisting of 7-12 atoms, which refers to a fused heterobicyclic group consisting of 7-12 ring atoms, which is monovalent or polyvalent, saturated or partially unsaturated, non-aromatic, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. Unless otherwise specified, the fused heterobicyclic group consisting of 7-12 atoms can be a carbon group or a nitrogen group, and the -CH2- group can be optionally replaced by -C(=O)-. The sulfur atom of the ring can be optionally oxidized to an S-oxide. The nitrogen atom of the ring can be optionally oxidized to an N-oxygen compound. The fused heterobicyclic group consisting of 7-12 atoms includes a saturated fused heterobicyclic group consisting of 7-12 atoms (i.e., a fused heterobicycloalkyl group consisting of 7-12 atoms) and a partially unsaturated fused heterobicyclic group. Examples of 7-12 atom fused heterobicyclic groups include, but are not limited to, octahydrocyclopenta[c]pyrrolyl, octahydro-1H-isoindolyl, indolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,3-benzodioxolyl, hexahydrofuro[3,2-b]furanyl, hexahydrofuro[2,3-b]furanyl, and dodecahydroisoquinolinyl. The 7-12 atom fused heterobicyclic groups may be optionally substituted with one or more substituents described herein.

[0196] The terms "bridged bicyclic," "bridged ring," "bridged bicyclic group," and "bridged cyclyl" are used interchangeably herein to refer to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic bicyclic ring system in which the two rings share two atoms and two or more single bonds. Such systems may contain independent or conjugated unsaturated systems, but the core structure does not contain aromatic or heteroaromatic rings (although aromatic groups may be substituents thereon).

[0197] The terms "fused bicyclic," "fused ring," "fused bicyclic group," and "fused cyclyl" are used interchangeably herein to refer to a monovalent or polyvalent, saturated or partially unsaturated, but non-aromatic, ring system in which two rings share a common bond. Such systems may contain separate or conjugated unsaturated systems, but the core structure does not contain aromatic or heteroaromatic rings (although aromatic groups may be substituents thereon).

[0198] The terms "spirocyclyl," "spirocycle," "spirobicyclyl," or "spirobicycle" are used interchangeably herein to refer to a monovalent or multivalent, saturated or partially unsaturated ring system in which one ring originates from a specific ring carbon atom of the other ring and the two rings share only one atom.

[0199] As used in this disclosure, the term "unsaturated" means that a group contains one or more degrees of unsaturation.

[0200] The term "heteroatom" refers to O, S, N, P and Si, including N, S and P in any oxidation state; in the form of primary, secondary, tertiary amines and quaternary ammonium salts; or in the form of a nitrogen atom in a heterocyclic ring substituted with a hydrogen, for example, N (such as N in 3,4-dihydro-2H-pyrrolyl), NH (such as NH in pyrrolidinyl) or NR (such as NR in N-substituted pyrrolidinyl).

[0201] The term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).

[0202] The term "azido" or "N3" refers to an azide structure. This group can be linked to other groups, for example, to a methyl group to form methyl azide (MeN3), or to a phenyl group to form phenyl azide (PhN3).

[0203] The term "aryl" refers to monocyclic, bicyclic, and tricyclic carbocyclic ring systems containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring system is aromatic, wherein each ring system comprises a ring consisting of 3-7 atoms and has one or more points of attachment to the rest of the molecule. The term "aryl" can be used interchangeably with the term "aromatic ring". Examples of aryl groups can include phenyl, naphthyl, and anthracenyl. The aryl groups can be independently optionally substituted with one or more substituents described herein.

[0204] The term "heteroaryl" refers to monocyclic, bicyclic, and tricyclic ring systems containing 5-12 ring atoms, or 5-10 ring atoms, or 5-6 ring atoms, wherein at least one ring system is aromatic and at least one aromatic ring system contains one or more heteroatoms, wherein each ring system contains 5-7 ring atoms and has one or more points of attachment to the rest of the molecule. The term "heteroaryl" can be used interchangeably with the terms "heteroaromatic ring" or "heteroaromatic compound." In some embodiments, the heteroaryl group is a 5-12 heteroaryl group containing 1, 2, 3, or 4 heteroatoms independently selected from O, S, and N. In other embodiments, the heteroaryl group is a 5-10 heteroaryl group containing 1, 2, 3, or 4 heteroatoms independently selected from O, S, and N. In still other embodiments, the heteroaryl group is a 5-6 heteroaryl group containing 1, 2, 3, or 4 heteroatoms independently selected from O, S, and N. The heteroaryl group is optionally substituted with one or more substituents described herein.

[0205] Examples of heteroaryl groups of 5 to 12 atoms include, but are not limited to, the following bicyclic heteroaryl groups: benzimidazolyl, benzofuranyl, benzothiophenyl, indolyl (e.g., 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), purinyl, quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl), isoquinolyl (e.g., 1-isoquinolyl, 3-isoquinolyl, or 4-isoquinolyl), indazolyl (e.g., 3-indazolyl, 4-indazolyl), benzothiophenyl, ... , 5-indazolyl, 6-indazolyl, 7-indazolyl), imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[4,3-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, and the like. The heteroaryl groups of 5 to 12 atoms also include monocyclic heteroaryl groups of 5 to 6 atoms, examples of which include, but are not limited to, the following monocyclic rings: furyl (e.g., 2-furyl, 3-furyl), imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyridonyl, pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyrimidonyl, pyrimidinedione, pyrimidinyl ... oxazinyl (such as 3-pyridazinyl, 4-pyridazinyl), pyrazinyl (such as 2-pyrazinyl, 3-pyrazinyl), thiazolyl (such as 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), tetrazolyl (such as 5-tetrazolyl), triazolyl (such as 2-triazolyl and 5-triazolyl), thienyl (such as 2-thienyl, 3-thienyl), pyrazolyl (such as 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl), pyrazolonyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyrazinyl and 1,3,5-triazinyl, etc.

[0206] The term "oxazolyl" refers to a heteroaromatic ring system consisting of 5 or 9 atoms containing at least two heteroatoms, at least one of which is a nitrogen atom. Examples of oxazolyl include, but are not limited to, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, triazolyl, indazolyl, pyrazolo[4,3-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, imidazo[4,5-b]pyridinyl, and 1H-benzo[d]imidazolyl.

[0207] The term "carboxy", whether used alone or in combination with other terms, such as "carboxyalkyl", refers to -CO2H; the term "carbonyl", whether used alone or in combination with other terms, such as "aminocarbonyl" or "acyloxy", refers to -(C=O)-.

[0208] The term "alkylamino" or "alkylamino" is used interchangeably, including "N-alkylamino" and "N,N-dialkylamino", wherein the amino group is independently substituted with one or two alkyl groups. In some embodiments, the alkylamino group is one or two C1-C 12 An alkyl group is a lower alkylamino group formed by attaching an alkyl group to a nitrogen atom. In other embodiments, an alkylamino group is a lower alkylamino group formed by attaching one or two C1-C6 alkyl groups to a nitrogen atom. In other embodiments, an alkylamino group is a lower alkylamino group formed by attaching one or two C1-C4 alkyl groups to a nitrogen atom. In still other embodiments, an alkylamino group is a lower alkylamino group formed by attaching one or two C1-C3 alkyl groups to a nitrogen atom. Suitable alkylamino groups can be monoalkylamino or dialkylamino groups. Examples of alkylamino groups include, but are not limited to, N-methylamino (-NHCH3), N-ethylamino, N,N-dimethylamino (-NH(CH3)2), N,N-diethylamino, N-ethylpropyl-2-amino, and the like.

[0209] The term "arylamino" refers to an amino group substituted with one or two aryl groups, such examples include, but are not limited to, N-phenylamino. In some embodiments, the aromatic ring on the arylamino group may be further substituted.

[0210] The term "aminoalkyl" includes C1-C 12 In some embodiments, aminoalkyl is a C1-C ... 12In some embodiments, the aminoalkyl group is a C1-C6 "lower aminoalkyl" substituted with one or more amino groups. In other embodiments, the aminoalkyl group is a C1-C4 alkyl substituted with one or more amino groups. In still other embodiments, the aminoalkyl group is a C1-C3 alkyl substituted with one or more amino groups. Examples of aminoalkyl groups include, but are not limited to, aminomethyl (-CH2NH2), aminoethyl (-CH2CH2NH2, -CH(NH2)CH3), aminopropyl, aminobutyl, and aminohexyl.

[0211] As described in the present disclosure, a substituent is attached to a central ring to form a ring system, which indicates that the substituent is selectively substituted at all substitutable positions on the ring system.

[0212] As described herein, a ring system formed by two linkages connected to the center of the ring (as shown in Formula i) indicates that both linkages can be connected to the rest of the molecule at any available position on the ring system, and the two ends of the linkage (endpoint Q and end point Q') are interchangeable. Formula i indicates that any two possible linkage positions on the G ring can be connected to the rest of the molecule.

[0213]

[0214] The term "prodrug" as used herein refers to a compound that is converted in vivo to a compound represented by Formula (I), Formula (II), Formula (III), or Formula (IV). Such conversion is affected by hydrolysis of the prodrug in the blood or by enzymatic conversion to the parent structure in the blood or tissues.

[0215] "Metabolite" refers to a product resulting from the in vivo metabolism of a specific compound or salt thereof. Metabolites of a compound can be identified using techniques known in the art, and their activity can be characterized using assays such as those described herein. Such products can be obtained by administering the compound through oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic cleavage, and the like. Accordingly, the present disclosure encompasses metabolites of compounds, including metabolites produced by contacting a compound of the present disclosure with a mammal for a period of time.

[0216] As used herein, "pharmaceutically acceptable salts" refer to organic and inorganic salts of the compounds of the present disclosure.

[0217] The term "deuterated compound" as used herein refers to a compound in which hydrogen is replaced by its isotope deuterium ( 2 H or D) to obtain the compound.

[0218] As used herein, the term "treating" any disease or condition refers to ameliorating the disease or condition (i.e., slowing or preventing or alleviating the development of the disease or at least one clinical symptom thereof) in some embodiments. In other embodiments, "treating" refers to alleviating or improving at least one physical parameter, including physical parameters that may not be perceived by the patient. In other embodiments, "treating" refers to regulating the disease or condition physically (e.g., stabilizing a perceptible symptom) or physiologically (e.g., stabilizing a physical parameter), or both. In other embodiments, "treating" refers to preventing or delaying the onset, occurrence, or worsening of a disease or condition.

[0219] As used herein, "inflammatory disease" refers to any disease, disorder, or symptom resulting from an excessive or uncontrolled inflammatory response that causes excessive inflammatory symptoms, host tissue damage, or loss of tissue function. "Inflammatory disease" also refers to a pathological state mediated by leukocyte influx and / or neutrophil chemotaxis.

[0220] As used herein, "inflammation" refers to a local protective response caused by tissue damage or destruction, which serves to destroy, dilute, or isolate (isolate) harmful substances and damaged tissue. Inflammation is significantly associated with leukocyte influx and / or neutrophil chemotaxis. Inflammation can result from infection with pathogenic organisms and viruses, as well as non-infectious causes such as trauma or reperfusion following myocardial infarction or stroke, immune responses to foreign antigens, and autoimmune responses. Therefore, inflammatory diseases that can be treated with the compounds disclosed herein include diseases associated with specific defense system responses as well as non-specific defense system responses.

[0221] "Specific defense system" refers to the components of the immune system that respond to the presence of specific antigens. Examples of inflammation resulting from specific defense system reactions include classical responses to foreign antigens, autoimmune diseases, and delayed hypersensitivity responses (mediated by T-cells). Chronic inflammatory diseases, rejection of transplanted solid tissues and organs (such as rejection of kidney and bone marrow transplants), and graft-versus-host disease (GVHD) are other examples of specific defense system inflammatory responses.

[0222] As used in this disclosure, "autoimmune disease" refers to a collection of any diseases that are associated with tissue damage that is either humoral or cell-mediated in response to the body's own components.

[0223] As used in this disclosure, "allergy" refers to any symptom, tissue damage or loss of tissue function that produces an allergy. As used in this disclosure, "arthritis disease" refers to any disease characterized by inflammatory lesions of the joints attributable to various etiologies. As used in this disclosure, "dermatitis" refers to any one of a large family of skin diseases characterized by inflammation of the skin attributable to various etiologies. As used in this disclosure, "transplant rejection" refers to any immune response against transplanted tissues, such as organs or cells (such as bone marrow), characterized by loss of function of the transplanted or surrounding tissues, pain, swelling, leukocytosis and thrombocytopenia. The therapeutic methods disclosed herein include methods for treating diseases associated with inflammatory cell activation.

[0224] The terms "cancer" and "cancerous" refer to or describe the physiological condition in a patient that is typically characterized by uncontrolled cell growth. A "tumor" comprises one or more cancerous cells. Examples of cancer include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas, and leukemias, or lymphoid malignancies. More specific examples of such cancers include squamous cell carcinoma (such as epithelial squamous cell carcinoma), lung cancer (including small cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, and lung squamous carcinoma), peritoneal cancer, hepatocellular cancer, gastric or stomach cancer (including gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, hepatic carcinoma, anal cancer, penile cancer, and head and neck cancer.

[0225] Description of the Disclosed Compounds

[0226] The present disclosure discloses a novel class of compounds that can be used as Crm1 inhibitors. Compounds that act as Crm1 inhibitors can be used to treat diseases, disorders, or conditions associated with abnormal cellular responses triggered by improper nuclear transport. Such diseases include proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, and their complications. In particular, the compounds of the present disclosure can be used to treat the following diseases, such as cancer, polycythemia vera, essential thrombocythemia, myelofibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic obstructive pulmonary disease, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type II diabetes, gout, post-traumatic stress disorder, respiratory allergic diseases, sinusitis, eczema, measles, food allergies, insect venom allergies, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, organ transplant rejection, tissue transplant rejection, cell transplant rejection, viral infections, ophthalmic disorders, neurodegenerative disorders, abnormal tissue growth disorders or new coronavirus pneumonia, etc.

[0227] In some embodiments, the compounds disclosed herein exhibit potent inhibitory activity against CRM1.

[0228] In one aspect, the present disclosure provides a compound represented by formula (I) or a stereoisomer, tautomer, deuterated product, metabolite, pharmaceutically acceptable salt or prodrug thereof,

[0229]

[0230] wherein A1, A2, and A3 are each independently C or N;

[0231] Ring B is C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl consisting of 5-12 atoms, wherein the ring B is optionally substituted by m Bn;

[0232] m is 0, 1, 2 or 3. When m is 1, 2 or 3, Bn are the same or different;

[0233] R1, R2, R3, R4, R5, Bn are each independently selected from hydrogen, deuterium, F, Cl, Br, I, -NO2, =O, N3, CN, -OH, -NH2, -C(=O)CH2CN, -NHC(=O)CH2CN, -N(CH3)C(=O)CH2CN, Cl-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl composed of 5-12 atoms, -NR 10a R 10b 、-O-(C0-C4 alkylene)-R 10c 、-O-(C1-C4 alkylene)-OR 10c 、-O-(C1-C4 alkylene)-NR 10a R 10b 、-C(=O)R 10d 、-N(R 10e )C(=O)R 10d 、-C(=O)NR 10a R 10b 、-N(R 10e )C(=O)NR 10a R 10b 、-N(R 10e )C(=O)OR 10a 、-C(=O)N(R 10e )C(=O)R 10d 、-S(=O)2R 10f 、-N(R 10e )S(=O)2R 10f or -S(=O)2NR 10a R 10b , or, R1 and R5 together with the atoms to which they are attached, or R1 and R2 together with the atoms to which they are attached, or R2 and R3 together with the atoms to which they are attached, or R3 and R4 together with the atoms to which they are attached, or R4 and Bn together with the atoms to which they are attached, or R5 and Bn together with the atoms to which they are attached, form C3-C 12 Cycloalkyl or heterocycloalkyl group composed of 3-12 atoms; wherein each C1-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms and heterocycloalkyl consisting of 3-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 11 substituted by a group;

[0234] R8 is C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 10 substituted by a group;

[0235] R9 is -C(=O)NR 10a R 10b 、C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 10 substituted by a group;

[0236] R 10 is selected from hydrogen, deuterium, F, Cl, Br or I;

[0237] R 10a 、R 10b 、R 10c 、R 10d 、R 10e 、R 10f are independently H, C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-12 atoms), -(C0-C4 alkylene)-(C6-C 12 aryl) or -(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms), or R 10a and R 10b Together with the nitrogen atom to which they are attached, they form a heterocyclic group consisting of 3 to 12 atoms, wherein each of the C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, -(C0-C4 alkylene)-(C3-C 12Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-12 atoms), -(C0-C4 alkylene)-(C6-C 12 -(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms) and heterocyclyl groups consisting of 3-12 atoms are optionally substituted with 1, 2, 3 or 4 substituents independently selected from F, Cl, Br, CN, N3, -NO2, -OH, -NH2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl or C1-C6 alkylamino;

[0238] Each R 11 are independently hydrogen, deuterium, F, Cl, Br, I, CN, -NO2, =O, N3, -OH, -NH2, C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Halogenated alkyl, C3-C 12 Cycloalkyl, C6-C 12 Aryl, heterocyclic group composed of 3-12 atoms, heteroaryl composed of 5-12 atoms, C1-C 12 Aminoalkyl, C1-C 12 Alkylamino, C1-C 12 Alkoxy, C1-C 12 Hydroxyalkyl, -NH(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -NH(C0-C4 alkylene)-(C6-C 12 aryl), -NH(C0-C4 alkylene)-(heterocyclic group composed of 3-12 atoms), -NH(C0-C4 alkylene)-(heteroaryl composed of 5-12 atoms), -N[(C0-C4 alkylene)-(C3-C 12 Cycloalkyl)]2, -N[(C0-C4 alkylene)-(C6-C 12 -N[(C0-C4 alkylene)-(heterocyclic group composed of 3-12 atoms)]2, -N[(C0-C4 alkylene)-(heteroaryl composed of 5-12 atoms)]2, -O-(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -O-(C0-C4 alkylene)-(C6-C 12 -O-(C0-C4 alkylene)-(heterocyclyl consisting of 3-12 atoms) or -O-(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms); and

[0239] The condition is that when R9 is -C(=O)NH2, Bn is not hydrogen at the same time or R1 and R3 are not C1-C 12 Halogenated alkyl or A1, A2, A3 are not C or R at the same time 10 Not hydrogen.

[0240] According to the embodiment of the present disclosure, its structural formula is shown in formula (II),

[0241]

[0242] Wherein, B1, B2, B3, B4 are each independently C or N, B5 is C, N or empty, and when B5 is C or N, said B5 is optionally replaced by R 11 replaced by;

[0243] n is 1 or 2, and when n is 2, B2 are the same or different;

[0244] B2 is optionally replaced by R 11 replaced by;

[0245] R1, R2, R3, R4, R5, R6, and R7 are each independently selected from hydrogen, deuterium, F, Cl, Br, I, -NO2, =O, N3, CN, -OH, -NH2, -C(=O)CH2CN, -NHC(=O)CH2CN, -N(CH3)C(=O)CH2CN, Cl-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl composed of 5-12 atoms, -NR 10a R 10b 、-O-(C0-C4 alkylene)-R 10c 、-O-(C1-C4 alkylene)-OR 10c 、-O-(C1-C4 alkylene)-NR 10a R 10b 、-C(=O)R 10d 、-N(R 10e )C(=O)R 10d 、-C(=O)NR 10a R 10b 、-N(R 10e )C(=O)NR 10a R 10b 、-N(R 10e )C(=O)OR 10a、-C(=O)N(R 10e )C(=O)R 10d 、-S(=O)2R 10f 、-N(R 10e )S(=O)2R 10f or -S(=O)2NR 10a R 10b , or, R1 and R5 together with the atoms to which they are attached or R1 and R2 together with the atoms to which they are attached or R2 and R3 together with the atoms to which they are attached or R3 and R4 together with the atoms to which they are attached or R4 and R6 together with the atoms to which they are attached or R5 and optionally a substituent R of B5 11 Together with the atoms to which they are attached, or together with R5 and R7 and the atoms to which they are attached, form C3-C 12 Cycloalkyl or heterocycloalkyl group composed of 3-12 atoms, wherein each C1-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms and heterocycloalkyl consisting of 3-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 11 group substituted.

[0246] According to the embodiment of the present disclosure, its structure is shown in formula (III),

[0247]

[0248] Among them, A is C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 11 group substituted.

[0249] According to the embodiment of the present disclosure, its structure is shown in formula (IV),

[0250]

[0251] According to an embodiment of the present disclosure, wherein A1 and A3 are C;

[0252] R1 and R3 are each independently selected from C1-C6 haloalkyl, C3-C6 cycloalkyl;

[0253] R2, R4, and R5 are H;

[0254] B1, B2, B3, and B4 are each independently C or N, B5 is empty, and n is 1;

[0255] R6 and R7 are each independently selected from hydrogen, deuterium, C1-C6 alkyl, and the C1-C6 alkyl is independently optionally substituted by 1, 2, 3, 4 or 5 R 11 Group substituted, each R 11 are independently hydrogen, deuterium, F, Cl, Br, I;

[0256] R8 is selected from a heteroaryl group consisting of 5 to 12 atoms, wherein the heteroaryl group consisting of 5 to 12 atoms is optionally replaced by 1, 2, 3, 4 or 5 R 10 substituted by a group;

[0257] R 10 selected from hydrogen and deuterium;

[0258] R 10a 、R 10b are independently H, or R 10a and R 10b Together with the nitrogen atom to which they are attached, they form a heterocyclyl group consisting of 3 to 6 atoms, and the heterocyclyl group consisting of 3 to 6 atoms is optionally substituted by 1, 2, 3 or 4 substituents independently selected from F, Cl, Br, and -OH.

[0259] According to an embodiment of the present disclosure, wherein A1, A2, and A3 are C;

[0260] R1 and R3 are each independently selected from C1-C3 haloalkyl;

[0261] R2, R4, and R5 are H;

[0262] B1, B2, B3, and B4 are each independently C or N, B5 is empty, and n is 1;

[0263] R6 and R7 are each independently selected from hydrogen, C1-C3 alkyl;

[0264] R8 is selected from a 5-6 atom N-containing heteroaryl group;

[0265] R 10 is hydrogen;

[0266] R 10a 、R 10b are independently H, or R 10aand R 10b Together with the nitrogen atom to which they are attached, they form a 3-6 atom heterocyclyl group, which is substituted by 1, 2, 3 or 4 -OH substituents.

[0267] Another aspect of the present disclosure provides a compound represented by formula (I) or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs,

[0268]

[0269] wherein A1, A2, and A3 are each independently C or N;

[0270] Ring B is C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl consisting of 5-12 atoms, wherein the ring B is optionally substituted by m Bn;

[0271] m is 0, 1, 2 or 3. When m is 1, 2 or 3, Bn are the same or different;

[0272] R1, R2, R3, R4, R5, and Bn are each independently selected from hydrogen, deuterium, halogen, -NO2, =O, N3, CN, -OH, -NH2, -C(=O)CH2CN, -NHC(=O)CH2CN, -N(CH3)C(=O)CH2CN, -C(C 1-3 Alkyl)3, C1-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl composed of 5-12 atoms, -C(C 1-3 alkyl)2-OH, -CH(C 1-3 Alkyl)OH, -NR 10a R 10b 、-O-CH(C 1-3 alkyl)2, -O-(C0-C4 alkylene)-R 10c 、-O-(C1-C4 alkylene)-OR 10c 、-O-(C1-C4 alkylene)-NR 10a R 10b 、-O-(C3-C 12 Cycloalkyl), -O-(heterocyclic group consisting of 3-12 atoms), -C(=O)R10d 、-N(R 10e )C(=O)R 10d 、-C(=O)NR 10a R 10b 、-N(R 10e )C(=O)NR 10a R 10b 、-N(R 10e )C(=O)OR 10a 、-C(=O)N(R 10e )C(=O)R 10d 、-S(=O)2R 10f 、-N(R 10e )S(=O)2R 10f 、-S(=O)(C 1-3 alkyl)(=N)R 10f or -S(=O)2NR 10a R 10b , or, R1 and R5 together with the atoms to which they are attached, or R1 and R2 together with the atoms to which they are attached, or R2 and R3 together with the atoms to which they are attached, or R3 and R4 together with the atoms to which they are attached, or R4 and Bn together with the atoms to which they are attached, or R5 and Bn together with the atoms to which they are attached, form C3-C 12 Cycloalkyl or heterocyclic group composed of 3-12 atoms; wherein each C1-C 12 Alkyl, C1-C 12 Halogenated alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl of 5-12 atoms and heterocyclyl of 3-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 11 substituted by a group;

[0273] R8 is optionally substituted C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms; wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 16 substituted by a group;

[0274] R9 is hydrogen, -C(=O)NR10a R 10b 、-COR 13 、C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 17 substituted by a group;

[0275] Or R9 does not exist, the group for Wherein, X1 and X2 are each independently selected from C, N, O or S;

[0276] R 10 is selected from hydrogen, deuterium, F, Cl, Br or I;

[0277] R 16 、R 17 Each is independently selected from hydrogen, deuterium, halogen, =O, -CN, -OH, -NH2, -COOH, C1-C6 alkyl, C1-C6 alkoxy, C 3-6 Cycloalkyl, -(C1-C4 alkylene)COOH, -(C1-C4 alkylene)N(C 1-3 alkyl)2, -(C1-C4 alkylene)NH(C 1-3 alkyl), -(C1-C4 alkylene)OH, -(C1-C4 alkylene)NH2, -CH(C1-C6 alkyl)OH, -(C1-C4 alkylene)OH, -(C1-C4 alkylene)CH(C 1-3 alkyl) OH, -(C0-C4 alkylene) CONH2, -(C0-C4 alkylene) CF3, -O(C 1-3 -(C0-C4 alkylene)O(C1-C4 alkylene)O(C1-C4 alkylene)OH, -(C0-C4 alkylene)O(C1-C4 alkylene)O(C1-C4 alkylene)COOH, -(C0-C4 alkylene)O(C1-C4 alkylene)OH, -(C0-C4 alkylene)CN, -(C0-C4 alkylene)CONH(C0-C4 alkylene)CN, -(C0-C4 alkylene)SO2(C 1-3 Alkyl), -SO2(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)O(C 1-3alkyl), -(C1-C4 alkylene)CHOH(C1-C4 alkylene)OH, -(C0-C4 alkylene)CH(NH2)COOH, -(C0-C4 alkylene)CH(OH)COOH, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-6 atoms), -(C0-C4 alkylene)-(C6-C 12 -(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms), wherein the alkylene, alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl may be further substituted with one or more of the following substituents: hydrogen, deuterium, halogen, -OCH3, -OH, -COOH, -NH2, -CN, -CH(CH3)OH;

[0278] R 10a 、R 10b 、R 10c 、R 10d 、R 10e 、R 10f are independently selected from hydrogen, deuterium, halogen, C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-12 atoms), -(C0-C4 alkylene)-(C6-C 12 aryl) or -(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms), or R 10a and R 10b Together with the nitrogen atoms to which they are connected, they form a heterocyclic group consisting of 3 to 12 atoms or a heteroaryl group consisting of 5 to 12 atoms, wherein each of the C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Alkoxy, C3-C 12 Cycloalkyl, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-12 atoms), -(C0-C4 alkylene)-(C6-C 12-(C1-C4 alkylene)NH2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxyC1-C6 alkyl, aminoC1-C6 alkyl or C1-C6 alkylamino substituents;

[0279] Each R 11 are independently hydrogen, deuterium, halogen, CN, -NO2, =O, N3, -OH, -NH2, C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C1-C 12 Halogenated alkyl, C3-C 12 Cycloalkyl, C6-C 12 Aryl, heterocyclic group composed of 3-12 atoms, heteroaryl composed of 5-12 atoms, C1-C 12 Aminoalkyl, C1-C 12 Alkylamino, C1-C 12 Alkoxy, C1-C 12 Hydroxyalkyl, -NH(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -NH(C0-C4 alkylene)-(C6-C 12 aryl), -NH(C0-C4 alkylene)-(heterocyclic group composed of 3-12 atoms), -NH(C0-C4 alkylene)-(heteroaryl composed of 5-12 atoms), -N[(C0-C4 alkylene)-(C3-C 12 Cycloalkyl)]2, -N[(C0-C4 alkylene)-(C6-C 12 -N[(C0-C4 alkylene)-(heterocyclic group composed of 3-12 atoms)]2, -N[(C0-C4 alkylene)-(heteroaryl composed of 5-12 atoms)]2, -O-(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -O-(C0-C4 alkylene)-(C6-C 12 -O-(C0-C4 alkylene)-(heterocyclic group consisting of 3-12 atoms) or -O-(C0-C4 alkylene)-(heteroaryl group consisting of 5-12 atoms);

[0280] R 13 Selected from C 3-6Cycloalkyl, -NH(C0-C4alkylene)CN, -NH(C0-C4alkylene)CF3;

[0281] R 14 、R 15 Each is independently selected from hydrogen, deuterium, halogen, =O, -CN, -OH, -NH2, -COOH, C1-C6 alkyl, C 3-6 Cycloalkyl, -(C1-C4 alkylene)COOH, -(C1-C4 alkylene)N(C 1-3 alkyl)2, -(C1-C4 alkylene)NH(C 1-3 alkyl), -(C1-C4 alkylene)NH2, -(C1-C4 alkylene)OH, -(C1-C4 alkylene)CH(C 1-3 alkyl) OH, -(C0-C4 alkylene) CONH2, -(C0-C4 alkylene) CF3, -O(C 1-3 -(C0-C4 alkylene)O(C1-C4 alkylene)O(C1-C4 alkylene)OH, -(C0-C4 alkylene)O(C1-C4 alkylene)O(C1-C4 alkylene)COOH, -(C0-C4 alkylene)O(C1-C4 alkylene)OH, -(C0-C4 alkylene)CN, -(C0-C4 alkylene)CONH(C0-C4 alkylene)CN, -(C0-C4 alkylene)SO2(C 1-3 Alkyl), -SO2(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)O(C 1-3 alkyl), -(C1-C4 alkylene)CHOH(C1-C4 alkylene)OH, -(C0-C4 alkylene)CH(NH2)COOH, -(C0-C4 alkylene)CH(OH)COOH, -(C0-C4 alkylene)-(C3-C 12 Cycloalkyl), -(C0-C4 alkylene)-(heterocyclic group consisting of 3-6 atoms), -(C0-C4 alkylene)-(C6-C 12 -(C0-C4 alkylene)-(heteroaryl consisting of 5-12 atoms) or -(C1-C4 alkylene)C(=O)-(heterocyclyl consisting of 3-6 atoms), wherein the alkylene, alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl may be further substituted with one or more of the following substituents: hydrogen, deuterium, halogen, -OCH3, -OH, -COOH, -NH2, -CN, -CH(CH3)OH; and

[0282] The condition is that when R9 is -C(=O)NH2, Bn is not hydrogen at the same time or R1 and R3 are not C1-C 12 Halogenated alkyl or A1, A2, A3 are not C or R at the same time10 Not hydrogen.

[0283] According to an embodiment of the present disclosure, the structural formula thereof is a compound of formula (V):

[0284]

[0285] wherein B1, B2, B3, and B4 are each independently C or N;

[0286] Among them, the group Select one of the following formulae:

[0287]

[0288] wherein ring A is selected from C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 16 substituted by a group;

[0289] Ring C is selected from C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl composed of 5-12 atoms, wherein each C3-C 12 Cycloalkyl, heterocyclic group composed of 3-12 atoms, C6-C 12 Aryl or heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 17 substituted by a group;

[0290] R7 is selected from hydrogen, deuterium, halogen, C1-C6 alkyl, -NO2, =O, -CN, -OH or -C(=O)NH2;

[0291] Each R 11 Independently selected from hydrogen, deuterium, F, Cl, Br, I, , -CN, -NO2, =O, N3, -OH, -NH2 or C1-C6 alkyl;

[0292] Among them, when R 10a 、R 10b When both are hydrogen, R7 is not hydrogen or A2 is N.

[0293] According to an embodiment of the present disclosure, the group Select one of the following structures:

[0294]

[0295] According to the embodiment of the present disclosure, its structural formula is shown in the following formula (VI):

[0296]

[0297] wherein R1 and R3 are each independently selected from halogen, -CF3, C3-C6 cycloalkyl, a heterocyclic group consisting of 3-6 atoms or a heteroaryl group consisting of 5-6 atoms, -C(CH3)2OH, -S(=O)(=NH)CH3, -S(=O)(=N)CH3Cl, -CF2CH3, -CF(CH3)2, -CONH2, -C(C 1-3 Alkyl)3, -O-CH(C 1-3 wherein the cycloalkyl, heteroaryl, and heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, =O, —OCH 3 , —OH, —COOH, —NH 2 , —CN, and —CH(CH 3 ) OH;

[0298] R2, R4, and R5 are all hydrogen.

[0299] According to an embodiment of the present disclosure, A1 is C;

[0300] R1 and R3 are each independently selected from -CF3, C3-C6 cycloalkyl;

[0301] R4 and R5 are H;

[0302] R7 is selected from hydrogen, deuterium, C1-C6 alkyl;

[0303] R8 is selected from C6-C 12 Aryl, heteroaryl composed of 5-12 atoms, wherein the C6-C 12 Aryl, heteroaryl consisting of 5-12 atoms are independently optionally substituted by 1 or 2 R 16 substituted by a group;

[0304] R9 is -C(=O)NR 10a R 10b ;

[0305] R 16 Selected from hydrogen, deuterium, C1-C6 alkoxy, -S(=O)2(C3-C 12 cycloalkyl);

[0306] R 10a 、R 10b are each independently selected from hydrogen or R 10a and R 10bTogether with the nitrogen atom to which they are attached, they form a heterocyclic group consisting of 3 to 12 atoms, wherein the heterocyclic group consisting of 3 to 12 atoms is optionally substituted by 1 or 2 -OH groups.

[0307] According to an embodiment of the present disclosure, R7 is selected from hydrogen, C1-C3 alkyl;

[0308] R8 is selected from C6-C 10 Aryl, heteroaryl composed of 6-10 atoms, wherein the C6-C 10 Aryl, heteroaryl consisting of 6-10 atoms are independently optionally replaced by 1 R 16 substituted by a group;

[0309] R9 is selected from -C(=O)NR 10a R 10b ;

[0310] R 16 Selected from hydrogen, C1-C6 alkoxy, -S(=O)2(C3-C6 cycloalkyl);

[0311] R 10a 、R 10b are each independently selected from hydrogen or R 10a and R 10b Together with the nitrogen atom to which they are attached, they form a heterocyclic group consisting of 4 to 10 atoms, wherein the heterocyclic group consisting of 4 to 10 atoms is optionally substituted by 1 -OH.

[0312] According to an embodiment of the present disclosure, when A2 is N, the group for

[0313] Among them, R 14 、R 15 Each independently selected from hydrogen, C1-C3 alkyl, -(C1-C4 alkylene)COOH, -(C1-C4 alkylene)N(C 1-3 -(C1-C4 alkylene) OH, -(C0-C4 alkylene) CONH2, -(C0-C4 alkylene) CF3, -(C0-C4 alkylene) O(C1-C4 alkylene) OH, -(C0-C4 alkylene) O(C1-C4 alkylene) O(C1-C4 alkylene) OH, -(C0-C4 alkylene) O(C1-C4 alkylene) O(C1-C4 alkylene) COOH, -(C1-C4 alkylene) CN, -(C1-C4 alkylene) CH(C 1-3 alkyl)OH, -(C0-C4 alkylene)SO2(C 1-3 alkyl), -(C0-C4 alkylene)O(C 1-3alkyl), -(C1-C4 alkylene)CHOH(C1-C4 alkylene)OH, -(C0-C4 alkylene)CH(NH2)COOH, -CH2CONHCH2CN,

[0314] According to the embodiment of the present disclosure, the structural formula is shown in the following formula (VII):

[0315]

[0316] Wherein, R1 and R3 are each independently selected from -CF3, C3-C6 cycloalkyl, heterocyclic group consisting of 3-6 atoms or heteroaryl consisting of 5-6 atoms, -C(C 1-3 Alkyl)3, -O-CH(C 1-3 wherein the cycloalkyl, heteroaryl, and heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, -OCH3, -OH, -COOH, -NH2, -CN, and -CH(CH3)OH.

[0317] According to an embodiment of the present disclosure, when R7 is not hydrogen, its structural formula is shown in the following formula (VIII):

[0318]

[0319] Wherein, R1 and R3 are each independently selected from -CF3, C3-C6 cycloalkyl, heterocyclic group consisting of 3-6 atoms or heteroaryl consisting of 5-6 atoms, -C(C 1-3 Alkyl)3, -O-CH(C 1-3 wherein the cycloalkyl, heteroaryl, and heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, -OCH3, -OH, -COOH, -NH2, -CN, and -CH(CH3)OH.

[0320] According to an embodiment of the present disclosure, the group for

[0321] Where X1 and X2 are both N, R 14 、R 15 Each independently selected from hydrogen, C1-C3 alkyl, -(C1-C4 alkylene)COOH, -(C1-C4 alkylene)N(C 1-3-(C1-C4 alkylene) OH, -(C0-C4 alkylene) CONH2, -(C0-C4 alkylene) CF3, -(C0-C4 alkylene) O(C1-C4 alkylene) OH, -(C0-C4 alkylene) O(C1-C4 alkylene) O(C1-C4 alkylene) OH, -(C0-C4 alkylene) O(C1-C4 alkylene) O(C1-C4 alkylene) COOH, -(C1-C4 alkylene) CN, -(C1-C4 alkylene) CH(C 1-3 alkyl)OH, -(C0-C4 alkylene)SO2(C 1-3 alkyl), -(C0-C4 alkylene)O(C 1-3 alkyl), -(C1-C4 alkylene)CHOH(C1-C4 alkylene)OH, -(C0-C4 alkylene)CH(NH2)COOH, -CH2CONHCH2CN,

[0322] According to an embodiment of the present disclosure, -NR 10a R 10b One selected from the following formulas: -NH2,

[0323] According to an embodiment of the present disclosure, R1 and R3 are each independently selected from -CF3 or C3-C6 cycloalkyl.

[0324] According to an embodiment of the present disclosure, Ring A and Ring C are each independently selected from

[0325]

[0326]

[0327] According to an embodiment of the present disclosure, the group Has the following structure:

[0328]

[0329]

[0330] According to an embodiment of the present disclosure, the compound has one of the following structures:

[0331]

[0332]

[0333]

[0334]

[0335]

[0336]

[0337]

[0338]

[0339]

[0340]

[0341]

[0342]

[0343]

[0344]

[0345]

[0346]

[0347]

[0348]

[0349] Preferably, the compound has one of the following structures:

[0350]

[0351]

[0352] Another aspect of the present disclosure provides a pharmaceutical composition comprising the aforementioned compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts, or prodrugs.

[0353] According to an embodiment of the present disclosure, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, vehicle, carrier, solvent or a combination thereof.

[0354] Another aspect of the present disclosure relates to the use of the aforementioned compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs, or pharmaceutical compositions in the preparation of a medicament for preventing, treating, curing or alleviating a CRM1 disorder-related disease in a mammal.

[0355] According to an embodiment of the present disclosure, the mammal is a human.

[0356] According to an embodiment of the present disclosure, the CRM1 disorder-related diseases include proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, polycythemia vera, essential thrombocythemia, myelofibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic obstructive pulmonary disease, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type II diabetes, gout, post-traumatic stress disorder, respiratory allergic diseases, sinusitis, eczema, measles, food allergies, insect venom allergies, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, organ transplant rejection, tissue transplant rejection, cell transplant rejection, viral infections, ophthalmic disorders, neurodegenerative disorders, abnormal tissue growth disorders or new coronavirus pneumonia.

[0357] According to an embodiment of the present disclosure, the cancer includes at least one of prostate cancer, colon cancer, lymphoma, myeloma, gastric cancer, lung cancer, breast cancer, pancreatic cancer, liver cancer, and kidney cancer.

[0358] Another aspect of the present disclosure relates to use of the aforementioned compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs, or pharmaceutical compositions in the preparation of a medicament for selectively antagonizing Crm1.

[0359] In another aspect, the present disclosure provides methods for preparing, separating and purifying compounds represented by formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII) and formula (VIII).

[0360] According to the embodiments of the present disclosure, the inventors found through biological experiments that the compounds provided by the present disclosure have Crm1 inhibitory activity and can be used as better Crm1 inhibitors.

[0361] Unless otherwise indicated, stereoisomers, tautomers, metabolites, deuterated products, salts and pharmaceutically acceptable prodrugs of the compounds represented by Formula (I) to Formula (V) are all included within the scope of the present disclosure.

[0362] The compounds of the present disclosure may contain asymmetric or chiral centers and, therefore, may exist in different stereoisomeric forms. This disclosure is intended to include all stereoisomeric forms of the compounds of Formulas (I) to (V), including but not limited to diastereomers, enantiomers, atropisomers, and geometric (or conformational) isomers, as well as mixtures thereof, such as racemic mixtures, as part of the present disclosure.

[0363] In the structures disclosed herein, when the stereochemistry of any particular chiral atom is not indicated, all stereoisomers of the structure are contemplated within the disclosure and are included herein as compounds of the disclosure. When stereochemistry is indicated by a solid wedge or dashed line representing a specific configuration, the stereoisomers of the structure are unambiguous and defined.

[0364] The compounds represented by formula (I) to formula (V) may exist in different tautomeric forms, and all of these tautomers, such as the tautomers described in the present disclosure, are included within the scope of the present disclosure.

[0365] The compounds represented by formula (I) to formula (V) may exist in the form of salts. In some embodiments, the salts are pharmaceutically acceptable salts. The term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammals treated therewith. In other embodiments, the salts are not necessarily pharmaceutically acceptable salts, but may be intermediates for preparing and / or purifying the compounds represented by formula (I) to formula (V) and / or for separating the enantiomers of the compounds represented by formula (I) to formula (V).

[0366] Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids.

[0367] Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.

[0368] It should be understood that deuterium in the present disclosure is regarded as a substituent of the compounds represented by formula (I) to formula (V). In another aspect, the present disclosure relates to intermediates for preparing the compounds represented by formula (I) to formula (V).

[0369] In another aspect, the present disclosure relates to methods for preparing, separating and purifying the compounds represented by formula (I) to formula (V).

[0370] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure. In some embodiments, the pharmaceutical composition of the present disclosure further comprises a pharmaceutically acceptable excipient, carrier, vehicle, solvent, or combination thereof. In other embodiments, the pharmaceutical composition can be in liquid, solid, semisolid, gel, or spray form.

[0371] On the other hand, the present disclosure relates to a method for treating a disease or disorder regulated by one or more Crm1, the method comprising administering to a patient an effective amount of a compound disclosed herein or a pharmaceutical composition. In some embodiments, the disease or disorder is selected from a proliferative disease, an autoimmune disease, an allergic disease, an inflammatory disease, a transplant rejection, a cancer, polycythemia vera, essential thrombocythemia, myelofibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic obstructive pulmonary disease, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type II diabetes, gout, post-traumatic stress disorder, respiratory allergic disease, sinusitis, eczema, measles, food allergy, insect venom allergy, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, organ transplant rejection, tissue transplant rejection, cell transplant rejection, viral infection, ophthalmological disorder, neurodegenerative disorder, abnormal tissue growth disorder or novel coronavirus pneumonia.

[0372] In another aspect, the present disclosure relates to the use of the disclosed compounds or pharmaceutical compositions to treat a disease or disorder selected from a proliferative disease, an autoimmune disease, an allergic disease, an inflammatory disease, transplant rejection, cancer, polycythemia vera, essential thrombocythemia, myelofibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic obstructive pulmonary disease, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type II diabetes, gout, post-traumatic stress disorder, allergic respiratory disease, sinusitis, eczema, measles, food allergy, insect venom allergy, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, organ transplant rejection, tissue transplant rejection, cell transplant rejection, viral infection, ophthalmic disorder, neurodegenerative disorder, abnormal tissue growth disorder, or COVID-19.

[0373] In another aspect, the present disclosure relates to the use of the disclosed compounds or pharmaceutical compositions in the preparation of medicaments for preventing, managing, treating or alleviating Crm1-mediated diseases. According to an embodiment of the present disclosure, the disease is selected from proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, polycythemia vera, essential thrombocythemia, myelofibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic obstructive pulmonary disease, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type II diabetes, gout, post-traumatic stress disorder, respiratory allergic diseases, sinusitis, eczema, measles, food allergies, insect venom allergies, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, organ transplant rejection, tissue transplant rejection, cell transplant rejection, viral infection, ophthalmic disorder, neurodegenerative disorder, abnormal tissue growth disorder or new coronavirus pneumonia.

[0374] In another aspect, the present disclosure relates to the use of the disclosed compounds or pharmaceutical compositions for preparing a medicament for inhibiting the activity of CRM1.

[0375] The present disclosure provides a pharmaceutical composition comprising a disclosed compound, or a compound listed in the Examples, and a pharmaceutically acceptable excipient, vehicle, carrier, or solvent, or a combination thereof. The amount of compound in the pharmaceutical composition disclosed herein is an amount effective to inhibit CRM1 in a biological sample or patient.

[0376] Uses of the disclosed compounds and compositions

[0377] The present disclosure provides methods of using the disclosed compounds and pharmaceutical compositions to treat, prevent, or ameliorate a disease or disorder mediated or otherwise affected by the action of Crm1, or one or more symptoms of a disease or disorder mediated or otherwise affected by the action of Crm1.

[0378] In some embodiments, the present disclosure provides compounds or pharmaceutical compositions comprising the disclosed compounds for treating, preventing, or ameliorating a disease or disorder mediated or otherwise affected by inappropriate Crm1 activity, or one or more symptoms of a disease or disorder mediated or otherwise affected by inappropriate Crm1 activity.

[0379] "Inappropriate Crm1 behavior" refers to Crm1 behavior that deviates from normal Crm1 behavior in a particular patient. Inappropriate Crm1 behavior can manifest, for example, as an abnormal increase in activity or deviations in the timing and control of Crm1 behavior. Such inappropriate Crm1 behavior results, for example, from overexpression or mutation of Crm1, leading to inappropriate or uncontrolled behavior. Accordingly, the present disclosure provides methods for treating these diseases and disorders.

[0380] Consistent with the above description, such diseases or disorders include, but are not limited to, proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, polycythemia vera, essential thrombocythemia, myelofibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic obstructive pulmonary disease, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type II diabetes, gout, post-traumatic stress disorder, allergic respiratory diseases, sinusitis, eczema, measles, food allergies, insect venom allergies, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, organ transplant rejection, tissue transplant rejection, cell transplant rejection, viral infections, ophthalmic disorders, neurodegenerative disorders, abnormal tissue growth disorders, or novel coronavirus pneumonia.

[0381] In one aspect, the present disclosure provides a class of disclosed compounds or pharmaceutical compositions comprising the disclosed compounds for preventing and / or treating proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, or transplant rejection in mammals (including humans).

[0382] In another aspect, the present disclosure provides a method for treating a mammal suffering from or at risk of suffering from a disease disclosed herein, the method comprising administering an effective amount of the disease to treat or an effective amount of the disease to prevent the disease to one or more pharmaceutical compositions or compounds disclosed herein. In another aspect, the present disclosure provides a method for treating a mammal suffering from or at risk of suffering from a proliferative disease, an autoimmune disease, an allergic disease, an inflammatory disease, or a transplant rejection.

[0383] In a method of treatment, the present disclosure provides a method for treating and / or preventing a mammal susceptible to or suffering from a proliferative disease, the method comprising administering an effective therapeutic amount or an effective preventive amount of one or more pharmaceutical compositions or compounds disclosed herein. On the other hand, a class of compounds disclosed herein is provided herein for treating and / or preventing proliferative diseases. On the other hand, a class of compounds disclosed herein, or a pharmaceutical composition comprising a compound disclosed herein, is provided herein for the preparation of a medicine for treating or preventing a proliferative disease. In a particular instance, the above-mentioned proliferative disease is selected from cancer (e.g., prostate cancer, colon cancer), polycythemia vera, essential thrombocythemia, myelofibrosis, leukemia (e.g., AML, CML, ALL or CLL) and multiple myeloma.

[0384] On the other hand, provided herein is a method for treating and / or preventing a mammal susceptible to or suffering from an autoimmune disease, the method comprising administering an effective therapeutic amount or an effective prophylactic amount of one or more pharmaceutical compositions or compounds disclosed herein. On the other hand, provided herein is a class of compounds disclosed herein for use in treating and / or preventing autoimmune diseases. On the other hand, provided herein is a class of compounds disclosed herein, or a pharmaceutical composition comprising a compound disclosed herein, for the preparation of a medicament for treating or preventing an autoimmune disease. In a specific embodiment, the above-mentioned autoimmune disease is selected from COPD, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type II diabetes and inflammatory bowel disease.

[0385] In another aspect, provided herein are methods for treating and / or preventing a mammal susceptible to or suffering from an allergic disease, the methods comprising administering a therapeutically effective or prophylactically effective amount of one or more pharmaceutical compositions or compounds disclosed herein.

[0386] In another aspect, provided herein are compounds disclosed herein for use in treating and / or preventing allergic diseases. In another aspect, provided herein are compounds disclosed herein, or pharmaceutical compositions comprising compounds disclosed herein, for use in preparing a medicament for treating or preventing allergic diseases. In certain embodiments, the allergic disease is selected from respiratory allergic diseases, sinusitis, eczema and measles, food allergies, and insect venom allergies.

[0387] In another aspect, provided herein are methods of treating and / or preventing a mammal susceptible to or suffering from an inflammatory disease, the methods comprising administering a therapeutically or prophylactically effective amount of one or more pharmaceutical compositions or compounds disclosed herein.

[0388] In another aspect, provided herein are compounds disclosed herein for use in treating and / or preventing inflammatory diseases.

[0389] In another aspect, provided herein are compounds disclosed herein, or pharmaceutical compositions comprising compounds disclosed herein, for use in the preparation of a medicament for treating or preventing an inflammatory disease. In certain embodiments, the inflammatory disease is selected from inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, and psoriatic arthritis.

[0390] In another aspect, provided herein are methods for treating and / or preventing a mammal susceptible to or suffering from transplant rejection, the methods comprising administering a therapeutically effective or prophylactically effective amount of one or more pharmaceutical compositions or compounds disclosed herein.

[0391] In another aspect, provided herein are compounds disclosed herein for use in treating and / or preventing transplant rejection.

[0392] In another aspect, the present invention provides a class of compounds disclosed herein, or pharmaceutical compositions comprising compounds disclosed herein, for use in preparing a medicament for treating or preventing transplant rejection. In a specific embodiment, the transplant rejection is organ transplant rejection, tissue transplant rejection, and cell transplant rejection.

[0393] In another aspect, provided herein are compounds disclosed herein for use as medicines, particularly for use as medicines for treating and / or preventing the aforementioned diseases. Also provided are methods for using the compounds disclosed herein to manufacture medicines for treating and / or preventing the aforementioned diseases.

[0394] A particular embodiment of this method comprises administering to a subject suffering from inflammation an effective amount of a compound of the present disclosure for a period of time sufficient to reduce the level of inflammation in the subject and preferably to terminate the progression of the inflammation. A particular embodiment of this method comprises administering to a subject suffering from or susceptible to rheumatoid arthritis of bone an effective amount of a compound of the present disclosure for a period of time sufficient to reduce or prevent joint inflammation in the subject and preferably to terminate the progression of the inflammation.

[0395] Another particular embodiment of the present method comprises administering to a subject suffering from a proliferative disease an effective amount of a compound of the present invention for a period of time sufficient to reduce the level of the proliferative disease in the subject and preferably to terminate the progression of the proliferative disease. A particular embodiment of the present method comprises administering to a subject suffering from cancer an effective amount of a compound of the present invention for a period of time sufficient to reduce or prevent the symptoms of the cancer in the subject and preferably to terminate the progression of the cancer.

[0396] Treatment

[0397] In some embodiments, the treatment methods of the present disclosure include administering a safe and effective amount of a compound of the present disclosure or a pharmaceutical composition comprising a compound of the present disclosure to a patient in need thereof. Various embodiments of the present disclosure include methods for treating the above-mentioned diseases by administering a safe and effective amount of a compound of the present disclosure or a pharmaceutical composition comprising a compound of the present disclosure to a patient in need thereof.

[0398] In some embodiments, a compound of the disclosure or a pharmaceutical composition comprising a compound of the disclosure can be administered by any suitable route of administration, including systemic administration and topical administration.

[0399] In some embodiments, the compounds of the present invention or pharmaceutical compositions comprising the compounds of the present invention can be administered once, or several times at different time intervals within a specified time period according to a dosing regimen. The compounds of the present invention can be administered simultaneously with one or more other therapeutic agents, or before or after them. The compounds of the present invention can be administered separately with other therapeutic agents by the same or different routes of administration, or in the form of the same pharmaceutical composition.

[0400] General synthetic steps

[0401] To illustrate the present disclosure, the following examples are listed, but it should be understood that the present disclosure is not limited to these examples, which are only provided to provide methods for practicing the present disclosure.

[0402] Generally, the compounds of the present disclosure can be prepared by the methods described herein, unless otherwise specified, wherein the substituents are defined as shown in Formula (I) to Formula (V). The following reaction schemes and examples are provided to further illustrate the present disclosure.

[0403] Those skilled in the art will recognize that the chemical reactions described herein can be used to appropriately prepare many other compounds of the present disclosure, and that other methods for preparing the compounds of the present disclosure are considered to be within the scope of the present disclosure. For example, the synthesis of compounds not exemplified herein can be successfully accomplished by those skilled in the art through modification methods, such as appropriate protection of interfering groups, by utilizing other known reagents in addition to those described herein, or by making conventional modifications to the reaction conditions. In addition, the reactions disclosed herein or known reaction conditions are also generally applicable to the preparation of other compounds of the present disclosure.

[0404] In the examples described below, all temperatures are set forth in degrees Celsius unless otherwise indicated.

[0405] Preparation Example

[0406] Example 1

[0407] Compound 1: (E)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-oxadiazole

[0408]

[0409] Synthesis of compound 1:

[0410]

[0411] Step S1: Synthesis of (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloylhydrazide:

[0412] Ethyl chloroformate (188.7 mg, 1.7 mmol) was added dropwise to a solution of (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (500 mg, 1.2 mmol) and NMM (175.9 mg, 1.7 mmol) in dry THF (50 mL) at 0°C. The reaction mixture was stirred under a nitrogen atmosphere for 30 min to form the active lipid intermediate. An excess of hydrazine hydrate (approximately 1 mL) was then added to the reaction mixture, and the reaction was stirred at 0°C for an additional 1 h. After completion of the reaction, the reaction mixture was quenched with water (30 mL) and extracted with ethyl acetate (30 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was purified by silica gel column chromatography (eluent: ethyl acetate / methanol = 100 / 1) to give a pale yellow solid (250 mg, yield 45.9%).

[0413] LCMS:ESI-MS[M+H] + :444.1

[0414] Step S2: Synthesis of (E)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-oxadiazole (1):

[0415] At room temperature, toluenesulfonic acid (7.68 mg, 0.04 mmol), (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloylhydrazide (90 mg, 0.2 mmol) and triethyl orthoformate (15 mL) were added to a 50 mL round-bottom flask in sequence. The reaction solution was reacted at 100°C for 3 h under a nitrogen atmosphere. After the reaction, the reaction solution was cooled to room temperature and then the solvent was removed by rotary evaporation to obtain a yellow solid crude product. The crude product was purified on a preparative plate (developing solvent: ethyl acetate / petroleum ether = 2 / 1) to obtain a white solid (1). (75 mg, yield 79.86%).

[0416] LCMS:ESI-MS[M+H] + :454.1;

[0417] HPLC: Purity: 100% (214nm), 100% (254nm);

[0418] 1H NMR (400MHz, CDCl3) δ9.31 (s, 1H), 8.78 (s, 2H), 8.45 (s, 1H), 8.29 (d, J = 26.2Hz, 2H), 8.15 (s, 2H), 7.83 (s, 1H).

[0419] Example 2

[0420] Compound 2: (E)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-4,5-dihydrooxazole

[0421]

[0422] Synthesis of compound 2

[0423]

[0424] Step S1: Synthesis of (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(2-hydroxyethyl)-2-(pyrimidin-5-yl)acrylamide

[0425] To a 25 ml three-necked round-bottom flask at room temperature were added (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (200 mg, 0.47 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (266 mg, 0.7 mmol), diisopropylethylamine (179 mg, 1.39 mmol), 2-aminoethanol (34 mg, 0.56 mmol), and N,N-dimethylformamide (4 mL). The reaction mixture was then allowed to react at room temperature for 12 hours. After completion of the reaction, water (30 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated to yield the crude product. The crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to give a white solid (100 mg, yield: 45%).

[0426] LCMS:ESI-MS[M+H] + :473.1.

[0427] Step S2: Synthesis of (E)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-4,5-dihydrooxazole (2)

[0428] To a 25 mL three-necked flask at room temperature, (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(2-hydroxyethyl)-2-(pyrimidin-5-yl)acrylamide (50 mg, 0.11 mmol), triethylamine (111 mg, 1.1 mmol) and dichloromethane (4 mL) were added. After nitrogen replacement, the reaction mixture was cooled to 0°C. Methanesulfonyl chloride (25 mg, 0.22 mmol) was then added dropwise to the reaction system. The reaction solution was warmed to room temperature and reacted for 15 hours. After completion of the reaction, water (25 mL) was added to the reaction solution, and the mixture was extracted with DCM (30 mL x 3). The organic phases were combined, washed once with saturated brine (40 mL), dried over anhydrous sodium sulfate, and concentrated to dryness to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to give a white solid (2) (12 mg, yield: 24%).

[0429] LCMS:ESI-MS[M+H] + :455.1

[0430] HPLC:Purity:100%(214nm),100%(254nm)

[0431] 1 H NMR (400MHz, DMSO) δ9.18(d,J=5.7Hz,2H),8.78(s,2H),8.43(s,1H),8.23(s,1H),8.07(s,2H),4.47(t,J=9.4Hz,2H),3.93(t,J=9.4Hz,2H).

[0432] Example 3

[0433] Compound 3: (Z)-5-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine

[0434]

[0435] Synthesis of compound 3

[0436]

[0437] Step S1: Synthesis of 2-(pyrimidin-5-yl)acetamide: To a 100 mL sealed vial, add methyl 2-(pyrimidin-5-yl)acetate (2.7 g, 17.76 mmol) and methanolic ammonia (27 mL, 7 M methanolic ammonia) at room temperature. The reaction mixture was stirred at 50°C for 4 hours. After completion of the reaction, the reaction mixture was concentrated to dryness to obtain a crude yellow oil (2.3 g), which was used directly in the next step.

[0438] LCMS:ESI-MS[M+H] + :138.1

[0439] Step S2: Synthesis of 2-(pyrimidin-5-yl)acetonitrile:

[0440] 2-(Pyrimidin-5-yl)acetamide (2.3 g, 16.7 mmol) was dissolved in 23 mL of DMF at room temperature, and phosphorus oxychloride (5.1 g, 33.4 mmol) was slowly added dropwise to the mixture at 0°C. The reaction mixture was stirred at 0°C for one hour. After completion of the reaction, the reaction mixture was poured into 100 mL of ice water and extracted with ethyl acetate (30 mL x 2). The organic phases were combined and washed sequentially with saturated sodium bicarbonate (50 mL x 2) and saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1 to 5 / 1) to obtain a light yellow liquid (1.7 g, yield: 79.8%).

[0441] LCMS:ESI-MS[M+H]+ :120.1

[0442] Step S3: Synthesis of 5-((2H-tetrazol-5-yl)methyl)pyrimidine:

[0443] In a 50 mL round-bottom flask, 2-(pyrimidin-5-yl)acetonitrile (1.7 g, 14.3 mmol), ammonium chloride (2.3 g, 42.9 mmol), and sodium azide (1.8 g, 28.6 mol) were dissolved in N,N-dimethylformamide (17 mL) at room temperature. The reaction mixture was stirred at 100°C under a nitrogen atmosphere for 2 hours. After the reaction was completed, the temperature was cooled to room temperature, filtered, and the filtrate was prepared into a 30 mL solution of 5-((2H-tetrazol-5-yl)methyl)pyrimidine and used directly in the next step without further treatment.

[0444] LCMS:ESI-MS[M+H] + :163.1

[0445] Step S4: Synthesis of 5-((2-methyl-2H-tetrazol-5-yl)methyl)pyrimidine:

[0446] At room temperature, 5-((2H-tetrazol-5-yl)methyl)pyrimidine (30 mL of the above solution), dimethyl carbonate (6 mL) and triethylenediamine (1.6 g, 14.3 mmol) were dissolved in N,N-dimethylformamide (15 mL) in a 100 mL three-necked round-bottom flask. The reaction solution was stirred at 130°C under a nitrogen atmosphere for 12 hours. After the reaction was completed, the temperature was cooled to room temperature, the reaction solution was poured into 20 mL of water, and extracted with ethyl acetate (50 mL x 2). The organic phases were combined, washed with water (40 mL x 2), washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to give 5-((2-methyl-2H-tetrazol-5-yl)methyl)pyrimidine (810 mg, two-step yield: 32%) as a white solid.

[0447] LCMS:ESI-MS[M+H] + :177.1

[0448] Step S5: Synthesis of (E)-2-(2-methyl-2H-tetrazol-5-yl)-2-(pyrimidin-5-yl)ethen-1-ol:

[0449] 5-((2-Methyl-2H-tetrazol-5-yl)methyl)pyrimidine (800 mg, 4.5 mmol) was dissolved in 5 mL of ethyl formate at room temperature. The temperature was then lowered to 0°C, and sodium hydride (544 mg, 13.6 mmol, 60% dispersion in mineral oil) was slowly added to the mixture. The reaction mixture was stirred at room temperature for one hour. After completion of the reaction, the reaction mixture was poured into 20 mL of ice water and adjusted to pH 3 with 1N hydrochloric acid. The mixture was then extracted with ethyl acetate (40 mL x 2). The organic phases were combined, washed with water (30 mL x 2), saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to afford (E)-2-(2-methyl-2H-tetrazol-5-yl)-2-(pyrimidin-5-yl)ethen-1-ol (800 mg, crude) as a pale yellow solid containing a mixture of cis and trans forms.

[0450] LCMS:ESI-MS[M+H] + :205.1

[0451] Step S6: Synthesis of (E)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine and (Z)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine:

[0452] At room temperature, (Z)-2-(2-methyl-2H-tetrazol-5-yl)-2-(pyrimidin-5-yl)ethen-1-ol (220 mg crude product) and N,N-dimethylformamide (7.4 mg, 0.10 mmol) were dissolved in toluene (10 mL) in a 25 mL round-bottom flask. Then, thionyl chloride (240 mg, 2.02 mol) was added and the reaction solution was stirred at 110 °C for 1 hour under nitrogen atmosphere. After the reaction was completed, the temperature was lowered to room temperature, and the reaction solution was directly concentrated to dryness to obtain a crude product, which was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to obtain white solids (Z)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine (16 mg, two-step yield: 5.8%) and (E)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine (43 mg, two-step yield: 15.6%).

[0453] LCMS:ESI-MS[M+H] + :223.1

[0454] Step S7: Synthesis of (Z)-5-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine (3):

[0455] In a 25 ml three-necked round-bottom flask, (Z)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine (16 mg, 0.07 mmol), 3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazole (20 mg, 0.07 mmol), and triethylenediamine (15.7 mg, 0.14 mmol) were dissolved in N,N-dimethylformamide (4 mL) at room temperature. The reaction system was incubated at 40°C for 12 hours. After completion of the reaction, water (10 mL) was added to the reaction solution, and extraction was performed with ethyl acetate (10 mL x 3). The combined organic phase was washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by preparative plate separation (developing solvent: petroleum ether / ethyl acetate = 1 / 1), concentrated in vacuo, and lyophilized to obtain a white solid (3) (4 mg, yield: 12.2%).

[0456] LCMS:ESI-MS[M+H] + :468.1

[0457] HPLC:Purity:98.44%(214nm),96.67%(254nm)

[0458] 1 H NMR (400MHz, DMSO) δ9.24(s,1H),8.99(s,1H),8.93(s,2H),8.40(s,1H),8.27(s,3H),4.43(s,3H).

[0459] Example 4

[0460] Compound 4: (E)-5-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-oxadiazol-2(3H)-one

[0461]

[0462] Synthesis of compound 4

[0463]

[0464] Step S1: Synthesis of (E)-5-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-oxadiazol-2(3H)-one (4)

[0465] At room temperature, (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloylhydrazide (30 mg, 0.068 mmol) and triphosgene (8.01 mg, 0.027 mmol) were dissolved in tetrahydrofuran (3 mL) in a 50 mL round-bottom flask. The reaction solution was stirred at 70°C for 3 hours under a nitrogen atmosphere. After the reaction was completed, the reaction mixture was cooled to room temperature and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column (dichloromethane / methanol = 100 / 0-80 / 20) to obtain a white solid, which was then lyophilized to obtain a white powdery solid (4) (17.14 mg, yield: 54%).

[0466] LCMS:ESI-MS[M+H] + :470.0.

[0467] HPLC: Purity: 97.48% (214nm), 98.29% (254nm).

[0468] 1 H NMR (400MHz, DMSO) δ12.74(s,1H),9.26(s,1H),9.16(s,1H),8.90(s,2H),8.46(s,1H),8.24(s,1H),8.07(s,2H).

[0469] 19 F NMR(376MHz,DMSO)δ-61.81(s,6F).

[0470] Example 5

[0471] Compound 5: (E)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-5-methyl-1,3,4-oxadiazole

[0472]

[0473] Synthesis of compound 5

[0474]

[0475] Step S1: Synthesis of (E)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-5-methyl-1,3,4-oxadiazole (5):

[0476] Under constant stirring, compound (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloylhydrazide (50 mg, 0.11 mmol) was added to a mixed solvent of triethyl orthoformate (1 mL) and acetic acid (1 mL) in a round-bottom flask. The reaction solution was reacted at 120°C under a nitrogen atmosphere for 2 hours. After the reaction, the reaction solution was cooled to room temperature and the solvent was removed by rotary evaporation to obtain a crude yellow solid. The crude product was separated by preparative TLC (developing solvent: EA / PE = 1 / 1), concentrated in vacuo, and then freeze-dried to obtain a light yellow solid (5) (20.5 mg, yield 40%).

[0477] LCMS:ESI-MS[M+H] + :468.0

[0478] HPLC:Purity:98%(214nm),99%(254nm)

[0479] 1 H NMR (400MHz, CDCl3) δ9.30(s,1H),8.77(s,2H),8.28(s,1H),8.16-8.15(m,3H),7.83(s,1H),2.56(s,3H).

[0480] Example 6

[0481] Compound 6: E)-2-(5-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,2,4-oxadiazol-3-yl)acetonitrile

[0482]

[0483] Synthesis of compound 6

[0484]

[0485] Step S1: Synthesis of ethyl 2-cyanoacetate hydrochloride

[0486] To a solution of dicyanomethane (500 mg, 7.56 mmol) in diethyl ether (5 mL) was added a solution of hydrochloric acid in ethanol (5 mL, 10 mmol, 2N) at 0°C. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated to obtain a crude white solid (600 mg, crude product), which was used directly in the next reaction.

[0487] LCMS:ESI-MS[M+H] + :493.1.

[0488] Step S2: Synthesis of (E)-2-(5-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,2,4-oxadiazol-3-yl)acetonitrile (6)

[0489] At room temperature, ethyl 2-cyanoethanecarboxylic acid ester (38 mg, 0.34 mmol) was added to a solution of (2E)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl}-2-(pyrimidin-5-yl)prop-2-enoylhydrazide (50 mg, 0.11 mmol) in acetonitrile (1 ml) in a 50 mL screw-capped tube. After nitrogen replacement, the reaction solution was stirred at 60°C for 24 hours. After the reaction was completed, the reaction system was cooled to room temperature and the reaction solution was directly concentrated in vacuo to obtain a crude product. The crude product was isolated using TFA and then lyophilized to obtain a white solid (6) (18 mg, 32% yield).

[0490] LCMS:ESI-MS[M+H] + :493.1.

[0491] HPLC: 99.53% (214nm), 99.03% (254nm).

[0492] 1H NMR (400MHz, DMSO) δ9.28 (d, J = 11.0Hz, 2H), 8.96 (s, 2H), 8.72 (s, 1H), 8.26 (s, 1H), 8.09 (s, 2H), 4.74 (s, 2H).

[0493] 19F NMR (376MHz, DMSO) δ-61.80 (s, 6F).

[0494] Example 7

[0495] Compound 7: (E)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-thiadiazole

[0496]

[0497] Synthesis of compound 7

[0498]

[0499] Step S1: Synthesis of 5-(1,3,4-thiadiazol-2-ylmethyl)pyrimidine

[0500] At room temperature, 2-(pyrimidin-4-yl) acetohydrazide (900mg, 5.9mmol) and formic acid (50mL) were added sequentially to a 250mL single-necked flask. The reaction mixture was stirred overnight at room temperature under a nitrogen atmosphere, and then the reaction solution was concentrated to remove the solvent formic acid, dissolved with 1,4-dioxane (50mL), and Lawesson's reagent (3110mg, 7.69mmol) was added. The reaction mixture was stirred at 100°C for 3 hours under a nitrogen atmosphere. After the reaction was completed, it was cooled to room temperature, and water (50mL) was added to the reaction mixture for dilution, extracted with ethyl acetate (45mL x 3), and the combined organic phases were washed with saturated brine (40mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (eluent: MEOH / DCM = 3%-10%) and concentrated in vacuo to give 5-(1,3,4-thiadiazol-2-ylmethyl)pyrimidine (855 mg, 81% yield) as a yellow solid.

[0501] LCMS:ESI-MS[M+H] + :179.1.

[0502] 1H NMR(400MHz,dmso)δ9.54(s,1H),9.12(s,1H),8.83(s,2H),4.60(s,2H).

[0503] Step S2: Synthesis of (E)-2-(pyrimidin-5-yl)-2-(1,3,4-thiadiazol-2-yl)ethen-1-ol

[0504] In a 100 mL round-bottom flask, 5-(1,3,4-thiadiazol-2-ylmethyl)pyrimidine (500 mg, 2.81 mmol), ethyl formate (1.66 g, 22.4 mmol), and sodium methoxide (454 mg, 8.42 mmol) were dissolved in methanol (10 mL) at room temperature. The reaction mixture was stirred at 65°C under a nitrogen atmosphere for 3 hours. After the reaction was complete, the mixture was cooled to room temperature and 1 M HCl was added to adjust the pH to 3. A precipitate formed, which was filtered to obtain a yellow solid (477 mg, 82% yield).

[0505] LCMS:ESI-MS[M+H] + :207.1.

[0506] Step S3: Synthesis of (E)-2-(2-chloro-1-(pyrimidin-5-yl)vinyl)-1,3,4-thiadiazole

[0507] At room temperature, (E)-2-(pyrimidin-5-yl)-2-(1,3,4-thiadiazol-2-yl)ethen-1-ol (425 mg, 2.06 mmol) and thionyl chloride (490 mg, 4.126 mmol) were dissolved in DMF (30 mg, 0.41 mmol) and toluene (20 mL) in a 100 mL single-necked flask. The reaction mixture was stirred at 110°C under a nitrogen atmosphere for 2 hours. After the reaction was completed, the temperature was cooled to room temperature and the reaction mixture was concentrated. Water (20 mL) was added to the reaction mixture for dilution, followed by extraction with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: ethyl acetate / petroleum ether = 1 / 100 to 1 / 1) and concentrated in vacuo to obtain a yellow solid (232 mg, 50% yield).

[0508] LCMS:ESI-MS (M+H): 225.1.

[0509] 1H NMR (400MHz, DMSO) δ9.84(s,1H),9.24(s,1H),8.91(s,2H),7.62(s,1H).

[0510] Step S4: Synthesis of (E)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-thiadiazole (7)

[0511] To a 25 mL single-necked flask at room temperature were added 3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazole (40 mg, 0.14 mmol), 1,4-diazabicyclo[2.2.2]octane (32 mg, 0.28 mmol), and DMF (3 mL). The reaction mixture was stirred at 0°C under a nitrogen atmosphere for 0.5 hours. (E)-2-(2-chloro-1-(pyrimidin-5-yl)vinyl)-1,3,4-thiadiazole (38 mg, 0.17 mmol) was then added, and the reaction mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. After completion of the reaction, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (25 mL x 3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated and purified by silica gel preparation plate (developing solvent: EA), concentrated in vacuo and lyophilized to obtain a white solid (7) (20 mg, yield 30%)

[0512] LCMS:ESI-MS[M+H]+:470.0

[0513] HPLC:Purity:95.67%(254nm),95.12%(214nm)

[0514] 1H NMR (400MHz, DMSO) δ9.87(s,1H),9.24(s,1H),9.01(s,1H),8.90(s,2H),8.46(s,1H),8.26(s,1H),8.23(s,2H).

[0515] Example 8

[0516] Compound 8: (E)-5-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-oxadiazol-2-amine

[0517]

[0518] Synthesis of compound 8

[0519]

[0520] Step S1: In a 50 mL round-bottom flask, (E)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloylhydrazide (30 mg, 0.0677 mmol), cyanogen bromide (9 mg, 0.088 mmol) and NaHCO3 (11 mg, 0.0135 mmol) were dissolved in dioxane (3 mL) at room temperature. The reaction mixture was stirred at room temperature under nitrogen atmosphere for 7 hours. After the reaction was completed, water (15 mL) was added to the reaction mixture, and then extracted with ethyl acetate (15 mL x 3). The combined organic phase was washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative plate (eluent: ethyl acetate), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (8) (16 mg, 50% yield).

[0521] LCMS:ESI-MS[M+H] + :469.1.

[0522] HPLC: Purity: 96.26% (214nm), 96.00% (254nm).

[0523] 1H NMR (400MHz, DMSO) δ9.24(s,1H),9.18(s,1H),8.89(s,2H),8.27(s,1H),8.23(s,1H),8.08(s,2H),7.45(s,2H).

[0524] Example 9

[0525] Compound 9: (E)-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-oxadiazol-2-yl)methanol

[0526]

[0527] Synthesis of compound 9

[0528]

[0529] Step S1: Synthesis of ethyl 2-((4-methoxybenzyl)oxy)acetate

[0530] At room temperature, ethyl 2-hydroxyacetate (1.45 g, 13.9 mmol) was dissolved in N, N-dimethylformamide (10 mL) in a 50 mL three-necked flask. The atmosphere was replaced with nitrogen, and the mixture was cooled to 0°C. Sodium hydride (0.83 g, 20.8 mmol, 60% dispersion in mineral oil) was added to the mixture in one portion. The mixture was stirred at 0°C for 1 hour. Subsequently, a solution of 1-(chloromethyl)-4-methoxybenzene (3.27 g, 20.8 mmol) in N, N-dimethylformamide (5 mL) was added. The reaction mixture was warmed to 25°C and stirred for 3 hours. After the reaction was complete, saturated ammonium chloride solution (30 mL) was added to quench the reaction, diluted with water (10 mL), and extracted with ethyl acetate (30 mL x 3). The organic phases were combined and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-50 / 50) to give ethyl 2-((4-methoxybenzyl)oxy)acetate (1 g, yield: 31%) as a light yellow solid.

[0531] LCMS:ESI-MS[M+H] + :225.1.

[0532] 1H NMR (400MHz, CDCl3) δ7.31-7.26(m,2H),6.90-6.87(m,2H),4.57(s,2H),4.25-4.20(m,2H),4.06(s,2H),3.80(s,2H),1.29(t,J=7.1Hz,3H).

[0533] Step S2: Synthesis of 2-((4-methoxybenzyl)oxy)acetohydrazide

[0534] At room temperature, ethyl 2-((4-methoxybenzyl)oxy)acetate (1 g, 4.5 mmol), ethanol (4 mL) and hydrazine hydrate (0.46 g, 9 mmol) were added to a 100 mL round-bottom flask in sequence. The mixture was stirred at 80 ° C for 3 hours. After the reaction solution was cooled to room temperature, the reaction solution was concentrated. Diluted with water (35 mL) and extracted with ethyl acetate (35 mL x 3). The organic phases were combined and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column (eluent: dichloromethane / methanol = 100 / 0-90 / 10) to give a light yellow solid (700 mg, yield: 74%).

[0535] LCMS: ESI-MS (M+H)+: 211.0.

[0536] Step S3: Synthesis of (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(2-((4-methoxybenzyl)oxy)acetyl)-2-(pyrimidin-5-yl)acryloylhydrazide

[0537] At room temperature, 2-((4-methoxybenzyl)oxy)acetohydrazide (100 mg, 0.48 mmol), (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (204.21 mg, 0.48 mmol), ethyl acetate (3 mL), triethylamine (144.41 mg, 1.43 mmol), and 1-propylphosphonic anhydride (756.8 mg, 1.19 mmol, 50 wt.% ethyl acetate solution) were added to a 50 mL round-bottom flask in sequence. The mixture was stirred at 25° C. under a nitrogen atmosphere for 2 hours. After the reaction was complete, the reaction solution was concentrated. The mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phases were combined and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-50 / 50) to give a light yellow solid (100 mg, yield: 33.6%).

[0538] LCMS:ESI-MS[M+H] + :622.1.

[0539] Step S4: Synthesis of (E)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-5-((4-methoxybenzyl)oxy)methyl)-1,3,4-oxadiazole

[0540] At room temperature, (E)-3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(2-((4-methoxybenzyl)oxy)acetyl)-2-(pyrimidin-5-yl)acryloylhydrazide (100 mg, 0.16 mmol) was dissolved in acetonitrile (4 mL) in a 50 mL round-bottom flask. The atmosphere was replaced with nitrogen and the temperature was lowered to 0°C. To the mixture were added p-toluenesulfonyl chloride (122.7 mg, 0.64 mmol) and N,N-diisopropylethylamine (124.77 mg, 0.97 mmol) in sequence. The temperature was raised to 25°C, and the mixture was stirred at 25°C for 2 hours. After the reaction was complete, the reaction solution was diluted with water (25 mL) and extracted with ethyl acetate (25 mL x 3). The organic phases were combined and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0 to 0 / 100) to give a light yellow solid (90 mg, yield: 93%).

[0541] LCMS:ESI-MS[M+H] + :604.2.

[0542] 1H NMR(400MHz,DMSO)δ9.29-9.25(m,2H),8.95(s,2H),8.72(s,1H),8.25(s,1H),8.09(s,2 H), 7.30 (d, J = 7.8Hz, 2H), 6.93 (d, J = 7.8Hz, 2H), 4.80 (s, 2H), 4.57 (s, 2H), 3.74 (s, 3H).

[0543] Step S5: Synthesis of (E)-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-oxadiazol-2-yl)methanol

[0544]

[0545] At room temperature, (E)-2-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-5-((4-methoxybenzyl)oxy)methyl)-1,3,4-oxadiazole (80 mg, 0.13 mmol), dichloromethane (3 mL) and trifluoroacetic acid (3 mL) were added to a 50 mL round-bottom flask in sequence. The mixture was stirred at 25°C for 2 hours. After the reaction was completed, the reaction solution was concentrated. Water (20 mL) was added for dissolution and extracted with dichloromethane (20 mL x 3). The organic phases were combined and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 100 / 0-80 / 20), concentrated in vacuo and lyophilized to obtain a white solid powder (9) (40 mg, yield: 64%).

[0546] LCMS: ESI-MS [M+H] + :484.0.

[0547] HPLC: 94.05% (214nm), 95.22% (254nm).

[0548] 1 H NMR (400MHz, DMSO) δ9.29(s,1H),9.25(s,1H),8.95(s,2H),8.73(s,1H),8.26(s,1H),8.09(s,2H),6.02-5.99(m,1H),4.74-4.72(m,2H).

[0549] 19 F NMR (376MHz, DMSO) δ-61.79 (s, 6F).

[0550] Example 10

[0551] Compound 10: (E)-3-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-5-methyl-1,2,4-oxadiazole

[0552]

[0553] Synthesis of compound 10

[0554]

[0555] Step S1: Synthesis of N-hydroxy-2-(pyrimidin-5-yl)acetimide:

[0556] At room temperature, equimolar amounts of NaHCO3 (528.9 mg, 6.29 mmol) and hydroxylamine hydrochloride (437.51 mg, 6.29 mmol) were added to a round-bottom flask containing 20 ml of anhydrous methanol. The reaction solution was stirred thoroughly for 5 minutes, and then 2-(pyrimidin-5-yl)acetonitrile (500 mg, 4.19 mmol) was added to the system. The reaction solution was refluxed at 65°C for 2 hours. After the reaction was completed, the insoluble solid was removed by filtration, and the filtrate was collected and concentrated in vacuo to obtain a white solid crude product N-hydroxy-2-(pyrimidin-5-yl)acetimide (750 mg, crude product).

[0557] LCMS:ESI-MS[M+H] + :153.1.

[0558] Step S2: Synthesis of 5-methyl-3-(pyrimidin-5-ylmethyl)-1,2,4-oxadiazole:

[0559] N-Hydroxy-2-(pyrimidin-5-yl)acetimidide (500 mg, 3.28 mmol) and trimethyl orthoacetate (789.65 mg, 6.57 mmol) were added all at once to a round-bottom flask containing 5 mL of acetic acid at room temperature. The reaction mixture was heated at 100°C for 2 hours. After cooling to room temperature, the solvent was removed by rotary evaporation to obtain a crude yellow oily liquid. The crude product was purified by column chromatography (eluent: ethyl acetate:petroleum ether = 2:1) to obtain a yellow-brown liquid (135 mg, 18.3% yield over two steps).

[0560] LCMS:ESI-MS[M+H] + :177.1;

[0561] 1 H NMR (400MHz, CDCl3) δ9.15(s,1H),8.75(s,2H),4.06(s,2H),2.58(s,3H).

[0562] Step S3: Synthesis of (E)-2-(5-methyl-1,2,4-oxadiazol-3-yl)-2-(pyrimidin-5-yl)ethen-1-ol:

[0563] 5-Methyl-3-(pyrimidin-5-ylmethyl)-1,2,4-oxadiazole (100 mg, 0.57 mmol) and NaH (45.6 mg, 1.14 mmol, 60% dispersion in mineral oil) were added to a round-bottom flask containing 2 mL of ethyl formate at room temperature. The reaction solution was stirred at room temperature under nitrogen for 12 hours. After the reaction, the solvent was removed by rotary evaporation, and the residue was dissolved in ethyl acetate (20 mL) and washed with 1N hydrochloric acid (15 mL) and saturated brine (15 mL x 2). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain the crude product (35 mg, crude) as a pale yellow solid.

[0564] LCMS:ESI-MS[M+H] + :205.1

[0565] Step S4: Synthesis of (E)-3-(2-chloro-1-(pyrimidin-5-yl)vinyl)-5-methyl-1,2,4-oxadiazole:

[0566] (E)-2-(5-methyl-1,2,4-oxadiazol-3-yl)-2-(pyrimidin-5-yl)ethen-1-ol (30 mg, 0.058 mmol) and DMF (0.43 mg, 0.0058 mmol) were added to a round-bottom flask containing 2 mL of DCM at room temperature. Oxalyl chloride (22.39 mg, 0.176 mmol) was then slowly added dropwise to the reaction mixture. The mixture was stirred at room temperature for 2 hours. After the reaction, the solvent was removed by rotary evaporation to obtain a crude yellow-brown solid. The crude product was first dissolved in ethyl acetate (10 mL) and then washed sequentially with saturated sodium bicarbonate aqueous solution (5 mL x 2) and saturated brine (5 mL x 2). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain the product as a yellow solid (11.79 mg, two-step yield: 11%).

[0567] LCMS:ESI-MS[M+H] + :223.1.

[0568] Step S4: Synthesis of (E)-3-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-5-methyl-1,2,4-oxadiazole:

[0569] (E)-3-(2-chloro-1-(pyrimidin-5-yl)vinyl)-5-methyl-1,2,4-oxadiazole (11.79 mg, 0.052 mmol), 4-(1H-1,2,4-triazol-3-yl)-2,6-bis(trifluoromethyl)pyridine (10 mg, 0.035 mmol), and triethylenediamine (7.92 mg, 0.070 mmol) were added all at once to a round-bottom flask containing 2 mL of DMF at room temperature. The mixture was stirred at room temperature for 1 hour. After the reaction, water (10 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (10 mL x 2). The combined organic phases were washed with water (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to yield a crude pale yellow solid. The crude product was separated and purified by preparative plate (developing solvent: ethyl acetate: petroleum ether = 1:1), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (10) (6.5 mg, three-step yield: 4%).

[0570] LCMS:ESI-MS[M+H] + :468.0;

[0571] HPLC: Purity: 99.53% (214nm), 98.95% (254nm);

[0572] 1 H NMR (400MHz, DMSO) δ9.27(s,2H),8.91(s,2H),8.75(s,1H),8.25(s,1H),8.08(s,2H),2.69(s,3H).

[0573] Example 11

[0574] Compound 11: (E)-2-(2-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-oxadiazole

[0575]

[0576] Synthesis of compound 11

[0577]

[0578] Step S1: Synthesis of (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloylhydrazide

[0579] In a 50 mL three-necked flask at 0°C, (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (30 mg, 0.07 mmol) was dissolved in tetrahydrofuran (3 mL). N-methylmorpholine (14 mg, 0.14 mmol) and isobutyl carboxyl chloride (19 mg, 0.14 mmol) were then added. The reaction mixture was stirred at 0°C for half an hour under a nitrogen atmosphere. A solution of hydrazine in tetrahydrofuran (0.4 mL, 0.4 mmol, 1 mol / L) was then added dropwise to the reaction mixture, and the reaction mixture was stirred at 0°C for 1 hour. After completion of the reaction, water (15 mL) was added to quench the reaction mixture, which was then extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative plate (eluent: ethyl acetate) and concentrated in vacuo to remove the solvent to give a white solid (20 mg, 65% yield).

[0580] LCMS:ESI-MS(M+H)+:445.1

[0581] Step S2: Synthesis of (E)-2-(2-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-1,3,4-oxadiazole

[0582] In a 25 mL round-bottom flask, (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloylhydrazide (20 mg, 0.045 mmol) and p-toluenesulfonic acid (1 mg, 0.0045 mmol) were dissolved in trimethyl orthoformate (2 mL). The reaction mixture was heated and stirred at 110°C for 1 hour. After completion of the reaction, the crude product was spin-dried to obtain the product. The crude product was purified on a preparative plate (eluent: ethyl acetate / petroleum ether = 1 / 1) and the solvent was removed by vacuum concentration to obtain a white solid. The solid was then lyophilized to obtain 11 as a white powder (15 mg, 73% yield).

[0583] LCMS:ESI-MS[M+H] + :455.1.

[0584] HPLC: Purity:98.86% (214nm), 99.66% (254nm)

[0585] 1H NMR (400MHz, DMSO) δ9.44 (s, 1H), 9.31 (d, J = 5.5Hz, 2H), 8.98 (s, 2H), 8.80 (s, 1H), 8.10 (s, 2H).

[0586] Example 12

[0587] Compound 12: (E)-2-(2-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1-(pyrimidin-5-yl)vinyl)-5-methyl-1,3,4-oxadiazole

[0588]

[0589] Synthesis of compound 12

[0590]

[0591] Step S1: Compound (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloylhydrazide (20 mg, 0.045 mmol) was added to a mixed solvent of triethyl orthoformate (1 mL) and acetic acid (1 mL) in a round-bottom flask at room temperature. The reaction solution was heated at 120°C under a nitrogen atmosphere for 2 hours. After the reaction, the reaction solution was cooled to room temperature and the solvent was removed by rotary evaporation to obtain a crude yellow solid. The crude product was separated and purified by preparative plate (developing solvent: EA / PE = 1 / 1) and then lyophilized to obtain a yellow solid (12) (6.5 mg, yield 30.22%).

[0592] LCMS:ESI-MS[M+H] + :469.1

[0593] HPLC:Purity:96.62%(214nm),98.11%(254nm)

[0594] 1 H NMR (400MHz, DMSO) δ9.31(s,1H),9.30(s,1H),8.95(s,2H),8.71(s,1H),8.09(s,2H),2.61(s,3H).

[0595] Examples 13 and 14

[0596] Compound 13: (E)-5-(2-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine

[0597] Compound 14: (Z)-5-(2-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1-(2-methyl-2H-tetrazol-5-yl)pyrimidine

[0598]

[0599] Step S1: Synthesis of (E)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine and (Z)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine

[0600] At room temperature, (Z)-2-(2-methyl-2H-tetrazol-5-yl)-2-(pyrimidin-5-yl)ethen-1-ol (500 mg, 2.45 mmol) and N,N-dimethylformamide (17.7 mg, 0.24 mmol) were dissolved in toluene (10 mL) in a 100 ml round-bottom flask. Then, thionyl chloride (583.1 mg, 4.90 mol) was added and the reaction solution was stirred at 110 °C under nitrogen atmosphere for 1 hour. After the reaction was completed, the temperature was lowered to room temperature, and the reaction solution was directly concentrated to dryness to obtain a crude product, which was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1 to 10 / 1) to obtain white solids (Z)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine (80 mg, yield: 14.6%) and (E)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine (200 mg, 36.6%).

[0601] LCMS:ESI-MS (M+H)+: 223.1

[0602] Step S2: Synthesis of (E)-5-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine

[0603] In a 25 ml three-necked round-bottom flask, (E)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine (80 mg, 0.36 mmol), 3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazole (132 mg, 0.36 mmol), and triethylenediamine (80.6 mg, 0.72 mmol) were dissolved in N,N-dimethylformamide (6 mL) at room temperature. The reaction system was incubated at 40°C for 12 hours. After completion of the reaction, water (20 mL) was added to the reaction solution, and extraction was performed with ethyl acetate (30 mL x 3). The combined organic phase was washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative plate separation (developing solvent: petroleum ether / ethyl acetate = 1 / 1), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (13) (21 mg, yield: 13%).

[0604] LCMS:ESI-MS[M+H] + :441.2

[0605] HPLC:Purity:96.61%(214nm),96.92%(254nm)

[0606] 1 H NMR(400MHz,DMSO)δ9.29(s,1H),9.22(s,1H),8.90(s,2H),8.79(s,1H),7.72(s,1H),7.5 3(d,J=1.1Hz,1H),4.40(s,3H),2.38–2.21(m,1H),1.18–1.05(m,2H),0.98–0.89(m,2H).

[0607] Step S3: Synthesis of (Z)-5-(2-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine

[0608] In a 25 mL three-necked round-bottom flask, (Z)-5-(2-chloro-1-(2-methyl-2H-tetrazol-5-yl)vinyl)pyrimidine (16 mg, 0.07 mmol), 3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazole (20 mg, 0.07 mmol), and triethylenediamine (15.7 mg, 0.14 mmol) were dissolved in N,N-dimethylformamide (4 mL) at room temperature. The reaction system was incubated at 40°C for 12 hours. After completion of the reaction, water (10 mL) was added to the reaction solution, and extraction was performed with ethyl acetate (10 mL x 3). The combined organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was separated and purified on a preparative silica gel plate (developing solvent: petroleum ether / ethyl acetate = 1 / 1), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (14) (4 mg, yield: 13%).

[0609] LCMS:ESI-MS[M+H] + :441.0

[0610] HPLC:Purity:86.65%(214nm),95.32%(254nm)

[0611] 1H NMR(400MHz,dmso)δ9.25(s,1H),8.98(s,1H),8.93(s,2H),8.35(s,1H),7.94(s,1H),7.7 5(d,J=1.2Hz,1H),4.44(s,3H),4.41-2.33(m,1H),1.13-1.08(m,2H),1.01-0.97(m,2H).

[0612] Example 15

[0613] Compound 15: (E)-3-(3,5-bis(trifluoromethyl)phenyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0614]

[0615] Synthesis of compound 15

[0616]

[0617] Step S1: Synthesis of 3-(3,5-bis(trifluoromethyl)phenyl)-5-methyl-1H-1,2,4-triazole

[0618] At room temperature, 3,5-bis(trifluoromethyl)benzylsulfamide (250 mg, 0.91 mmol), 80% hydrazine hydrate (73 mg, 1.82 mmol), and trimethyl orthoacetate (2 mL) were added sequentially to a 50 mL round-bottom flask. The mixture was stirred at 25°C for 1 hour under a nitrogen atmosphere. Acetic acid (2 mL) was then added to the reaction solution. The reaction mixture was stirred at 90°C for 2 hours. After the reaction solution was cooled to room temperature, it was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by silica gel column separation (eluent: petroleum ether / ethyl acetate = 100 / 0-50 / 50) to obtain a light yellow solid (130 mg, yield: 48%).

[0619] LCMS:ESI-MS[M+H] + :296.1.

[0620] 1H NMR (400MHz, DMSO) δ14.06(s,1H),8.49(s,2H),8.17(s,1H),2.45(s,3H).

[0621] Step S2: Synthesis of methyl (E)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0622] To a 60 mL round-bottom flask at room temperature were added 3-(3,5-bis(trifluoromethyl)phenyl)-5-methyl-1H-1,2,4-triazole (130 mg, 0.44 mmol), methyl (2E)-3-chloro-2-(pyrimidin-5-yl)prop-2-enoate (86.87 mg, 0.44 mmol), and N,N-dimethylformamide (3 mL). The atmosphere was replaced with nitrogen, and the mixture was cooled to 0°C. Triethylenediamine (98.13 mg, 0.87 mmol) was added all at once. The reaction mixture was stirred at 0°C for 4 hours. Upon completion of the reaction, the reaction solution was diluted with water (15 mL) and extracted with ethyl acetate (15 mL x 3). The organic phases were combined, washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-50 / 50) to give a light yellow solid (110 mg, yield: 54%).

[0623] LCMS:ESI-MS[M+H] + :458.1.

[0624] Step S3: Synthesis of (E)-3-(3,5-bis(trifluoromethyl)phenyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[0625] At room temperature, 50 mL of methyl (E)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (90 mg, 0.20 mmol) and tetrahydrofuran (4 mL) were added. The mixture was cooled to 0°C and a solution of lithium hydroxide monohydrate (16 mg, 0.39 mmol) in water (2 mL) was added dropwise. The mixture was stirred at 0°C for 1 hour. After the reaction was completed, water (10 mL) was added to the reaction solution for dilution, the pH was adjusted to 6 with 1N HCl, and then extracted with ethyl acetate (15 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product (90 mg, light yellow solid). The crude product was used directly in the next reaction.

[0626] LCMS:ESI-MS[M+H] + :444.1.

[0627] Step S4: Synthesis of (E)-3-(3,5-bis(trifluoromethyl)phenyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide. To a 50 mL round-bottom flask were added (E)-3-(3,5-bis(trifluoromethyl)phenyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (90 mg, 0.20 mmol), ammonium chloride (108.1 mg, 2.02 mmol), N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (115.27 mg, 0.3 mmol), N,N-diisopropylethylamine (78.36 mg, 0.61 mmol) and N,N-dimethylformamide (3 mL) in sequence at room temperature. The mixture was stirred at 25°C for 1 hour under nitrogen atmosphere. After the reaction was completed, the reaction solution was concentrated to obtain a crude product. The crude product was separated and purified by silica gel column (eluent: dichloromethane / methanol = 100 / 0-80 / 20) to obtain a white solid (15) (40 mg, yield: 45%).

[0628] LCMS:ESI-MS[M+H]+:443.1.

[0629] HPLC: Purity: 100% (214nm), 100% (254nm).

[0630] 1 H NMR (400MHz, DMSO) δ9.16(s,1H),8.68(s,2H),8.20(s,1H),8.10(s,1H),7.99(s,2H),7.64(s,2H),2.70(s,3H).

[0631] 19 F NMR(376MHz,DMSO)δ-61.80(s,6F).

[0632] Example 16

[0633] Compound 16: (E)-3-(3,5-bis(trifluoromethyl)phenyl)-4-fluoro-1H-pyrazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0634]

[0635] Synthesis of compound 16

[0636]

[0637] Step S1: Synthesis of 4-fluoro-1-(4-methoxybenzyl)-1H-pyrazole

[0638] At room temperature, 4-fluoro-1H-pyrazole (1.0 g, 11.62 mmol) and tetrahydrofuran (50 mL) were added sequentially to a 100 mL three-necked flask. Sodium hydride (698 mg, 17.44 mmol, 60% dispersion in mineral oil) was then added under an ice bath and stirred at 0°C for 0.5 hours. p-Methoxybenzyl chloride (2.72 g, 17.44 mmol) was then added to the reaction mixture. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 12 hours. After completion of the reaction, the reaction mixture was quenched with water (40 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) and the solvent was removed in vacuo to afford a pale yellow liquid (1.1 g, 46% yield).

[0639] LCMS:ESI-MS[M+H] + :207.1.

[0640] Step S2: Synthesis of 5-bromo-4-fluoro-1-(4-methoxybenzyl)-1H-pyrazole

[0641] To a 100 mL three-necked flask at room temperature, 4-fluoro-1-(4-methoxybenzyl)-1H-pyrazole (1.1 g, 5.34 mmol) and tetrahydrofuran (30 mL) were added sequentially. n-Butyl lithium (3.33 mL, 8 mmol, 2.4 M solution in n-hexane) was added dropwise at -78°C under a nitrogen atmosphere. The reaction mixture was stirred at -78°C under a nitrogen atmosphere for 30 minutes. 1,2-Dibromo-1,1,2,2-tetrachloroethane (2.6 g, 8.01 mmol) was then added, and the reaction mixture was stirred at -78°C for 2 hours. After completion of the reaction, saturated aqueous ammonium chloride (30 mL) was slowly added, and the mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-10 / 1) and concentrated in vacuo to remove the solvent to obtain a white solid (400 mg, yield 26.3%).

[0642] LCMS:ESI-MS[M+H] + :285.2.

[0643] Step S3: Synthesis of 3-(3,5-bis(trifluoromethyl)phenyl)-4-fluoro-1-(4-methoxybenzyl)-1H-pyrazole

[0644] To a 100 mL round-bottom flask at room temperature were added 5-bromo-4-fluoro-1-(4-methoxybenzyl)-1H-pyrazole (200 mg, 0.704 mmol), (3,5-bis(trifluoromethyl)phenyl)boronic acid (272.5 mg, 1.05 mmol), potassium carbonate (291 mg, 2.11 mmol), dichlorodi-tert-butyl-(4-dimethylaminophenyl)phosphine palladium(II) (50 mg, 0.07 mmol), water (10 mL), and 1,4-dioxane (50 mL). The reaction mixture was stirred and heated at 110°C under a nitrogen atmosphere for 3 hours. After completion of the reaction, the mixture was quenched with water (30 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-3 / 1) and concentrated in vacuo to remove the solvent to obtain a colorless transparent liquid (205 mg, yield 69.6%).

[0645] LCMS:ESI-MS[M+H] + :419.1.

[0646] Step S4: Synthesis of 3-(3,5-bis(trifluoromethyl)phenyl)-4-fluoro-1H-pyrazole

[0647] 3-(3,5-bis(trifluoromethyl)phenyl)-4-fluoro-1-(4-methoxybenzyl)-1H-pyrazole (200 mg, 0.478 mmol) was added to a 25 mL round-bottom flask at room temperature, followed by trifluoroacetic acid (5 mL). The reaction was stirred at 80°C for 2 hours. After the reaction, the solvent was evaporated, and the pH was adjusted to 8 by adding saturated sodium bicarbonate solution. The reaction mixture was extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified on a silica gel preparative plate (eluent: petroleum ether / ethyl acetate = 1 / 1) and the solvent was removed in vacuo to afford a white solid (100 mg, 70.2% yield).

[0648] LCMS:ESI-MS[M+H] + :299.1.

[0649] Step S5: Synthesis of methyl (E)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-4-fluoro-1H-pyrazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0650] At 0°C, 3-(3,5-bis(trifluoromethyl)phenyl)-4-fluoro-1H-pyrazole (100 mg, 0.33 mmol), triethylenediamine (74 mg, 0.66 mmol), and DMF (2 mL) were added sequentially to a 100 mL three-necked flask. The mixture was stirred at 0°C under a nitrogen atmosphere for 30 minutes, and then (E)-methyl 3-chloro-2-(pyrimidin-5-yl)acrylate (79.2 mg, 0.396 mmol) was added to the system at 0°C. The reaction mixture was stirred at 80°C under a nitrogen atmosphere for 12 hours. After the reaction was completed, water (15 mL) was added to the reaction system to quench the reaction mixture. The mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by separation on a preparative silica gel plate (eluent: petroleum ether / ethyl acetate = 1:1) and concentrated in vacuo to remove the solvent to give a white solid (115 mg, yield 75.7%).

[0651] LCMS:ESI-MS[M+H] + :461.1.

[0652] Step S6: Synthesis of (E)-3-(3,5-bis(trifluoromethyl)phenyl)-4-fluoro-1H-pyrazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[0653] Methyl (E)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-4-fluoro-1H-pyrazol-1-yl)-2-(pyrimidin-5-yl)acrylate (113 mg, 0.24 mmol) and tetrahydrofuran (6 mL) were added sequentially at room temperature to a 25 mL round-bottom flask. A solution of lithium hydroxide monohydrate (30.77 mg, 0.73 mmol) in water (2 mL) was then added dropwise at 0°C. The reaction mixture was stirred at 0°C for 30 minutes under a nitrogen atmosphere. After completion of the reaction, the solvent was evaporated, and 1N aqueous hydrochloric acid was added to adjust the pH to 4. The mixture was then extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was slurried with ethyl acetate / petroleum ether (1 / 10) and filtered to obtain a white solid (80 mg, 74.7% yield).

[0654] LCMS:ESI-MS[M+H] + :447.1.

[0655] 1H NMR (400MHz, DMSO) δ13.31 (s, 1H), 9.13 (s, 1H), 8.74 (s, 2H), 8.60 (d, J = 4.4Hz, 1H), 8.43 (s, 1H), 8.16 (s, 1H), 7.80 (s, 2H).

[0656] Step S7: Synthesis of (E)-3-(3,5-bis(trifluoromethyl)phenyl)-4-fluoro-1H-pyrazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0657] To a 50 mL three-necked flask at 0°C under a nitrogen atmosphere, (E)-3-(3,5-bis(trifluoromethyl)phenyl)-4-fluoro-1H-pyrazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (40 mg, 0.089 mmol) and tetrahydrofuran (10 mL) were added sequentially. N-methylmorpholine (18.05 mg, 0.178 mmol) and isobutyl carboxychloride (24.36 mg, 0.178 mmol) were then added. The reaction mixture was stirred at 0°C under a nitrogen atmosphere for half an hour. Ammonia in tetrahydrofuran (1.3 mL, 0.535 mmol, 0.4 mol / L) was then added dropwise, and the reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, water (20 mL) was added to quench the reaction mixture, which was then extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was purified by separation on a preparative silica gel plate (eluent: ethyl acetate), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (16) (26 mg, yield 65.6%).

[0658] LCMS: ESI-MS [M+H] + :446.1.

[0659] HPLC: Purity: 100.0% (214nm), 99.21% (254nm)

[0660] 1H NMR (400MHz, DMSO) δ9.16 (s, 1H), 8.69 (s, 2H), 8.50 (d, J = 4.4Hz, 1H), 8.18 (s, 1H), 8.14 (s, 1H), 7.79 (s, 2H), 7.54 (s, 1H), 7.29 (s, 1H).

[0661] Example 17

[0662] Compound 17: (E)-3-(3-(2-hydroxypropan-2-yl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0663]

[0664] Synthesis of compound 17

[0665]

[0666] Step S1: Synthesis of 3-bromo-N-methoxy-N-methyl-5-(trifluoromethyl)benzamide

[0667] To a 250 mL round-bottom flask, 3-bromo-5-(trifluoromethyl)benzoic acid (5 g, 18.5 mmol), N,-dimethylhydroxylamine (1.7 g, 27.7 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uracil (8.44 g, 22.1 mmol), triethylamine (7.49 g, 74 mmol), and dichloromethane (120 mL) were added sequentially. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours, during which time the solution changed from a turbid light yellow to a transparent orange color. After the reaction, water (60 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (100 mL x 3). The organic phases were combined, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-10 / 1) and concentrated in vacuo to remove the solvent to obtain a colorless transparent liquid (5 g, yield 87.2%).

[0668] LCMS:ESI-MS[M+H] + :311.9.

[0669] Step S2: Synthesis of 1-(3-bromo-5-(trifluoromethyl)phenyl)ethan-1-one

[0670] 3-Bromo-N-methoxy-N-methyl-5-(trifluoromethyl)benzamide (5.0 g, 16 mmol) and tetrahydrofuran (100 mL) were added to a 250 mL three-necked flask at 0°C. Methylmagnesium bromide (10.7 mL, 32 mmol) was added dropwise under a nitrogen atmosphere. The reaction was allowed to warm to room temperature and stirred for 2 hours. After completion of the reaction, the mixture was quenched with water (50 mL) and then extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0 to 20 / 1) and the solvent was removed in vacuo to obtain a light yellow liquid (3.6 g, 84.5% yield).

[0671] 1H NMR (400MHz, DMSO) δ8.39(s,1H),8.28(s,1H),8.19(s,1H),2.67(s,3H).

[0672] Step S3: Synthesis of 1-(3-bromo-5-(trifluoromethyl)phenyl)ethan-1-one

[0673] At 0°C, 1-(3-bromo-5-(trifluoromethyl)phenyl)ethan-1-one (1.5 g, 5.59 mmol) and tetrahydrofuran (30 mL) were added to a 100 mL three-necked flask. Methylmagnesium bromide (28 mL, 28 mmol, 1 mol / L) was added dropwise under a nitrogen atmosphere. The reaction was allowed to warm to room temperature and stirred for 5 hours. After completion, the reaction was quenched with water (40 mL) and then extracted with ethyl acetate (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0 to 10 / 1) and the solvent was removed in vacuo to obtain a white solid (0.6 g, 98% purity, 36.99% yield).

[0674] LCMS:ESI-MS(M-OH):265.0.

[0675] 1H NMR (400MHz, DMSO) δ7.98 (d, J = 20.7Hz, 1H), 7.77 (dd, J = 26.6, 5.8Hz, 2H), 5.37 (d, J = 36.4Hz, 1H), 1.41 (d, J = 30.6Hz, 6H).

[0676] Step S4: Synthesis of 2-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0677] In a 100 mL round-bottom flask, 1-(3-bromo-5-(trifluoromethyl)phenyl)ethane-1-one (600 mg, 2.11 mmol), bis(pinacolato)diboron (1.07 g, 4.22 mmol), potassium acetate (829 mg, 8.44 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (309 mg, 0.422 mmol), and 1,4-dioxane (20 mL) were added in sequence. The reaction was stirred at 80 ° C. under a nitrogen atmosphere for 16 hours. After the reaction was completed, the solvent was removed by rotary evaporation, water (20 mL) was added, and then extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 7 / 1) and concentrated in vacuo to remove the solvent to obtain a white solid (500 mg, yield 75.8%).

[0678] LCMS:ESI-MS (M-OH): 313.2.

[0679] Step S5: Synthesis of 2-(3-(trifluoromethyl)-5-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazol-3-yl)phenyl)propan-2-ol

[0680] To a 100 mL round-bottom flask were added 2-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (500 mg, 1.51 mmol), 3-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole (843 mg, 3.03 mmol), potassium carbonate (626 mg, 4.53 mmol), tetrakistriphenylphosphine palladium (174 mg, 0.15 mmol), water (4 mL), and ethylene glycol dimethyl ether (20 mL). The reaction mixture was stirred and heated at 90°C under a nitrogen atmosphere for 18 hours. After completion of the reaction, the mixture was quenched with water, extracted with ethyl acetate (50 mL x 3), and washed with saturated brine (30 mL x 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) and concentrated in vacuo to remove the solvent to obtain a white solid (500 mg, yield 82.5%).

[0681] LCMS:ESI-MS[M+H] + :402.2.

[0682] Step S6: Synthesis of 2-(3-(1H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)phenyl)propan-2-ol

[0683] In a 50 mL round-bottom flask, 2-(3-(trifluoromethyl)-5-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazol-3-yl)phenyl)propan-2-ol (300 mg, 0.75 mmol) was dissolved in dichloromethane (10 mL). Trifluoroacetic acid (3 mL) was then added, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction, the solvent was evaporated, and the pH was adjusted to 8 by adding saturated sodium bicarbonate aqueous solution. The reaction mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified on a silica gel preparative plate (eluent: petroleum ether / ethyl acetate = 1 / 1) and the solvent was removed in vacuo to afford a white solid (120 mg, 59.2% yield).

[0684] LCMS:ESI-MS[M+H] + :272.1.

[0685] Step S7: Synthesis of methyl (E)-3-(3-(2-hydroxypropane-2-yl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0686] To a 50 mL three-necked flask at 0°C, 2-(3-(1H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)phenyl)propan-2-ol (100 mg, 0.368 mmol), triethylenediamine (82.7 mg, 0.737 mmol), and DMF (5 mL) were added sequentially. The reaction solution was stirred under a nitrogen atmosphere for 30 minutes, and then (E)-methyl 3-chloro-2-(pyrimidin-5-yl)acrylate (73.23 mg, 0.368 mmol) was added to the reaction system. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. After the reaction, water (30 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative plate (eluent: petroleum ether / ethyl acetate = 1:1) and concentrated in vacuo to remove the solvent to give a white solid (50 mg, yield 31.3%).

[0687] LCMS:ESI-MS[M+H] + :434.2.

[0688] Step S8: Synthesis of (E)-3-(3-(2-hydroxypropane-2-yl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[0689] Methyl (E)-3-(3-(2-hydroxypropan-2-yl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (50 mg, 0.115 mmol) and tetrahydrofuran (3 mL) were added sequentially. A solution of lithium hydroxide (14 mg, 0.346 mmol) in water (3 mL) was then added dropwise at room temperature. The reaction mixture was stirred at 0°C for 1 hour under a nitrogen atmosphere. After the reaction, the solvent was evaporated, and the pH was adjusted to 4 with 1N aqueous hydrochloric acid. The mixture was then extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified on a preparative plate (eluent: dichloromethane / methanol = 10:1) and the solvent was removed in vacuo to afford a white solid (35 mg, 72.6% yield).

[0690] LCMS:ESI-MS[M+H] + :402.1.

[0691] Step S9: Synthesis of (E)-3-(3-(2-hydroxypropane-2-yl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0692] To a 50 mL three-necked flask at 0°C, (E)-3-(3-(2-hydroxypropan-2-yl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (35 mg, 0.087 mmol) and tetrahydrofuran (5 mL) were added sequentially, followed by N-methylmorpholine (17.6 mg, 0.174 mmol) and isobutyl carbochloride (24 mg, 0.174 mmol). The reaction mixture was stirred at 0°C for half an hour under a nitrogen atmosphere. A solution of ammonia in tetrahydrofuran (1.05 mL, 0.522 mmol, 0.5 M) was then added dropwise, and the reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, water (20 mL) was added to quench the reaction mixture, which was then extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was purified by preparative plate (eluent: ethyl acetate) and concentrated in vacuo to remove the solvent to give a white solid (17) (8 mg, 22.0% yield).

[0693] LCMS: ESI-MS [M+H] + :419.0.

[0694] HPLC: Purity: 98.70% (214nm), 98.65% (254nm)

[0695] 1H NMR(400MHz,DMSO)δ9.20(s,1H),9.06(s,1H),8.71(s,2H),8.40(s,1H),7.88(d, J=19.5Hz,2H),7.70(s,1H),7.60(s,1H),7.37(s,1H),5.38(s,1H),1.45(s,6H).

[0696] Example 18

[0697] Compound 18: (E)-3-(3-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0698]

[0699] Synthesis of compound 18

[0700]

[0701] Step S1: Synthesis of 1-chloro-3-cyclopropyl-5-(trifluoromethyl)benzene

[0702] To a 50 mL round-bottom flask, cyclopropylboranediol (200 mg, 2.31 mmol), 1,3-dichloro-5-(trifluoromethyl)benzene (500 mg, 2.31 mmol), potassium phosphate (1719 mg, 8.1 mmol), palladium acetate (26 mg, 0.115 mmol), tricyclohexylphosphine (65 mg, 0.23 mmol), toluene (20 mL), and water (1 mL) were added sequentially. The reaction mixture was stirred at 100°C under a nitrogen atmosphere for 3 hours. After completion of the reaction, the solvent was removed by rotary evaporation, water (30 mL) was added, and the mixture was extracted with diethyl ether (30 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to yield a yellow oil (500 mg), which was used directly in the next step.

[0703] Step S2: Synthesis of 2-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

[0704]

[0705] To a 100 mL round-bottom flask, tris(dibenzylideneacetone)dipalladium (103 mg, 0.112 mmol), tricyclohexylphosphine (63 mg, 0.225 mmol), and 1,4-dioxane (20 mL) were added sequentially and stirred at room temperature under a nitrogen atmosphere for 30 minutes. Then, 1-chloro-3-cyclopropyl-5-(trifluoromethyl)benzene (500 mg, crude), bis(pinacolato)diboron (687 mg, 2.7 mmol), and potassium acetate (443 mg, 4.51 mmol) were added at room temperature. The reaction mixture was stirred at 80°C under a nitrogen atmosphere for 20 hours. After completion of the reaction, the solvent was removed by rotary evaporation, water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a yellow oil (600 mg) that was used directly in the next step.

[0706] LCMS:ESI-MS[M+H] + :313.2.

[0707] Step S3: Synthesis of 3-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole

[0708] To a 100 mL round-bottom flask were added 2-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (600 mg), 3-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole (1.07 g, 3.83 mmol), potassium carbonate (794 mg, 5.74 mmol), tetrakistriphenylphosphine palladium (110 mg, 0.09 mmol), water (4 mL), and ethylene glycol dimethyl ether (20 mL). The reaction mixture was heated and stirred at 90°C under a nitrogen atmosphere for 18 hours. After completion of the reaction, the mixture was quenched with water (30 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine (30 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) and concentrated in vacuo to remove the solvent to give a yellow oil (300 mg, purity 98%, three-step yield 34%).

[0709] LCMS:ESI-MS[M+H] + :384.1.

[0710] Step S4: Synthesis of 3-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazole

[0711] In a 50 mL round-bottom flask, 3-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole (250 mg, 0.65 mmol) was dissolved in dichloromethane (10 mL). Trifluoroacetic acid (3 mL) was then added, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction, the solvent was evaporated, and the pH was adjusted to 8 by adding saturated aqueous sodium bicarbonate. The reaction mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified on a silica gel preparative plate (eluent: petroleum ether / ethyl acetate = 1 / 1) and the solvent was removed in vacuo to afford a white solid (100 mg, 60.5% yield).

[0712] LCMS:ESI-MS[M+H] + :254.1.

[0713] Step S5: Synthesis of methyl (E)-3-(3-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0714] To a 50 mL three-necked flask at 0°C, 3-[3-cyclopropyl-5-(trifluoromethyl)phenyl]-1H-1,2,4-triazole (98 mg, 0.39 mmol), triethylenediamine (86.82 mg, 0.77 mmol), and DMF (5 mL) were added sequentially. The mixture was stirred under a nitrogen atmosphere for 30 minutes, followed by the addition of (E)-methyl 3-chloro-2-(pyrimidin-5-yl)acrylate (92.23 mg, 0.46 mmol). The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. After completion of the reaction, water (20 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (40 mL x 3). The organic phases were combined, washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified on a preparative plate (eluent: petroleum ether / ethyl acetate = 1:1) and the solvent was removed in vacuo to afford a white solid (60 mg, 37.3% yield).

[0715] LCMS:ESI-MS[M+H] + :416.1.

[0716] Step S6: Synthesis of (E)-3-(3-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[0717] Methyl (E)-3-(3-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (60 mg, 0.14 mmol) and tetrahydrofuran (3 mL) were added sequentially to a 25 mL round-bottom flask. A solution of lithium hydroxide (10 mg, 0.43 mmol) in water (3 mL) was then added dropwise at room temperature. The reaction mixture was stirred at 0°C for 1 hour under a nitrogen atmosphere. After the reaction was completed, the solvent was dried, and a 1N aqueous hydrochloric acid solution was added to adjust the pH to 4. The mixture was then extracted with dichloromethane / methanol = 10 / 1 (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was slurried with dichloromethane, washed, and filtered to obtain a white solid (50 mg, 86.6% yield).

[0718] LCMS:ESI-MS[M+H] + :402.1.

[0719] Step S7: Synthesis of (E)-3-(3-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0720] To a 50 mL three-necked flask at 0°C, (E)-3-(3-(3-cyclopropyl-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (45 mg, 0.112 mmol) and tetrahydrofuran (5 mL) were added sequentially, followed by N-methylmorpholine (22.69 mg, 0.224 mmol) and isobutyl carboxyl chloride (30.62 mg, 0.224 mmol). The reaction mixture was stirred at 0°C for half an hour under a nitrogen atmosphere. Ammonia in tetrahydrofuran (1.3 mL, 0.672 mmol, 0.5 mol / L) was then added dropwise, and the reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, water (20 mL) was added to the reaction mixture to quench the reaction, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative plate (eluent: ethyl acetate) and concentrated in vacuo to remove the solvent to give a white solid (18) (30 mg, 66.9% yield).

[0721] LCMS: ESI-MS [M+H] + :401.1.

[0722] HPLC: Purity: 100.0% (214nm), 99.68% (254nm).

[0723] 1H NMR(400MHz,DMSO)δ9.22(s,1H),9.05(s,1H),8.71(s,2H),8.39(s,1H),7.61(d,J=9.2Hz,2H), 7.56(s,1H),7.41(s,1H),7.36(s,1H),2.12-2.06(m,1H),1.11-1.06(m,2H),0.77–0.65(m,2H).

[0724] Example 19

[0725] Compound 19: (E)-3-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0726]

[0727] Synthesis of compound 19

[0728]

[0729] Step S1: Synthesis of 1-bromo-3-(tert-butyl)-5-(trifluoromethyl)benzene

[0730] In a 100 mL three-necked flask, titanium tetrachloride (1.14 g, 6.0 mmol) was added to 15 mL of dichloromethane under a nitrogen atmosphere at -30°C, followed by the dropwise addition of dimethylzinc (6 mL, 6.0 mmol, 1 M tetrahydrofuran solution). The reaction solution was stirred at -30°C for half an hour, followed by the dropwise addition of 1-(3-bromo-5-(trifluoromethyl)phenyl)ethan-1-one (0.8 g, 3.0 mmol). The reaction mixture was allowed to warm to room temperature and stirred for 1 hour, followed by stirring at 40°C for 16 hours, during which time the solution turned from colorless to black. After completion of the reaction, the mixture was quenched with water (20 mL) and extracted with dichloromethane (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product (200 mg).

[0731] Step S2: Synthesis of 2-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxolane

[0732] In a 50 mL round-bottom flask, 1-bromo-3-(tert-butyl)-5-(trifluoromethyl)benzene (100 mg, 0.36 mmol), pinacol borate (117 mg, 0.72 mmol), potassium acetate (106 mg, 1.08 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (26 mg, 0.036 mmol) were dissolved in anhydrous 1,4-dioxane (6 mL) at room temperature. The reaction mixture was heated and stirred at 100°C under a nitrogen atmosphere for 16 hours. After the reaction, the reaction system was cooled to room temperature, quenched by the addition of water (20 mL), and extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield a crude brown oil (200 mg), which was used directly in the next step without purification.

[0733] Step S3: Synthesis of 3-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-1-(2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole

[0734] In a 50 mL round-bottom flask, 2-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxolane (200 mg, 0.61), 3-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole (339 mg, 1.22 mmol), potassium carbonate (252.5 mg, 1.83 mmol), and tetrakistriphenylphosphine palladium (70.2 mg, 0.061 mmol) were dissolved in water (2 mL) and ethylene glycol dimethyl ether (10 mL). The reaction mixture was heated and stirred at 90°C under a nitrogen atmosphere for 18 hours. After completion of the reaction, the mixture was quenched with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) and concentrated in vacuo to remove the solvent to give a white solid (10 mg, three-step yield 1.7%).

[0735] LCMS:ESI-MS[M+H] + :400.1.

[0736] Step S4: Synthesis of 3-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazole

[0737] In a 50 mL round-bottom flask, 3-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-1-(2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole (10 mg, 0.025 mmol) was dissolved in dichloromethane (3 mL). Trifluoroacetic acid (1 mL) was then added, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction, the solvent was evaporated, and the pH was adjusted to 8 by adding saturated aqueous sodium bicarbonate. The reaction mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified on a silica gel preparative plate (eluent: petroleum ether / ethyl acetate = 1 / 1) and the solvent was removed in vacuo to afford a white solid (5 mg, 74.2% yield).

[0738] LCMS:ESI-MS[M+H] + :270.1.

[0739] Step S5: Synthesis of methyl (E)-3-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0740] At 0°C, 3-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazole (5 mg, 0.0186 mmol) and triethylenediamine (4.2 mg, 0.0372 mmol) were dissolved in DMF (1 mL) in a 50 mL three-necked flask. The mixture was stirred at 0°C under a nitrogen atmosphere for 30 minutes. Then, (E)-methyl 3-chloro-2-(pyrimidin-5-yl)acrylate (5 mg, 0.0242 mmol) was added to the system at 0°C. The reaction solution was stirred at room temperature under a nitrogen atmosphere for 2 hours. After the reaction was completed, water (15 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative plate (eluent: petroleum ether / ethyl acetate = 1:1) and concentrated in vacuo to remove the solvent to give a white solid (5 mg, yield 62.5%).

[0741] LCMS:ESI-MS[M+H] + :432.2.

[0742] Step S6: Synthesis of (E)-3-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[0743] In a 25 mL round-bottom flask, methyl (E)-3-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (5 mg, 0.012 mmol) was dissolved in tetrahydrofuran (1 mL). A solution of lithium hydroxide (1.5 mg, 0.036 mmol) in water (1 mL) was then added dropwise at 0°C. The reaction mixture was stirred at 0°C for 1 hour under a nitrogen atmosphere. After completion of the reaction, the solvent was evaporated, and 1N aqueous hydrochloric acid was added to adjust the pH to 4. The mixture was then extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield a crude white solid (5 mg, crude) that was used directly in the next reaction.

[0744] LCMS:ESI-MS[M+H] + :418.1.

[0745] Step S7: Synthesis of (E)-3-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0746] In a 50 mL three-necked flask at 0°C under a nitrogen atmosphere, (E)-3-(3-(tert-butyl)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (5 mg, 0.012 mmol) was dissolved in anhydrous tetrahydrofuran (1 mL). N-methylmorpholine (2.5 mg, 0.024 mmol) and isobutyl carboxyl chloride (3.5 mg, 0.024 mmol) were then added. The reaction mixture was stirred at 0°C under a nitrogen atmosphere for half an hour. Ammonia in tetrahydrofuran (0.1 mL, 0.072 mmol, 0.5 mol / L) was then added dropwise to the reaction mixture, and the reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, water (10 mL) was added to quench the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative plate (eluent: ethyl acetate) and concentrated in vacuo to remove the solvent to obtain a white solid, which was then lyophilized to obtain a white powdery solid (19) (2 mg, two-step yield: 41.5%).

[0747] LCMS: ESI-MS [M+H] + :417.2.

[0748] HPLC: Purity: 80.89% (214nm), 82.16% (254nm)

[0749] 1H NMR(400MHz,DMSO)δ9.20(s,1H),9.08(s,1H),8.73(s,2H),8.41(s,1H),7. 80(s,1H),7.76(s,1H),7.73(s,1H),7.60(s,1H),7.37(s,1H),1.31(s,9H).

[0750] Example 20

[0751] Compound 20: (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0752]

[0753] Synthesis of compound 20

[0754]

[0755] Step S1: Synthesis of 3-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole

[0756] To a 100 mL three-necked flask, 3-bromo-1H-1,2,4-triazole (10 g, 67.6 mmol) and dichloromethane (100 mL) were added sequentially. Under a nitrogen atmosphere at 0°C, triethylamine (13.68 g, 13.5 mmol) and 2-(trimethylsilyl)ethoxymethyl chloride (13.52 g, 81.1 mmol) were added sequentially. The reaction mixture was stirred at room temperature under nitrogen for 16 hours. After the reaction, water (70 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (100 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0 to 2 / 1). The solvent was removed by vacuum concentration to obtain a light yellow liquid (12 g, 64% yield).

[0757] 1H NMR (400MHz, CDCl3) δ8.02(d,J=87.9Hz,1H),5.78–5.25(m,2H),3.65(t,J=8.2Hz,2H),0.93(t,J=8.3Hz,2H),0.19–0.17(m,9H).

[0758] Step S2: Synthesis of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,6-bis(trifluoromethyl)pyridine

[0759] To a 100 mL round-bottom flask, pinacol borate (584 mg, 2.3 mmol), 4,4'-di-tert-butyl-2,2'-bipyridine (6.18 mg, 0.023 mmol), methoxy(cyclooctadiene)iridium dimer (7.63 mg, 0.0115 mmol), and n-hexane (30 mL) were added sequentially. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 10 minutes, during which time the solution turned from colorless to black. 2,6-Bis(trifluoromethyl)pyridine (1.0 g, 4.6 mmol) was then added, and the reaction mixture was stirred at 50°C under a nitrogen atmosphere for 6 hours. After the reaction, the organic solvent was removed by rotary evaporation, and water was added to the reaction mixture, which was extracted with ethyl acetate (50 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-10 / 1) and concentrated in vacuo to remove the solvent to obtain a white solid (580 mg, yield 37%).

[0760] 1H NMR (400MHz, DMSO) δ8.20 (s, 2H), 1.32 (s, 12H).

[0761] Step S3: Synthesis of 2,6-bis(trifluoromethyl)-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazol-3-yl)pyridine

[0762] To a 50 mL round-bottom flask were added 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,6-bis(trifluoromethyl)pyridine (550 mg, 1.6 mmol), 3-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole (447 mg, 1.6 mmol), potassium carbonate (663.7 mg, 4.8 mmol), tetrakistriphenylphosphine palladium (92.6 mg, 0.08 mmol), water (2 mL), and ethylene glycol dimethyl ether (10 mL). The reaction mixture was heated and stirred at 90°C under a nitrogen atmosphere for 18 hours. After completion of the reaction, the mixture was quenched with water (30 mL), extracted with ethyl acetate (20 mL x 3), washed with saturated brine (30 mL x 2), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-10 / 1) and concentrated in vacuo to remove the solvent to obtain a colorless transparent liquid (160 mg, yield 24%).

[0763] Step S4: Synthesis of 4-(1H-1,2,4-triazol-3-yl)-2,6-bis(trifluoromethyl)pyridine

[0764] In a 10 mL sealed tube, 2,6-bis(trifluoromethyl)-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazol-3-yl)pyridine (150 mg, 0.326 mmol) was dissolved in dioxane hydrochloride (6 mL) and the tube was heated to 60°C for 6 hours. After the reaction, the solvent was evaporated, and saturated aqueous sodium bicarbonate was added to adjust the pH to 8. The reaction mixture was extracted with ethyl acetate (20 mL x 3), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified on a silica gel preparative plate (eluent: petroleum ether / ethyl acetate = 1 / 1) and the solvent was removed in vacuo to obtain a white solid (60 mg, 57.44% yield).

[0765] LCMS:ESI-MS[M+H] + :283.0.

[0766] Step S5: Synthesis of methyl (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0767] To a 25 mL round-bottom flask at 0°C, 4-(1H-1,2,4-triazol-3-yl)-2,6-bis(trifluoromethyl)pyridine (60 mg, 0.212 mmol), triethylenediamine (47.6 mg, 0.425 mmol), and DMF (5 mL) were added sequentially. The mixture was stirred at 0°C under a nitrogen atmosphere for 30 minutes. Then, methyl (E)-3-chloro-2-(pyrimidin-5-yl)acrylate (50.3 mg, 0.254 mmol) was added to the reaction system. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. After the reaction, water (20 mL) was added to the reaction system, and the mixture was extracted with ethyl acetate (30 mL x 3). The organic phases were combined, washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative plate (eluent: petroleum ether / ethyl acetate = 1:1) and concentrated in vacuo to remove the solvent to give a white solid (80 mg, yield 84.7%).

[0768] LCMS:ESI-MS[M+H] + :445.1.

[0769] Step S6: Synthesis of (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[0770] Methyl (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (70 mg, 0.157 mmol) and tetrahydrofuran (3 mL) were added sequentially to a 25 mL round-bottom flask. A 3 mL aqueous solution of lithium hydroxide (13 mg, 0.315 mmol) was then added dropwise at room temperature. The reaction mixture was stirred at 0°C for 1 hour under a nitrogen atmosphere. After the reaction, the solvent was evaporated, and 1N aqueous hydrochloric acid was added to adjust the pH to 4. The mixture was then extracted with dichloromethane / methanol (10 / 1) (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified on a preparative plate (eluent: dichloromethane / methanol (10 / 1)) and the solvent was removed in vacuo to afford a white solid (35 mg, 51.6% yield).

[0771] LCMS:ESI-MS[M+H] + :431.1.

[0772] Step S7: Synthesis of (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0773] To a 50 mL three-necked flask at 0°C, (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (50 mg, 0.115 mmol) and tetrahydrofuran (10 mL) were added sequentially, followed by N-methylmorpholine (23.46 mg, 0.231 mmol) and isobutyl carbochloride (31.66 mg, 0.231 mmol). The reaction mixture was stirred at 0°C for half an hour under a nitrogen atmosphere. A solution of ammonia in tetrahydrofuran (1.4 mL, 1.39 mmol, 0.5 mol / L) was then added dropwise, and the reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, water was added to quench the reaction mixture, which was then extracted with ethyl acetate (30 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative plate (eluent: ethyl acetate) and concentrated in vacuo to remove the solvent to give a white solid (25 mg, 50.67% yield).

[0774] LCMS: ESI-MS [M+H] + :430.1.

[0775] HPLC: Purity: 98.32% (214nm), 98.30% (254nm).

[0776] 1H NMR (400MHz, DMSO) δ9.22 (d, J = 7.1Hz, 2H), 8.74 (s, 2H), 8.45 (s, 1H), 8.07 (s, 2H), 7.68 (s, 1H), 7.43 (s, 1H).

[0777] Example 21

[0778] Compound 21: (2E)-3-{3-[2,6-bis(trifluoromethyl)pyridin-4-yl]-1,2,4-triazacyclopentan-1-yl}-1-(3,3-difluoroazetidin-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one

[0779]

[0780] Synthesis of compound 21

[0781]

[0782] Step S1: Synthesis of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,6-bis(trifluoromethyl)pyridine

[0783] At room temperature, 2,6-bis(trifluoromethyl)pyridine (6523 mg, 30.0 mmol), bis(1,5-cyclooctadiene)dimethoxyiridium (50 mg, 0.0751 mmol) and 4,4'-di-tert-butyl-2,2'-bipyridine (40 mg, 0.150 mmol) were dissolved in n-hexane (90 mL) in a 250 mL three-necked flask. The mixture was stirred at 50°C for 10 minutes under a nitrogen atmosphere, and then bis(pinacolato)diboron (3815 mg, 15.0 mmol) was added. Finally, the reaction mixture was stirred at 50°C for 6 hours under a nitrogen atmosphere. After the reaction was completed, the temperature was lowered to room temperature, and the reaction solution was concentrated. A small amount of water was added to the reaction mixture, and then extracted with ethyl acetate (30 mL x 3). The combined organic phase was washed with saturated brine (25 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product as a yellow waxy solid, which was used directly in the next step without purification (9 g, crude product).

[0784] Step S2: Synthesis of 2,6-bis(trifluoromethyl)-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazol-3-yl)pyridine

[0785] At room temperature, in a 250 mL single-necked flask, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,6-bis(trifluoromethyl)pyridine (3.25 g, 9.53 mmol), 3-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole (2.65 g, 9.53 mmol), potassium carbonate (3.94 g, 0.0285 mol) and Pd(PPh3)4 (0.55 g, 0.46 mmol) were dissolved in DME (50 mL) and water (10 mL) in sequence, and the reaction mixture was stirred at 90°C under a nitrogen atmosphere for 18 hours. After the reaction was completed, the temperature was cooled to room temperature, and the reaction solution was concentrated. A small amount of water was added to the reaction mixture, and then extracted with ethyl acetate (50 mL x 3). The combined organic phase was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column (eluent: petroleum ether / ethyl acetate = 100 / 0-10 / 1), and the solvent was removed by vacuum concentration to obtain a light yellow oily liquid product (0.9 g, two-step yield: 23%).

[0786] Step S3: Synthesis of 4-(1H-1,2,4-triazol-3-yl)-2,6-bis(trifluoromethyl)

[0787] 2,6-bis(trifluoromethyl)-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazol-3-yl)pyridine (900 mg, 2.18 mmol) was dissolved in 1,4-dioxane / HCl (30 mL) at room temperature in a 100 mL single-necked flask. The reaction mixture was stirred at 60°C under a nitrogen atmosphere for 6 hours. After completion of the reaction, the reaction solution was cooled to room temperature and concentrated in vacuo to obtain a crude product. The product was then washed with saturated aqueous sodium bicarbonate (50 mL) and extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0 to 1 / 1). The solvent was removed by vacuum concentration to obtain a pale yellow solid (493 mg, 80% yield).

[0788] LCMS:ESI-MS[M+H] + :283.1.

[0789] 1H NMR(400MHz,dmso)δ14.82(s,1H),8.86(s,1H),8.58(s,2H).

[0790] Step S4: Synthesis of methyl (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0791] In a 25 mL single-necked flask at 0°C, 4-(1H-1,2,4-triazol-3-yl)-2,6-bis(trifluoromethyl)pyridine (600 mg, 2.12 mmol) and 1,4-diazabicyclo[2.2.2]octane (475 mg, 4.238 mmol) were dissolved in DMF (10 mL). The reaction mixture was stirred at 0°C under a nitrogen atmosphere for 0.5 hours. Methyl (E)-3-chloro-2-(pyrimidin-5-yl)acrylate (631 mg, 3.18 mmol) was then added, and the reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, water (30 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by column chromatography (eluent: ethyl acetate / petroleum ether = 1:1) and concentrated in vacuo to remove the solvent to give a white solid (500 mg, yield 53%).

[0792] LCMS:ESI-MS[M+H] + :445.1

[0793] Step S5: Synthesis of (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[0794] In a 100 mL round-bottom flask at 0°C, methyl (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (500 mg, 1.12 mmol) and lithium hydroxide monohydrate (118 mg, 2.81 mol) were dissolved in THF (10 mL) and water (3 mL) in sequence. The reaction mixture was stirred at 0°C for 1 hour. After the reaction, 2N HCl solution was added to the mixture to adjust the pH to 3. The mixture was extracted with ethyl acetate (30 mL x 3 mL). The combined organic phases were washed with saturated brine (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was slurried in a mixture of petroleum ether / ethyl acetate (10 / 1, 20 mL), filtered, and the filter cake was dried to obtain a white powder (443 mg, 92% yield).

[0795] LCMS: ESI-MS (M+H)+: 431.1.

[0796] Step S6: Synthesis of (E)-3-(3,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1-(3,3-difluoroazetidine-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one

[0797] To a 50 mL round-bottom flask at room temperature, (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (30 mg, 0.069 mol), 3,3-difluoroazetidine (10 mg, 0.104 mmol), HATU (40 mg, 0.104 mmol), and N,N-diisopropylethylamine (18 mg, 0.139 mmol) were added in sequence in DMF (4 mL). The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. After the reaction, water (20 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative plate separation (eluent: petroleum ether / ethyl acetate = 1:1), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (15 mg, yield 43%).

[0798] LCMS:ESI-MS[M+H]+:506.1

[0799] HPLC: Purity: 100% (214nm), 98.01% (254nm)

[0800] 1H NMR (400MHz, DMSO) δ9.23(s,1H),9.15(s,1H),8.85(s,2H),8.32(s,1H),8.09(s,2H),4.59(s,4H).

[0801] Example 22

[0802] Compound 22: (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1-(3-hydroxyazetidin-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one

[0803]

[0804] Synthesis of compound 22

[0805]

[0806] Step S1: At room temperature, to a solution of (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (30 mg, 0.07 mmol) in N,N-dimethylformamide (1 mL) were added N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (39 mg, 0.10 mmol) and 3-hydroxyazetidine hydrochloride (11 mg, 0.10 mmol). After nitrogen replacement, N,N-diisopropylethylamine (18 mg, 0.14 mmol) was added, and the reaction solution was stirred at room temperature under nitrogen for 1 hour. After completion of the reaction, the reaction solution was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated to give a crude product. The crude product was purified by silica gel TLC thin plate preparation (developing solvent: dichloromethane / methanol = 20 / 1), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (13.11 mg, yield: 19%).

[0807] LCMS:ESI-MS[M+H]+:486.1.

[0808] HPLC: 99.12% (214nm), 98.18% (254nm).

[0809] 1H NMR(400MHz,DMSO)δ9.23(s,1H),9.18(s,1H),8.83(s,2H),8.22(s,1H),8.10(s,2 H),5.76(d,J=5.9Hz,1H),4.49–4.42(m,1H),4.25–4.21(m,2H),3.82–3.72(m,2H).

[0810] 19F NMR (376MHz, DMSO) δ-67.12 (s, 6F).

[0811] Example 23

[0812] Compound 23: (E)-1-(3-aminoazetidin-1-yl)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one

[0813]

[0814] Synthesis of compound 23

[0815]

[0816] Step S1: Synthesis of tert-butyl (E)-(1-(3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloyl)azetidin-3-yl)carbamate

[0817] At room temperature, in a 25 mL round-bottom flask, (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (40 mg, 0.093 mmol), tert-butyl azetidin-3-ylcarbamate (19.22 mg, 0.111 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uracil (53 mg, 0.139 mmol), N,N-diisopropylethylamine (36 mg, 0.279 mmol) and DMF (2 mL) were added sequentially and stirred at room temperature under nitrogen atmosphere for 2 hours. After the reaction was completed, water (10 mL) was added to the reaction system to quench the reaction mixture. The mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative silica gel separation (eluent: ethyl acetate) and concentrated in vacuo to remove the solvent to obtain a white solid (30 mg, 55.1% yield).

[0818] LCMS:ESI-MS[M+H] + :585.1

[0819] Step S2: Synthesis of (E)-1-(3-aminoazetidin-1-yl)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one

[0820] To a 25 mL round-bottom flask at room temperature, tert-butyl (E)-(1-(3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloyl)azetidin-3-yl)carbamate (25 mg, 0.042 mmol) and dichloromethane (2 mL) were added sequentially, followed by the addition of trifluoroacetic acid (0.4 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the solvent was evaporated, and the pH was adjusted to 8 by adding saturated aqueous sodium bicarbonate. The mixture was then extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative silica gel separation (eluent: dichloromethane / methanol = 10 / 1), concentrated in vacuo to remove the solvent, and lyophilized to obtain a white solid (12 mg, 58.9% yield).

[0821] LCMS: ESI-MS [M+H] + :485.1.

[0822] HPLC: Purity: 98.7% (214nm), 98.91% (254nm)

[0823] 1H NMR (400MHz, DMSO) δ9.24(s,1H),9.19(s,1H),8.83(s,2H),8.21(s,1H),8.10(s,2H),4.14(s,2H),3.69-3.63(m,3H).

[0824] Example 24

[0825] Compound 24: (E)-1-(3-(aminomethyl)azetidin-1-yl)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one

[0826]

[0827] Synthesis of compound 24:

[0828]

[0829] Step S1: Synthesis of tert-butyl (E)-(1-(3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloyl)azetidin-3-yl)methylcarbamate:

[0830] (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (60 mg, 0.14 mmol), tert-butyl(azetidin-3-ylmethyl)carbamate hydrochloride (46.57 mg, 0.21 mmol), HATU (79.51 mg, 0.21 mmol), and DIPEA (36.03 mg, 0.28 mmol) were added all at once to a round-bottom flask containing 5 ml of DMF at room temperature, and the reaction solution was stirred at room temperature for 2 hours. After the reaction, the reaction solution was quenched with 10 ml of water and extracted with EA (15 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain a pale yellow oily crude product. The crude product was purified by preparative plate (developing solvent EA:PE = 3:1) and concentrated in vacuo to obtain a white solid (35 mg, yield 46%).

[0831] LCMS:ESI-MS[M+H] + :543.1

[0832] Step S2: Synthesis of (E)-1-(3-(aminomethyl)azetidin-1-yl)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one:

[0833] Tert-butyl (E)-(1-(3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloyl)azetidin-3-yl)methylcarbamate (30 mg, 0.05 mmol) was added to 6 mL of a DCM / TFA (3:1, v / v) mixture in a round-bottom flask at room temperature. The reaction was stirred under nitrogen for 1 hour at room temperature. The solvent was removed by rotary evaporation, and the residue was dissolved in 5 mL of dilute NaHCO₃ solution and extracted with ethylene acetate (15 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain a crude white solid. The crude product was purified on a silica gel prep plate (developing solvent: dichloromethane / methanol = 10 / 1), concentrated in vacuo, and lyophilized to obtain a white solid (4.3 mg, 17.25% yield).

[0834] LCMS:ESI-MS[M+H] + :499.1

[0835] HPLC:Purity:90.03%(214nm),91.09%(254nm)

[0836] 1 H NMR(400MHz,DMSO)δ9.24(s,1H),9.19(s,1H),8.83(s,2H),8.25(s,1H),8.10(s,2H),4.04(t ,J=9.0Hz,2H),3.79–3.74(m,2H),3.52(s,2H),2.83(d,J=6.5Hz,2H),0.85(t,J=6.8Hz,1H).

[0837] Example 25

[0838] Compound 25: (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1-(3-methoxyazetidin-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one

[0839]

[0840] Synthesis of compound 25

[0841]

[0842] Step S1: At room temperature, a 50 mL round-bottom flask was added with (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (30 mg, 0.07 mmol), 3-methoxyazetidine hydrochloride (10 mg, 0.084 mmol), N, N, N', N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (39.7 mg, 0.1 mmol), N, N-diisopropylethylamine (26.99 mg, 0.21 mmol) and N, N-dimethylformamide (1.5 mL). The mixture was stirred at 25 ° C for 2 hours under a nitrogen atmosphere. After the reaction was completed, water (10 mL) was added to dilute the reaction solution and extracted with ethyl acetate (10 mL × 3). The organic phases were combined and concentrated to give a crude product, which was purified by preparative HPLC (developing solvent: dichloromethane / methanol = 100 / 5), concentrated in vacuo, and lyophilized to give a white solid powder (10.5 mg, yield: 29%).

[0843] LCMS: ESI-MS [M+H] +:500.1.

[0844] HPLC: Purity: 95.00% (214nm), 95.17% (254nm).

[0845] 1 H NMR(400MHz,DMSO)δ9.23(s,1H),9.16(s,1H),8.83(s,2H),8.24(s,1H),8. 10(s,2H),4.27-4.20(m,2H),3.97-3.82(m,2H),3.30(s,1H),3.21(s,3H).

[0846] 19 F NMR (376MHz, DMSO) δ-67.11 (s, 6F).

[0847] Example 26

[0848] Compound 26: (E)-1-(3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloyl)azetidin-3-carbonitrile

[0849]

[0850] Synthesis of compound 26

[0851]

[0852] Step S1: At room temperature, to a solution of (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (30 mg, 0.07 mmol) in N,N-dimethylformamide (1 mL) was added N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (39 mg, 0.10 mmol) and 3-acetonitrile azetidine hydrochloride (13 mg, 0.11 mmol). After nitrogen replacement, N,N-diisopropylethylamine (18 mg, 0.14 mmol) was added and the reaction solution was stirred at room temperature under nitrogen for 2 hours. After completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by silica gel TLC preparation plate (developing solvent: dichloromethane / methanol = 10 / 1), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (11.85 mg, yield: 34%).

[0853] LCMS:ESI-MS[M+H]+:495.1

[0854] HPLC: Purity: 95.40% (214nm), 92.68% (254nm).

[0855] 1H NMR (400MHz, DMSO) δ9.23(s,1H),9.16(s,1H),8.84(s,2H),8.26(s,1H),8.09(s,2H),4.42–4.23(m,4H),3.84–4.77(m,1H).

[0856] 19F NMR (376MHz, DMSO) δ-67.12 (s, 6F).

[0857] Example 27

[0858] Compound 27: Synthesis of (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1-morpholin-2-(pyrimidin-5-yl)prop-2-en-1-one

[0859]

[0860] Synthesis of compound 27

[0861]

[0862] Step S1: At 0 ° C, in a 50 mL round-bottom flask, (2E)-3-{3-[2,6-bis(trifluoromethyl)pyridin-4-yl]-1,2,4-triazole-1-yl}-2-(pyrimidin-5-yl)prop-2-enoic acid (30 mg, 0.070 mmol), morpholine (6 mg, 0.070 mmol) and HATU (40 mg, 0.105 mmol) and N, N-diisopropylethylamine (18 mg, 0.140 mmol) were dissolved in DMF (1.5 mL). The reaction mixture was stirred at 0 ° C for 1 hour under a nitrogen atmosphere. After the reaction was completed, water (15 mL) was added to the reaction mixture to quench the mixture, and the mixture was extracted with ethyl acetate (15 mL x 3). The combined organic phase was washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was separated and purified by preparative silica gel plate (developing solvent: ethyl acetate) and concentrated in vacuo to remove the solvent and then freeze-dried to obtain a white solid (10 mg, yield 29%).

[0863] LCMS:ESI-MS[M+H] + :500.1

[0864] 1H NMR (400MHz, DMSO) δ9.22(s,1H),9.04(s,1H),8.88(s,2H),8.16(s,2H),7.88(s,1H),3.64(s,8H).

[0865] Example 28

[0866] Compound 28: (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-N-(cyanomethyl)-2-(pyrimidin-5-yl)acrylamide

[0867]

[0868] Synthesis of compound 28

[0869]

[0870] Step S1: At room temperature, (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (40 mg, 0.093 mol), 2-aminoacetonitrile hydrochloride (10 mg, 0.112 mmol), HATU (53 mg, 0.140 mmol) and N,N-diisopropylethylamine (60 mg, 0.465 mmol) were dissolved in DMF (3 mL) in a 50 mL round-bottom flask. The reaction mixture was stirred at room temperature for 1 hour under a nitrogen atmosphere. After the reaction was completed, water (5 mL) was added to the reaction mixture to quench the mixture, which was extracted with ethyl acetate (8 mL x 3). The combined organic phases were washed with saturated brine (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was slurried in dichloromethane and then freeze-dried to give a light yellow solid (20 mg, yield: 46%)

[0871] LCMS:ESI-MS[M+H]+:469.1

[0872] HPLC:Purity:99.14%(214nm),97.44%(254nm)

[0873] 1H NMR (400MHz, DMSO) δ9.29 (s, 2H), 8.80 (s, 2H), 8.58 (s, 1H), 8.49 (t, J = 5.4Hz, 1H), 8.05 (s, 2H), 4.22 (d, J = 5.4Hz, 2H).

[0874] Example 29

[0875] Compound 29: (E)-1-(3-amino-3-methylazetidin-1-yl)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one

[0876]

[0877] Synthesis of compound 29

[0878]

[0879] Step S1: Synthesis of tert-butyl (E)-(1-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloyl)-3-methylazetidin-3-yl)carbamate

[0880] At room temperature, in a 25 mL round-bottom flask, (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (40 mg, 0.093 mmol), tert-butyl(3-methylazetidin-3-yl)carbamate (20.6 mg, 0.111 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uracil (53 mg, 0.139 mmol), N,N-diisopropylethylamine (36 mg, 0.279 mmol) and DMF (2 mL) were added in sequence and stirred at room temperature under nitrogen atmosphere for 2 hours. After the reaction, the reaction system was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative silica gel separation (eluent: ethyl acetate) and concentrated in vacuo to remove the solvent to obtain a white solid (40 mg, 72% yield).

[0881] LCMS:ESI-MS[M+H] + :599.1.

[0882] Step S2: Synthesis of (E)-1-(3-amino-3-methylazetidin-1-yl)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one

[0883] To a 25 mL round-bottom flask at room temperature, tert-butyl (E)-(1-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acryloyl)-3-methylazetidin-3-yl)carbamate (40 mg, 0.066 mmol) and dichloromethane (2 mL) were added sequentially, followed by the addition of trifluoroacetic acid (0.4 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the solvent was evaporated, and the pH was adjusted to 8 by adding saturated aqueous sodium bicarbonate. The mixture was then extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by preparative silica gel separation (eluent: dichloromethane / methanol = 10 / 1), concentrated in vacuo to remove the solvent, and lyophilized to obtain a white solid (15 mg, 45% yield).

[0884] LCMS: ESI-MS [M+H] + :499.1.

[0885] HPLC: Purity: 98.48% (214nm), 98.37% (254nm)

[0886] 1H NMR (400MHz, DMSO) δ9.23(s,1H),9.19(s,1H),8.82(s,2H),8.22(s,1H),8.10(s,2H),3.77-3.56(m,4H),2.25(s,2H),1.29(s,3H).

[0887] Example 30

[0888] Compound 30: (E)-3-(3-(2-(azetidin-1-yl)-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0889]

[0890] Synthesis of compound 30

[0891]

[0892] Step S1: Synthesis of 2-(azetidin-1-yl)-6-(trifluoromethyl)pyridine

[0893] At room temperature, 2-chloro-6-trifluoromethylpyridine (1000 mg, 5.5 mmol), N,N-diisopropylethylamine (2.13 g, 16.5 mmol), azetidine (3.14 g, 55 mmol), and N-methylpyrrolidone (15 mL) were added sequentially to a 50 mL sealed tube. The mixture was stirred at 100°C for 2 hours. After completion of the reaction, the reaction mixture was quenched with water (30 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether) and the solvent was removed in vacuo to afford a pale yellow liquid (1.0 g, 90% yield).

[0894] LCMS:ESI-MS[M+H] + :203.1.

[0895] Step S2: Synthesis of 2-(azetidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxybenzofuran-2-yl)-6-(trifluoromethyl)pyridine

[0896] At room temperature, pinacol borate (2512 mg, 9.89 mmol), 4,4'-di-tert-butyl-2,2'-bipyridine (53 mg, 0.19 mmol), methoxy(cyclooctadiene)iridium dimer (65.57 mg, 0.098 mmol), and n-hexane (50 mL) were added to a 100 mL round-bottom flask. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 10 minutes, during which time the solution turned from colorless to black. 2-(azetidin-1-yl)-6-(trifluoromethyl)pyridine (1000 mg, 4.94 mmol) was then added, and the reaction mixture was stirred at 50°C under a nitrogen atmosphere for 6 hours. After the reaction, the organic solvent was removed by rotary evaporation, and the reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-10 / 1) and concentrated in vacuo to remove the solvent to obtain a white solid (1.4 g, yield 86.4%).

[0897] LCMS:ESI-MS[M+H] + :329.2.

[0898] Step S3: Synthesis of 2-(azacyclodextrin-1-yl)-6-(trifluoromethyl)-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazol-3-yl)pyridine

[0899] To a 150 mL round-bottom flask were added 2-(azetidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxybenzofuran-2-yl)-6-(trifluoromethyl)pyridine (1.4 g, 4.26 mmol), 3-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole (2.55 g, 9.14 mmol), potassium carbonate (1.89 mg, 13.7 mmol), tetrakistriphenylphosphine palladium (528 mg, 0.45 mmol), water (10 mL), and ethylene glycol dimethyl ether (50 mL) in sequence at room temperature. The reaction mixture was stirred and heated at 90°C under a nitrogen atmosphere for 18 hours. After the reaction, the reaction mixture was cooled to room temperature and quenched with water (30 mL). The mixture was then extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0 to 10 / 1). The solvent was removed by vacuum concentration to obtain the product as a colorless, transparent liquid (1.5 g, 88.3% yield).

[0900] LCMS:ESI-MS[M+H] + :400.1.

[0901] Step S4: Synthesis of 2-(nitrogen mustard-1-yl)-4-(1H-1,2,4-triazol-3-yl)-6-(trifluoromethyl)pyridine

[0902] In a 25 mL round-bottom flask at room temperature, 2-(azacyclodextrin-1-yl)-6-(trifluoromethyl)-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazol-3-yl)pyridine (1500 mg, 3.74 mmol) was dissolved in dichloromethane (30 mL). Trifluoroacetic acid (10 mL) was then added, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction, the solvent was evaporated, and the pH was adjusted to 8 by adding saturated aqueous sodium bicarbonate. The reaction mixture was extracted with ethyl acetate (50 mL x 3), and the combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified on silica gel preparative silica gel plates (eluent: petroleum ether / ethyl acetate = 1 / 1). The solvent was removed in vacuo to afford a white solid (700 mg, 69.2% yield).

[0903] LCMS:ESI-MS[M+H] + :270.1.

[0904] 1H NMR (400MHz, DMSO) δ8.78 (s, 1H), 7.48 (d, J = 0.9Hz, 1H), 7.07 (s, 1H), 4.08 (t, J = 7.4Hz, 4H), 2.46–2.29 (m, 2H).

[0905] Step S5: Synthesis of methyl (E)-3-(3-(2-(azetidin-1-yl)-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0906] At 0°C, 2-(nitrogen mustard-1-yl)-4-(1H-1,2,4-triazol-3-yl)-6-(trifluoromethyl)pyridine (100 mg, 0.37 mmol), triethylenediamine (83.3 mg, 0.74 mmol), and DMF (2 mL) were added sequentially to a 100 mL three-necked flask. The mixture was stirred at 0°C under a nitrogen atmosphere for 30 minutes. Then, (E)-methyl 3-chloro-2-(pyrimidin-5-yl)acrylate (118 mg, 0.59 mmol) was added to the system at 0°C. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. After completion of the reaction, water (20 mL) was added to the reaction system to quench the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by separation on a preparative silica gel plate (eluent: petroleum ether / ethyl acetate = 1:1) and concentrated in vacuo to remove the solvent to obtain a white solid (60 mg, yield 37.5%).

[0907] LCMS:ESI-MS[M+H] + :432.1.

[0908] Step S6: Synthesis of (E)-3-(3-(2-(azetidin-1-yl)-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[0909] At room temperature, methyl (E)-3-(3-(2,6-bis(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (60 mg, 0.139 mmol) and tetrahydrofuran (3 mL) were added sequentially to a 25 mL round-bottom flask. The reaction mixture was then cooled to 0°C and a solution of lithium hydroxide (17.5 mg, 0.417 mmol) in water (1 mL) was added dropwise. The reaction mixture was stirred at 0°C for 30 minutes under a nitrogen atmosphere. After completion of the reaction, the solvent was evaporated, and 1N aqueous hydrochloric acid was added to adjust the pH to 4. The mixture was then extracted with ethyl acetate (20 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was slurried with (petroleum ether / ethyl acetate = 10 / 1, 10 mL) and filtered to obtain a white solid (45 mg, yield: 77.6%).

[0910] LCMS:ESI-MS[M+H] + :418.1.

[0911] Step S7: Synthesis of (E)-3-(3-(2-(azetidin-1-yl)-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0912] To a 50 mL three-necked flask at 0°C, (E)-3-(3-(2-(azetidin-1-yl)-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (40 mg, 0.095 mmol) and tetrahydrofuran (5 mL) were added sequentially, followed by N-methylmorpholine (20 mg, 0.19 mmol) and isobutyl carboxychloride (26 mg, 0.19 mmol). The reaction mixture was stirred at 0°C for half an hour under a nitrogen atmosphere. A solution of ammonia in tetrahydrofuran (1.1 mL, 0.574 mmol, 0.5 M tetrahydrofuran solution) was then added dropwise, and the reaction solution was stirred at room temperature for 1 hour. After the reaction, water (15 mL) was added to the reaction mixture to quench the reaction. The mixture was then extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product. The crude product was slurried with ethyl acetate / petroleum ether (1 / 3, 10 mL), filtered, and lyophilized to yield a white solid (22 mg, 55% yield).

[0913] LCMS: ESI-MS [M+H] + :417.1.

[0914] HPLC: Purity: 95.17% (214nm), 92.88% (254nm)

[0915] 1H NMR(400MHz,DMSO)δ9.22(s,1H),9.09(s,1H),8.71(s,2H),8.40(s,1H),7.62(s,1H),7. 38(s,1H),6.97(d,J=0.7Hz,1H),6.67(s,1H),4.03(t,J=7.4Hz,4H),2.44–2.29(m,2H).

[0916] Example 31

[0917] Compound 31: (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0918]

[0919] Synthesis of compound 31

[0920]

[0921] Step S1: Synthesis of ethyl (2E)-2-(hydroxyimino)propionate

[0922] To a solution of ethyl 2-oxopropanoate (1 g, 8.60 mmol) in methanol (10 mL) was added hydroxylamine hydrochloride (2.39 g, 34.45 mmol) and pyridine (2.72 g, 0.0344 mol) at room temperature. After replacing the atmosphere with nitrogen, the reaction mixture was stirred at 60°C for 1 hour. After the reaction was completed, the reaction mixture was cooled to room temperature and concentrated in vacuo to obtain a crude product. The crude product was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with 1N dilute hydrochloric acid (40 mL) and saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain a white solid (1.1 g, crude product). The crude product was used directly in the next step without purification.

[0923] LCMS:ESI-MS[M+H] + :132.1.

[0924] Step S2: Synthesis of ethyl (2E)-2-[(acetoxy)imino]propionate

[0925] To a solution of ethyl (2E)-2-(hydroxyimino)propanoate (1.1 g, 8.39 mmol) in pyridine (10 mL) were added acetic anhydride (1.72 g, 16.78 mmol) and a 4-dimethylaminopyridine solution (20 mg, 1.68 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was diluted with water (50 mL) and washed with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford a crude white solid (1.3 g, crude product) which was used in the next step without purification.

[0926] LCMS:ESI-MS[M+H] + :174.1.

[0927] Step S3: Synthesis of ethyl 4,6-bis(trifluoromethyl)pyridine-2-carboxylate

[0928] To a solution of ethyl (2E)-2-[(acetoxy)imino]propanoate (1.3 g, 7.51 mmol) in toluene (10 mL) at room temperature in a screw-capped tube were added ammonium iodide (1.09 g, 7.51 mmol) and sodium dithionite (1.3 g, 7.51 mmol). After nitrogen replacement, 1,3-difluoromethylmalonyl difluoride (3.13 g, 15.02 mmol) was added, and the reaction mixture was stirred at 130°C for 16 hours. After the reaction was completed, the reaction system was cooled to room temperature, diluted with ethyl acetate (50 mL), filtered through celite, and the filtrate was concentrated in vacuo to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0 to 1 / 1) and concentrated in vacuo to obtain a white solid (500 mg, two-step yield: 21%).

[0929] LCMS:ESI-MS[M+H] + :288.0.

[0930] 1 H NMR (400MHz, DMSO) δ8.63 (s, 1H), 8.55 (s, 1H), 4.45 (d, J = 7.1Hz, 2H), 1.38 (m, 3H).

[0931] Step S4: Synthesis of 4,6-bis(trifluoromethyl)pyridine-2-carboxamide

[0932] To a solution of ethyl 4,6-bis(trifluoromethyl)pyridine-2-carboxylate (500 mg, 1.74 mmol) in methanol (5 mL) was added ammonia-methanol (1.2 mL, 8.71 mmol, 7 N in methanol) in a screw-capped tube at room temperature. The reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was concentrated in vacuo to afford a crude white solid (400 mg), which was used directly in the next reaction.

[0933] LCMS:ESI-MS[M+H] + :259.0.

[0934] Step S5: Synthesis of 4,6-bis(trifluoromethyl)pyridine-2-thioamide

[0935] To a solution of 4,6-bis(trifluoromethyl)pyridine-2-carboxamide (400 mg, 1.55 mmol) in tetrahydrofuran (4 mL) at room temperature was added Lawesson's reagent (376 mg, 0.93 mmol). The reaction mixture was stirred at 60°C under a nitrogen atmosphere for 2 hours. After the reaction was completed, the reaction system was cooled to room temperature, the reaction mixture was diluted with water (30 mL), and extracted with ethyl acetate (30 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-1 / 1) and concentrated in vacuo to obtain a yellow solid (350 mg, two-step yield: 73%).

[0936] LCMS:ESI-MS[M+H] + :275.0.

[0937] Step S6: Synthesis of 2-(1H-1,2,4-triazol-3-yl)-4,6-bis(trifluoromethyl)pyridine

[0938] To a solution of 4,6-bis(trifluoromethyl)pyridine-2-thioamide (300 mg, 1.09 mmol) in dimethylformamide (2 mL) at room temperature was added hydrazine hydrate (48 mg, 1.2 mmol). After nitrogen replacement, the mixture was stirred at room temperature for 1 hour. Formic acid (2 mL) was then added, and the reaction mixture was stirred at 90°C for 2 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, diluted with ice water (20 mL), and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0 to 1 / 1) and concentrated in vacuo to obtain a yellow solid (230 mg, yield: 75%).

[0939] LCMS:ESI-MS[M+H] + :283.0.

[0940] Step S7: Synthesis of (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1,5-dihydro-4H-1,2,4-triazol-4-yl)-2-(pyrimidin-5-yl)acrylate and methyl (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate:

[0941] To a solution of 2-(1H-1,2,4-triazol-3-yl)-4,6-bis(trifluoromethyl)pyridine (194 mg, 0.69 mmol) in N,N-dimethylformamide (3 mL) was added triethylenediamine (154 mg, 1.38 mmol) and methyl (2E)-3-chloro-2-(pyrimidin-5-yl)prop-2-enoate (246 mg, 1.24 mmol) at room temperature. The reaction mixture was stirred at room temperature under nitrogen for 2 hours. After completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were concentrated in vacuo to yield the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-1 / 2) and concentrated in vacuo to give white solid methyl (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (90 mg, yield: 29%) and (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1,5-dihydro-4H-1,2,4-triazol-4-yl)-2-(pyrimidin-5-yl)acrylate (40 mg, yield: 13%), respectively.

[0942] Methyl (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0943] LCMS:ESI-MS[M+H] + :445.1.

[0944] 1H NMR (400MHz, DMSO) δ9.60 (d, J = 0.7Hz, 1H), 9.15 (s, 1H), 8.73 (s, 2H), 8.70 (s, 1H), 8.66 (s, 1H), 8.27 (d, J = 0.7Hz, 1H), 3.81 (s, 3H).

[0945] (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1,5-dihydro-4H-1,2,4-triazol-4-yl)-2-(pyrimidin-5-yl)acrylate

[0946] LCMS:ESI-MS[M+H] + :445.1.

[0947] 1H NMR (400MHz, DMSO) δ9.26(s,1H),9.18(s,1H),8.79(s,2H),8.76(s,1H),8.40(s,1H),3.82(s,3H).

[0948] Step S8: Synthesis of (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid:

[0949] To a solution of methyl (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (90 mg, 0.20 mmol) in tetrahydrofuran (2 mL) and water (1 mL) was added lithium hydroxide monohydrate (17 mg, 0.40 mmol) at 0°C, and the reaction was stirred at 0°C for 1 hour. After the reaction, the reaction mixture was diluted with water (10 mL) and washed with ethyl acetate (10 mL × 2). The pH of the aqueous phase was adjusted to 3-4 with dilute hydrochloric acid (1 mol / L), and then the aqueous phase was extracted with ethyl acetate (10 mL × 2). The combined organic phases were concentrated in vacuo to give a white solid (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (60 mg, crude product), which was used directly in the next reaction.

[0950] ESI-MS[M+H] + :431.1.

[0951] Step S9: Synthesis of (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0952] To a solution of (E)-3-(3-(4,6-bis(trifluoromethyl)pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (40 mg, crude product) in tetrahydrofuran (2 mL) were added N-methylmorpholine (18 mg, 0.18 mmol) and 2-methylpropyl chloroformate (18 mg, 0.14 mmol) at 0°C. The reaction mixture was stirred at 0°C for 0.5 hour. Ammonia in tetrahydrofuran (1.8 mL, 0.9 mmol, 0.5 N solution in tetrahydrofuran) was then added. The reaction mixture was stirred at room temperature for 1.5 hours. After completion of the reaction, the reaction mixture was diluted with ice water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were concentrated in vacuo to yield the crude product. The crude product was separated and purified using a preparative HPLC, concentrated, and lyophilized to obtain a white solid (7.9 mg, two-step yield: 20%).

[0953] LCMS:ESI-MS[M+H] + :430.1

[0954] HPLC: Purity: 100% (214nm), 99.13% (254nm).

[0955] 1H NMR (400MHz, DMSO) δ9.15(d,J=25.3Hz,1H),8.72(s,2H),8.42(d,J=18.5Hz,2H),7.93(s,1H),7.67(s,1H),7.46(s,1H).

[0956] 19F NMR(377MHz,DMSO)δ-63.66(s,3F),-66.67(s,3F).

[0957] Example 32

[0958] Compound 32: (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0959]

[0960] Synthesis of compound 32

[0961]

[0962] Step S1: Synthesis of 2-cyclopropyl-6-(trifluoromethyl)isonicotinonitrile

[0963] To a 50 mL round-bottom flask at room temperature were added 2-chloro-6-(trifluoromethyl)isonicotinonitrile (300 mg, 1.45 mmol), cyclopropylboronic acid (187.14 mg, 2.18 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (117.73 mg, 0.15 mmol), potassium carbonate (401.47 mg, 2.90 mmol), dioxane (3 mL), and water (0.6 mL). The mixture was stirred at 100°C under a nitrogen atmosphere for 3 hours. The reaction mixture was cooled to room temperature, diluted with water (20 mL), and extracted with dichloromethane (20 mL x 3). The organic phases were combined and concentrated to yield a yellow oil (300 mg, crude product), which was used directly in the next reaction without further purification.

[0964] LCMS:ESI-MS[M+H] + :212.1.

[0965] 1H NMR (400MHz, DMSO) δ8.19(s,1H),8.15(s,1H),2.325-2.28(m,1H),1.17-1.12(m,2H),1.03-0.99(m,2H).

[0966] Step S2: Synthesis of 2-cyclopropyl-6-(trifluoromethyl)pyridine-4-thioamino

[0967] At room temperature, 2-cyclopropyl-6-(trifluoromethyl)isonicotinonitrile (300 mg, 1.41 mmol), 70% sodium hydrosulfide (226 mg, 2.83 mmol), magnesium chloride (148.09 mg, 1.56 mmol) and N, N-dimethylformamide (5 mL) were added to a 50 mL round-bottom flask in sequence. The mixture was stirred at 25 ° C for 3 hours under a nitrogen atmosphere. After the reaction was completed, water (20 mL) was added to dilute the reaction solution and extracted with ethyl acetate (20 mL×3). The organic phases were combined and concentrated to obtain a yellow oily liquid (300 mg, crude product) which was used directly in the next reaction without further purification.

[0968] LCMS:ESI-MS[M+H] + :247.1.

[0969] Step S3: Synthesis of 2-cyclopropyl-4-(5-methyl-1H-1,2,4-triazol-3-yl)-6-(trifluoromethyl)pyridine

[0970] At room temperature, 2-cyclopropyl-6-(trifluoromethyl)pyridine-4-thioamino (150 mg, 0.61 mmol), trimethyl orthoacetate (2.5 mL) and hydrazine hydrate (61.64 mg, 1.22 mmol) were added sequentially to a 50 mL round-bottom flask. The mixture was stirred at 25 ° C for 1 hour under a nitrogen atmosphere. Acetic acid (2.5 mL) was then added to the mixture. The mixture was continued to stir at 90 ° C for 1 hour under a nitrogen atmosphere. After the reaction solution was cooled to room temperature, the reaction solution was concentrated. Water (20 mL) was added for dilution and extracted with ethyl acetate (20 mL×3). The organic phases were combined and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column (eluent: petroleum ether / ethyl acetate = 100 / 0-50 / 50) to obtain a light yellow solid (100 mg, three-step yield: 51%).

[0971] LCMS:ESI-MS[M+H] + :269.1.

[0972] 1H NMR (400MHz, DMSO) δ14.12(s,1H),8.09(s,1H),7.99(s,1H),2.45(s,3H),2.38-2.33(m,1H),1.10-1.05(m,2H),1.01-0.97(m,2H).

[0973] Step S4: Synthesis of methyl (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0974] At room temperature, 2-cyclopropyl-4-(5-methyl-1H-1,2,4-triazol-3-yl)-6-(trifluoromethyl)pyridine (50 mg, 0.19 mmol), (E)-methyl 3-chloro-2-(pyrimidin-5-yl)acrylate (40.72 mg, 0.21 mmol), triethylenediamine (41.82 mg, 0.37 mmol) and N,N-dimethylformamide (2 mL) were added to a 50 mL round-bottom flask in sequence. The mixture was stirred at 25° C. for 1 hour under a nitrogen atmosphere. After the reaction was completed, water (15 mL) was added to dilute the reaction solution, and the solution was extracted with ethyl acetate (15 mL×3). The organic phases were combined and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0 to 50 / 50) to obtain a light yellow solid (40 mg, yield: 49%).

[0975] LCMS:ESI-MS[M+H] + :431.1.

[0976] 1H NMR(400MHz,DMSO)δ9.21(s,1H),8.76(s,2H),8.31(s,1H),7.64(s,1H),7.41(s,1H) ,3.82(s,3H),2.73(s,3H),2.31-2.20(m,1H),1.15-1.04(m,2H),0.98-0.86(m,2H).

[0977] Step S5: Synthesis of (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[0978] At room temperature, methyl (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (40 mg, 0.093 mmol) and tetrahydrofuran (2 mL) were added sequentially to a 50 mL round-bottom flask. The mixture was cooled to 0°C and a solution of lithium hydroxide monohydrate (4.45 mg, 0.19 mmol) in water (1 mL) was added dropwise. The mixture was stirred at 0°C for 30 minutes. After the reaction was completed, water (10 mL) was added to dilute the mixture and the mixture was extracted with ethyl acetate (10 mL). 1N HCl was then added to the aqueous phase and the pH was adjusted to 5. The aqueous phase was extracted with ethyl acetate (10 mL×3). The organic phases were combined and concentrated to give a light yellow solid (30 mg, crude product) which was used directly in the next reaction without further purification.

[0979] LCMS:ESI-MS[M+H] + :417.1.

[0980] Step S6: Synthesis of (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0981] To a 50 mL round-bottom flask at room temperature were added (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (30 mg, 0.072 mmol) and tetrahydrofuran (1 mL). The atmosphere was replaced with nitrogen and the mixture was cooled to 0°C. Chloro(2-methylpropoxy)methanone (19.69 mg, 0.14 mmol) and N-methylmorpholine (14.59 mg, 0.14 mmol) were then added to the mixture. The mixture was stirred at 0°C for 30 minutes. Subsequently, a solution of ammonia in tetrahydrofuran (1 mL, 0.43 mmol, 0.5 M) was added to the mixture. The temperature was raised to 25°C and the reaction solution was stirred for another 30 minutes. After the reaction was complete, ice water (10 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined and concentrated to give a crude product. The crude product was slurried with (ethyl acetate / petroleum ether = 30 / 100), filtered, and lyophilized to give a white solid powder (9 mg, two-step yield: 23%).

[0982] LCMS: ESI-MS [M+H] + :416.2.

[0983] HPLC: 92.83% (214nm), 93.92% (254nm).

[0984] 1 H NMR(400MHz,DMSO)δ9.19(s,1H),8.68(s,2H),8.12(s,1H),7.71-7.65(m,2H),7.63(s, 1H),7.41(s,1H),2.70(s,3H),2.28-2.24(m,1H),1.12-1.07(m,2H),0.95-0.91(m,2H).

[0985] Example 33

[0986] Compound 33: (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[0987]

[0988] Synthesis of compound 33

[0989]

[0990] Step S1: Synthesis of 2-cyclopropyl-4-(1H-1,2,4-triazol-3-yl)-6-(trifluoromethyl)pyridine

[0991] At room temperature, 2-cyclopropyl-6-(trifluoromethyl)pyridine-4-thioamino (200 mg, 0.8 mmol) was dissolved in N,N-dimethylformamide (3 mL) in a 20 mL sealed tube. Hydrazine hydrate (60 mg, 1.21 mmol) was then added and stirred at room temperature for 1 hour. Formic acid (3 mL) was then added and the sealed tube was heated to 90°C and stirred for 1 hour. After the reaction, the solvent was evaporated and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-3 / 1) and the solvent was removed in vacuo to obtain a white solid (150 mg, 73.8% yield).

[0992] LCMS:ESI-MS[M+H] + :255.1.

[0993] 1H NMR (400MHz, DMSO) δ14.59(s,1H),8.78(s,1H),8.15(s,1H),8.05(s,1H),2.42–2.31(m,1H),1.1-1.06(m,2H),1.03–0.95(m,2H).

[0994] Step S2: Synthesis of methyl (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate

[0995] To a 50 mL round-bottom flask at 0°C, 2-cyclopropyl-4-(1H-1,2,4-triazol-3-yl)-6-(trifluoromethyl)pyridine (70 mg, 0.275 mmol), triethylenediamine (62 mg, 0.55 mmol), and DMF (2 mL) were added sequentially. The mixture was stirred at 0°C under a nitrogen atmosphere for 30 minutes. Then, methyl (E)-3-chloro-2-(pyrimidin-5-yl)acrylate (76.57 mg, 0.385 mmol) was added to the system at 0°C. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. After the reaction, the reaction system was diluted with water (15 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by separation on a preparative silica gel plate (eluent: petroleum ether / ethyl acetate = 1:1) and concentrated in vacuo to remove the solvent to obtain a white solid (100 mg, yield 87.6%).

[0996] LCMS:ESI-MS[M+H] + :417.1

[0997] 1H NMR (400MHz, DMSO) δ9.24 (d, J = 7.5Hz, 2H), 8.80 (s, 1H), 8.73 (s, 2H), 7.69 (s, 1H), 7.48 (d,J=1.1Hz,1H),3.82(s,3H),2.35–2.20(m,1H),1.16–1.04(m,1H),1.01–0.81(m,1H).

[0998] Step S3: Synthesis of (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[0999] Methyl (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (80 mg, 0.192 mmol) and tetrahydrofuran (3 mL) were added sequentially at room temperature. A solution of lithium hydroxide (24 mg, 0.576 mmol) in water (1 mL) was then added dropwise under an ice bath. The reaction mixture was stirred at 0°C for 30 minutes under a nitrogen atmosphere. After completion of the reaction, the solvent was evaporated, and 1N aqueous hydrochloric acid was added to adjust the pH to 4. The mixture was then extracted with ethyl acetate (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was slurried with petroleum ether / ethyl acetate (10 / 1, 10 mL), filtered, and dried to obtain a white solid (50 mg, yield: 64.8%).

[1000] LCMS:ESI-MS[M+H] + :403.1.

[1001] Step S4: Synthesis of (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[1002] At 0 ° C, to a 50 mL three-necked flask, ((E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (50 mg, 0.124 mmol) and tetrahydrofuran (5 mL) were added in sequence, followed by N-methylmorpholine (26 mg, 0.248 mmol) and isobutyl carboxychloride (34 mg, 0.248 mmol). The reaction mixture was stirred at 0 ° C for half an hour under a nitrogen atmosphere. Then, ammonia in tetrahydrofuran solution (1.1 mL, 0.574 mmol, 0.5 M tetrahydrofuran solution) was added dropwise to the reaction solution. The reaction solution was stirred at room temperature for 1 hour. After the reaction was completed, water (20 mL) was added to the reaction mixture to quench the reaction, and ethyl acetate (30 mL x 3) Extraction, drying of the combined organic phases over anhydrous sodium sulfate, filtration, and concentration gave a crude product, which was slurried with (ethyl acetate / petroleum ether = 1 / 3, 10 mL), filtered, and freeze-dried to give a white solid (20 mg, 40% yield).

[1003] LCMS: ESI-MS [M+H] + :402.1.

[1004] HPLC: Purity: 100.0% (214nm), 100.0% (254nm)

[1005] 1H NMR(400MHz,DMSO)δ9.24(s,1H),9.14(s,1H),8.73(s,2H),8.42(s,1H),7.69(s,1H),7.66 (s,1H),7.49(s,1H),7.41(s,1H),2.34–2.21(m,1H),1.17–1.04(m,2H),1.01–0.83(m,2H).

[1006] Example 34

[1007] Compound 34: (E)-3-(3-(6-cyclopropyl-2-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[1008]

[1009] Synthesis of compound 34

[1010]

[1011] Step S1: Synthesis of 4-chloro-6-cyclopropyl-2-(trifluoromethyl)pyrimidine

[1012] At room temperature, 4,6-dichloro-2-(trifluoromethyl)pyrimidine (2 g, 9.2 mmol), cyclopropylboronic acid (0.79 g, 9.2 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (0.75 mg, 0.92 mmol), potassium phosphate (4.88 g, 23 mmol), and tetrahydrofuran (30 mL) were added to a 100 mL round-bottom flask in sequence. The mixture was stirred at 70°C under a nitrogen atmosphere for 16 hours. The reaction mixture was cooled to room temperature, diluted with water (40 mL), and extracted with dichloromethane (40 mL x 3). The organic phases were combined and concentrated to obtain a crude product. The crude product was purified by silica gel column separation (eluent: petroleum ether / ethyl acetate = 100 / 0-50 / 50) to obtain a yellow oily liquid (1 g, yield: 49%).

[1013] 1H NMR (400MHz, DMSO) δ8.01 (s, 1H), 2.34-2.27 (m, 1H), 1.28-1.23 (m, 2H), 1.14-1.12 (m, 2H).

[1014] Step S2: Synthesis of 6-cyclopropyl-2-(trifluoromethyl)pyrimidine-4-carbonitrile

[1015] At room temperature, 4-chloro-6-cyclopropyl-2-(trifluoromethyl)pyrimidine (1 g, 4.5 mmol), sodium cyanide (0.26 g, 5.3 mmol), triethylenediamine (0.05 g, 0.4 mmol), N,N-dimethylformamide (5 mL) and water (1 mL) were added to a 50 mL round-bottom flask in sequence. The mixture was stirred at 25 ° C for 2 hours under a nitrogen atmosphere. After the reaction was completed, water (30 mL) was added to dilute the mixture and the mixture was extracted with ethyl acetate (30 mL×3). The organic phases were combined and concentrated to obtain a yellow oily liquid (1 g, crude product) which was used directly in the next reaction without further purification.

[1016] LCMS:ESI-MS[M+H] + :214.1.

[1017] Step S3: Synthesis of 6-cyclopropyl-2-(trifluoromethyl)pyrimidine-4-thioamide

[1018] At room temperature, 6-cyclopropyl-2-(trifluoromethyl)pyrimidine-4-carbonitrile (1 g, 4.7 mmol), sodium thiocyanate (0.53 g, 9.4 mmol), magnesium chloride (0.49 g, 5.1 mmol), and N,N-dimethylformamide (5 mL) were added to a 50 mL round-bottom flask in this order. The mixture was stirred at 25°C under a nitrogen atmosphere for 3 hours. After the reaction was complete, the mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic phases were combined and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0 to 50 / 50) and the solvent was removed by vacuum concentration to obtain a yellow solid powder (750 mg, two-step yield: 67%).

[1019] LCMS:ESI-MS[M+H] + :248.1.

[1020] Step S4: Synthesis of 2-cyclopropyl-4-(1H-1,2,4-triazol-3-yl)-6-(trifluoromethyl)pyrimidine

[1021]

[1022] At room temperature, 6-cyclopropyl-2-(trifluoromethyl)pyrimidine-4-thioamide (150 mg, 0.61 mmol), N,N-dimethylformamide (2.5 mL) and hydrazine hydrate (61.4 mg, 1.21 mmol) were added sequentially to a 50 mL round-bottom flask. The mixture was stirred at 25°C for 1 hour under a nitrogen atmosphere. Formic acid (2.5 mL) was then added to the reaction solution. The reaction solution was stirred at 90°C for 1 hour. After the reaction solution was cooled to room temperature, it was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The organic phases were combined and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-50 / 50) and the solvent was removed by vacuum concentration to obtain a light yellow solid (130 mg, yield: 83.6%).

[1023] LCMS:ESI-MS[M+H] + :256.1.

[1024] 1H NMR (400MHz, dmso) δ14.69(s,1H),8.84(s,1H),8.29(s,1H),2.47-2.42(m,2H),1.24-1.20(m,2H),1.18-1.12(m,2H).

[1025] Step S5: Synthesis of methyl (E)-3-(3-(6-cyclopropyl-2-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (34-8) and methyl (Z)-3-(3-(6-cyclopropyl-2-(trifluoromethyl)pyrimidin-4-yl)-4H-1,2,4-triazol-4-yl)-2-(pyrimidin-5-yl)acrylate

[1026] To a 50 mL round-bottom flask at room temperature were added 2-cyclopropyl-4-(1H-1,2,4-triazol-3-yl)-6-(trifluoromethyl)pyrimidine (130 mg, 0.51 mmol), methyl (E)-3-chloro-2-(pyrimidin-5-yl)acrylate (111.29 mg, 0.56 mmol), triethylenediamine (114.28 mg, 1.02 mmol), and N,N-dimethylformamide (3 mL). The mixture was stirred at 25°C under a nitrogen atmosphere for 1 hour. Upon completion of the reaction, the reaction solution was diluted with water (15 mL) and extracted with ethyl acetate (15 mL x 3). The organic phases were combined and concentrated to obtain the crude product. The crude product was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 100 / 0-50 / 50), and the solvent was removed by vacuum concentration to give yellow solid methyl (E)-3-(3-(6-cyclopropyl-2-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (34-8) (90 mg, yield: 42%); yellow oily liquid methyl (Z)-3-(3-(6-cyclopropyl-2-(trifluoromethyl)pyrimidin-4-yl)-4H-1,2,4-triazol-4-yl)-2-(pyrimidin-5-yl)acrylate (40 mg, yield: 19%).

[1027] LCMS:ESI-MS[M+H] + :418.1.

[1028] 1H NMR(400MHz,DMSO)δ9.24(s,1H),9.21(s,1H),8.78(s,2H),8.74(s,1H),7.67 (s,1H),3.82(s,3H),2.33-2.28(m,1H),1.27-1.24(m,2H),1.10-1.06(m,2H).

[1029] Step S6: Synthesis of (E)-3-(3-(6-cyclopropyl-2-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid

[1030] Methyl (E)-3-(3-(6-cyclopropyl-2-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (90 mg, 0.2 mmol) and tetrahydrofuran (3 mL) were added sequentially to a 50 mL round-bottom flask at room temperature. The mixture was cooled to 0°C and a solution of lithium hydroxide (18.09 mg, 0.43 mmol) in water (1.5 mL) was added dropwise. The mixture was stirred at 0°C for 1 hour. After the reaction was completed, water (10 mL) was added to dilute the mixture and the mixture was washed with ethyl acetate (10 mL). The aqueous phase was retained and then 1N HCl was added to the aqueous phase to adjust the pH to 5. The aqueous phase was extracted with ethyl acetate (10 mL x 3). The organic phases were combined and concentrated to give a crude product (75 mg, crude product). The crude product was used directly in the next reaction without further purification.

[1031] LCMS:ESI-MS[M+H] + :404.1.

[1032] Step S7: Synthesis of (E)-3-(3-(6-cyclopropyl-2-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[1033] At room temperature, (E)-3-(3-(6-cyclopropyl-2-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (75 mg, crude product) and tetrahydrofuran (2 mL) were added to a 50 mL round-bottom flask. The atmosphere was replaced with nitrogen, and the mixture was cooled to 0°C. Chloro(2-methylpropoxy)methanone (50.81 mg, 0.37 mmol) and N-methylmorpholine (37.63 mg, 0.37 mmol) were then added to the mixture. The mixture was stirred at 0°C for 30 minutes. Subsequently, a solution of ammonia in tetrahydrofuran (2.8 mL, 1.12 mmol, 0.4 M) was added to the mixture. The temperature was raised to 25°C, and the reaction solution was stirred for another 30 minutes. After the reaction was completed, ice water (10 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (10 mL x 3). The organic phases were combined and concentrated to obtain a crude product, which was slurried with (ethyl acetate / petroleum ether = 30 / 100, 10 mL), filtered, and lyophilized to obtain a white solid powder (25 mg, two-step yield: 31%).

[1034] LCMS: ESI-MS [M+H] + :403.0.

[1035] HPLC: 98.91% (214nm), 98.62% (254nm).

[1036] 1H NMR(400MHz,DMSO)δ9.22(s,1H),9.07(s,1H),8.71(s,2H),8.40(s,1H),7.68(s,1H) ,7.67(s,1H),7.47(s,1H),2.33-2.29(m,1H),1.28-1.24(m,2H),1.10-1.07(m,2H).

[1037] 19 F NMR (376MHz, DMSO) δ-69.42 (s, 3F).

[1038] Example 35

[1039] Compound 35: (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[1040]

[1041] Synthesis of compound 35:

[1042]

[1043] Step S1: Synthesis of 2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-ol:

[1044] In a 100 mL round-bottom flask, ethyl 4,4,4-trifluoro-3-oxobutanoate (3.0 g, 16.2 mmol), cyclopropanecarboxamide hydrochloride (1.95 g, 16.2 mmol), and sodium methoxide (2.63 g, 48.6 mmol) were dissolved in methanol (30 mL) at room temperature. The reaction mixture was stirred at 80°C under a nitrogen atmosphere for 10 hours. After the reaction, the reaction mixture was concentrated to remove the methanol. The crude product was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phases were concentrated to dryness to obtain the crude product, which was then purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to afford a white solid (2.6 g, yield: 78.7%).

[1045] LCMS:ESI-MS[M+H] + :205.1

[1046] Step S2: Synthesis of 4-chloro-2-cyclopropyl-6-(trifluoromethyl)pyrimidine:

[1047] To a 100 mL round-bottom flask at room temperature, 2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-ol (1.8 g, 8.8 mmol), acetonitrile (18 mL), and phosphorus oxychloride (2.7 g, 17.6 mol) were added sequentially. The reaction mixture was stirred at 80°C under a nitrogen atmosphere for 4 hours. After the reaction was completed, the temperature was cooled to room temperature and the reaction mixture was poured into ice water (50 mL). Extraction was performed with ethyl acetate (50 mL x 3). The combined organic phases were concentrated to dryness to obtain a white solid (1.6 g, crude product), which was used in the next step without purification.

[1048] 1H NMR (400MHz, DMSO) δ8.04 (s, 1H), 2.51-2.30 (m, 1H), 1.18-1.09 (m, 2H), 1.09-1.07 (m, 2H).

[1049] Step S3: Synthesis of 2-cyclopropyl-6-(trifluoromethyl)pyrimidine-4-carbonitrile:

[1050] To a 100 mL round-bottom flask at 0°C, 4-chloro-2-cyclopropyl-6-(trifluoromethyl)pyrimidine (2.0 g, 8.9 mmol), sodium cyanide (0.84 g, 17.8 mol), triethylenediamine (0.1 g, 0.89 mmol), and N,N-dimethylformamide (20 mL) were added sequentially. The reaction mixture was stirred at 0°C under a nitrogen atmosphere for 2 hours. After the reaction was completed, the reaction solution was poured into water (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude white solid (1.3 g, crude product), which was used directly in the next step.

[1051] 1H NMR (400MHz, DMSO) δ8.51(s,1H),2.51-2.38(m,1H),1.29-1.25(m,2H),1.21-1.11(m,2H).

[1052] Step S4: Synthesis of 2-cyclopropyl-6-(trifluoromethyl)pyrimidine-4-thioamino:

[1053] To a 100 mL round-bottom flask at room temperature were added 2-cyclopropyl-6-(trifluoromethyl)pyrimidine-4-carbonitrile (2.0 g, 9.3 mmol), sodium hydrosulfide (0.78 g, 13.9 mol), magnesium chloride (1.06 g, 11.1 mmol), and N,N-dimethylformamide (20 mL). The reaction mixture was stirred at room temperature for 2 hours under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was poured into water (30 mL) and extracted with ethyl acetate (40 mL x 3). The combined organic phases were washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1 to 3 / 1) to afford a white solid (2 g, three-step yield: 47.8%).

[1054] LCMS:ESI-MS[M+H] + :248.1

[1055] Step S5: Synthesis of 2-cyclopropyl-4-(1H-1,2,4-triazol-3-yl)-6-(trifluoromethyl)pyrimidine:

[1056] 2-Cyclopropyl-6-(trifluoromethyl)pyrimidine-4-thioamino (900 mg, 3.6 mmol) was dissolved in N,N-dimethylformamide (10 mL) at room temperature, followed by the addition of hydrazine hydrate (272.2 mg, 5.4 mmol) at room temperature. The reaction mixture was stirred at room temperature for one hour, and then formic acid (834.4 mg, 18.1 mmol) was added to the reaction system. The reaction mixture was stirred at 80°C under a nitrogen atmosphere for two hours. After the reaction was completed, the temperature was cooled to room temperature and the reaction mixture was poured into ice water (20 mL). The pH was adjusted to 3 with 1N hydrochloric acid solution, and then extracted with ethyl acetate (30 mL x 2). The organic phases were combined, washed with water (30 mL x 2), washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a pale yellow solid (800 mg, crude product).

[1057] LCMS:ESI-MS[M+H] + :256.1

[1058] Step S6: Synthesis of methyl (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-yl)-4H-1,2,4-triazol-4-yl)-2-(pyrimidin-5-yl)acrylate and methyl (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate:

[1059] To a 100 mL three-necked round-bottom flask, add 2-cyclopropyl-4-(1H-1,2,4-triazol-3-yl)-6-(trifluoromethyl)pyrimidine (200 mg, 0.78 mmol), methyl (E)-3-chloro-2-(pyrimidin-5-yl)acrylate (170.8 mg, 0.86 mmol), triethylenediamine (174.7 mg, 1.56 mmol), and N,N-dimethylformamide (8 mL) in sequence at room temperature. The reaction system was allowed to react at room temperature for 2 hours. After completion of the reaction, water (20 mL) was added to the reaction solution, and extraction was performed with ethyl acetate (30 mL x 3). The combined organic phase was washed with saturated brine (40 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product, which was separated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to give white solid methyl (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-yl)-4H-1,2,4-triazol-4-yl)-2-(pyrimidin-5-yl)acrylate (70 mg, two-step yield 18.6%); methyl (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (180 mg, two-step yield: 48%).

[1060] LCMS:ESI-MS[M+H] + :418.1

[1061] Step S7: Synthesis of (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-yl)-4H-1,2,4-triazol-4-yl)-2-(pyrimidin-5-yl)acrylic acid:

[1062] At room temperature, methyl (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-yl)-4H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylate (70 mg, 0.167 mmol), tetrahydrofuran (4 mL), water (4 mL) and lithium hydroxide monohydrate (20.6 mg, 0.503 mmol) were added to a 50 mL three-necked flask in sequence, and the reaction mixture was reacted at 0° C. for 0.5 hour. After the reaction is completed, hydrochloric acid (1N aqueous solution) is slowly added to the reaction solution to adjust the pH to 2-3, and then extracted with ethyl acetate (20 mL x 3). The combined organic phase is washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product, which is separated and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 50 / 1-10 / 1), and the solvent is removed under vacuum to obtain a white solid (50 mg, yield: 74%).

[1063] LCMS:ESI-MS[M+H] + :404.1

[1064] 1 H NMR (400MHz, DMSO) δ9.12 (s, 1H), 8.98 (s, 1H), 8.58 (s, 2H), 8.21 (d, J = 4.5Hz, 2H), 7.68(s,1H),7.52(s,1H),2.46-2.41(m,1H),1.37-1.30(m,2H),1.29-1.25(m,2H).

[1065] Step S8: Synthesis of (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide:

[1066] To a 25 ml three-necked round-bottom flask at room temperature, (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyrimidin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylic acid (70 mg, 0.17 mmol), N-methylmorpholine (34.3 mg, 0.34 mmol), and tetrahydrofuran (5 mL) were added sequentially. After nitrogen replacement, the reaction system was cooled to 0°C and isobutyl carboxychloride (34.8 mg, 0.25 mmol) was added dropwise. The reaction mixture was stirred at 0°C for 10 min, and then aqueous ammonia (0.1 mL) was added to the mixture. The reaction system was warmed to room temperature and reacted for 1 hour. After completion of the reaction, the reaction solution was quenched with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product, which was separated and purified on a preparative silica gel plate (eluent: dichloromethane / methanol = 10 / 1), concentrated in vacuo to remove the solvent, and then lyophilized to give a white solid (30 mg, yield: 44%).

[1067] LCMS:ESI-MS[M+H]+:403.0

[1068] HPLC:Purity:99.24%(214nm),97.46%(254nm)

[1069] 1H NMR(400MHz,DMSO)δ9.21(s,1H),9.14(s,1H),8.70(s,2H),8.43(s,1H),7.66(s,1H) ,7.62(s,1H),7.42(s,1H),2.35-2.28(m,1H),1.20-1.16(m,2H),1.06-1.02(m,2H).

[1070] Example 36

[1071] Compound 36: (E)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1-(3-hydroxyazetidin-1-yl)-2-(pyrimidin-5-yl)prop-2-en-1-one

[1072]

[1073] Synthesis of compound 36

[1074]

[1075] Step S1: At room temperature, to a solution of (2E)-3-{3-[2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazole-1-yl}-2-(pyrimidin-5-yl)prop-2-enoic acid (50 mg, 0.12 mmol) in N,N-dimethylformamide (2 mL) was added N,N,N′,N′-tetramethyl-O-(7-azabenzotriazole-1-yl)urea hexafluorophosphate (71 mg, 0.19 mmol), N,N-diisopropylethylamine (32 mg, 0.25 mmol), 3-hydroxyazetidine hydrochloride (20 mg, 0.19 mmol), and the reaction mixture was stirred at room temperature for 2 hours. The reaction solution was stirred at room temperature for 2 hours under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product, which was purified using silica gel thin plate (developing solvent: dichloromethane / methanol = 10 / 1), concentrated in vacuo to remove the solvent, and lyophilized to give a white solid (31.1 mg, yield: 57%).

[1076] LCMS:ESI-MS[M+H]+:458.2

[1077] HPLC: Purity: 98.32% (214nm), 99.38% (254nm).

[1078] 1H NMR(400MHz,DMSO)δ9.23(s,1H),9.11(s,1H),8.82(s,2H),8.19(s,1H),7.71(s,1H),7.52(s,1H),5.79–5.73(m,1H ),4.48–4.41(m,1H),4.24–4.20(m,2H),3.93–3.83(m,2H),2.31–2.25(m,1H),1.12–1.08(m,2H),0.96–0.92(m,2H).

[1079] 19F NMR (376MHz, DMSO) δ-67.31 (s, 6F).

[1080] Example 37

[1081] Compound 37: (E)-2-pyrimidin-5-yl-3-(2-tetrahydrofuran-3-yl)oxy)-6-trifluoromethylpyridin-4-yl)-1H-1,2,4-triazol-1-yl)acrylamide

[1082]

[1083] Synthesis of compound 37

[1084]

[1085] Step S1: Synthesis of 2-(tetrahydrofuran-3-yl)oxy-6-trifluoromethylpyridine

[1086] At room temperature, tetrahydrofuran-3-ol (582.37 mg, 6.61 mmol) and tetrahydrofuran (6 mL) were added sequentially to a 50 mL round-bottom flask. Nitrogen was replaced and potassium tert-butoxide (741.71 mg, 6.61 mmol) was added to the mixture at one time. The mixture was stirred at 25 ° C for 20 minutes under a nitrogen atmosphere. 2-chloro-6-trifluoromethylpyridine (300 mg, 1.65 mmol) was subsequently added. The temperature was raised to 50 ° C, and the reaction solution was stirred at 50 ° C for 3 hours. The reaction solution was cooled to room temperature and concentrated. Water (20 mL) was added to dilute and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over sodium sulfate, and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 100 / 0-80 / 20) to give a yellow oily liquid (300 mg, yield: 78%).

[1087] LCMS:ESI-MS[M+H] + :234.1.

[1088] 1H NMR (400MHz, CDCl3) δ7.73-7.69(m,1H),7.26-7.24(m,1H),6.92-6.90(m,1H) ,5.63-5.59(m,1H),4.07-3.87(m,4H),2.34-2.25(m,1H),2.17-2.11(m,1H).

[1089] Step S2: Synthesis of 2-(tetrahydrofuran-3-yl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-trifluoromethylpyridine

[1090] To a 50 mL round-bottom flask at room temperature were added 2-(tetrahydrofuran-3-yl)oxy-6-trifluoromethylpyridine (100 mg, 0.43 mmol), biboronic acid pinacol ester (326.67 mg, 1.29 mmol), methoxy(cyclooctadiene)iridium dimer (28.08 mg, 0.043 mmol), 4,4'-di-tert-butyl-2,2'-bipyridine (22.98 mg, 0.086 mmol), and tetrahydrofuran (2 mL). The mixture was stirred at 80°C under a nitrogen atmosphere for 5 hours. The reaction mixture was cooled to room temperature and concentrated. The mixture was diluted with water (20 mL) and extracted with dichloromethane (20 mL x 3). The organic phases were combined, washed with saturated brine (20 mL), dried over sodium sulfate, and concentrated to yield a yellow oil (100 mg, yield: 65%), which was used directly in the next reaction without further purification.

[1091] LCMS:ESI-MS[M+H] + :360.1.

[1092] Step S3: Synthesis of (E)-3-bromo-1H-1,2,4-triazol-1-yl-2-pyrimidine-5-acrylamide

[1093] At room temperature, (Z)-2-bromo-3-(3-bromo-1H-1,2,4-triazol-1-yl)acrylamide (1 g, 3.4 mmol), pyrimidine-5-boric acid (630 mg, 5.1 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (280 mg, 0.34 mmol), potassium acetate (670 mg, 6.8 mmol), dioxane (15 mL) and water (1.5 mL) were added sequentially to a 100 mL round-bottom flask. The mixture was stirred at 80 ° C for 5 hours under a nitrogen atmosphere. After the reaction solution was cooled to room temperature, the reaction solution was concentrated. Water (20 mL) was added for dilution and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL), dried over sodium sulfate, and concentrated to obtain a crude product. The crude product was separated and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 100 / 0-80 / 20) to give a yellow solid (300 mg, yield: 30%).

[1094] LCMS:ESI-MS[M+H] + :295.1.

[1095] Step S4: Synthesis of (E)-2-pyrimidin-5-yl-3-(2-tetrahydrofuran-3-yl)oxy)-6-trifluoromethylpyridin-4-yl)-1H-1,2,4-triazol-1-yl)acrylamide

[1096] To a 50 mL round-bottom flask at room temperature were added (E)-3-bromo-1H-1,2,4-triazol-1-yl-2-pyrimidine-5-acrylamide (50 mg, 0.17 mmol), 2-(tetrahydrofuran-3-yl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6-trifluoromethylpyridine (91.26 mg, 0.25 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (13.83 mg, 0.017 mmol), potassium carbonate (46.83 mg, 0.34 mmol), dioxane (2 mL), and water (0.2 mL). The mixture was stirred at 90°C under a nitrogen atmosphere for 2 hours. The reaction mixture was cooled to room temperature and concentrated. Dilute with water (20 mL) and extract with dichloromethane (20 mL x 3). The organic phases were combined, washed with saturated brine (20 mL), dried over sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by preparative HPLC (eluent: dichloromethane / methanol = 20 / 1) to obtain a white solid (10 mg, yield: 13%).

[1097] LCMS: ESI-MS [M+H] + :448.1.

[1098] HPLC: 99.29% (214nm), 99.46% (254nm).

[1099] 1 H NMR(400MHz,DMSO)δ9.22(s,1H),9.13(s,1H),8.72(s,2H),8.41(s,1H),7.64(s,1H),7.41(s,1H) ,7.34(s,1H),7.22(s,1H),5.51(s,1H),3.93-3.75(m,4H),2.30-2.23(m,1H),2.06-1.99(m,1H).

[1100] Example 38

[1101] Compound 38: 3-(3-(2-cyclopropyl-6-trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl-1-(3-methoxyazetidin-1-yl)-2-(pyrimidin-5-yl)propyl-2-en-1-one

[1102]

[1103] Synthesis of compound 38

[1104]

[1105] Step S1: At room temperature, to a solution of (2E)-3-{3-[2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazol-1-yl}-2-(pyrimidin-5-yl)prop-2-enoic acid (40 mg, 0.10 mmol) in N,N-dimethylformamide (2 mL), N,N,N′,N′-tetramethyl-O-(7-azabenzotriazole-1-yl)uronium hexafluorophosphate (57 mg, 0.15 mmol), N,N-diisopropylethylamine (26 mg, 0.20 mmol), 3-methoxyazetidine hydrochloride (19 mg, 0.15 mmol) were added, and the reaction mixture was stirred at room temperature for 2 hours under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product. The crude product was purified by silica gel TLC preparation plate (developing solvent: dichloromethane / methanol = 20 / 1), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (22.7 mg, yield: 48%).

[1106] LCMS:ESI-MS[M+H]+:472.2

[1107] HPLC: Purity: 100% (214nm), 99.52% (254nm).

[1108] 1 H NMR (400MHz, DMSO) δ9.23(s,1H),9.10(s,1H),8.82(s,2H),8.21(s,1H),7.71(s,1H),7.52(s,1H),4.32–4. 16(m,3H),3.97(s,1H),3.81(s,1H),3.20(s,3H),2.31–2.25(m,1H),1.12–1.08(m,2H),0.96–0.92(m,2H).

[1109] Example 39

[1110] Compound 39: 3-(3-(2-cyclopropyl-6-trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl-1-(3-methoxyazetidin-1-yl)-2-(pyrimidin-5-yl)propyl-2-en-1-one

[1111]

[1112] Synthesis of compound 39

[1113]

[1114] Step S1: To a solution of (2E)-3-{3-[2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazol-1-yl}-2-(pyrimidin-5-yl)prop-2-enoic acid (40 mg, 0.10 mmol) in N,N-dimethylformamide (2 mL) was added N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (57 mg, 0.15 mmol), N,N-diisopropylethylamine (26 mg, 0.20 mmol), and azetidine-3-carbonitrile hydrochloride (18 mg, 0.15 mmol) at room temperature. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. After the reaction was completed, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel TLC preparation plate (developing solvent: dichloromethane / methanol = 20 / 1), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (31.3 mg, yield: 67%).

[1115] LCMS:ESI-MS[M+H]+:467.2.

[1116] HPLC: Purity: 97.39% (214nm), 97.29% (254nm).

[1117] 1 H NMR(400MHz,DMSO)δ9.23(s,1H),9.09(s,1H),8.83(s,2H),8.23(s,1H),7.71(s,1H),7.52(s,1H ),4.34–4.12(m,4H),3.82–3.85(m,1H),2.31–2.25(m,1H),1.13–1.08(m,2H),0.97–0.91(m,2H).

[1118] Example 40

[1119] Compound 40: Synthesis of (E)-N-(cyanomethyl)-3-(3-(2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide

[1120]

[1121] Synthesis of compound 40

[1122]

[1123] Step S1: In a 50 mL round-bottom flask were added (2E)-3-{3-[2-cyclopropyl-6-(trifluoromethyl)pyridin-4-yl]-1,2,4-triazol-1-yl}-2-(pyrimidin-5-yl)prop-2-enoic acid (40 mg, 0.10 mol), 2-aminoacetonitrile hydrochloride (11 mg, 0.12 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uracil (57 mg, 0.15 mmol), N,N-diisopropylethylamine (64 mg, 0.50 mmol) and DMF (3 mL) in sequence. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. After completion of the reaction, 5 mL of water was added to the reaction mixture to quench the reaction mixture, which was then extracted with ethyl acetate (8 mL x 3). The combined organic phases were washed with saturated brine (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was separated on a preparative plate (developing solvent: ethyl acetate), concentrated in vacuo to remove the solvent, and then lyophilized to obtain a white solid (25 mg, 57% yield).

[1124] LCMS:ESI-MS[M+H] + :441.1

[1125] 1H NMR (400MHz, DMSO) δ9.29 (s, 1H), 9.21 (s, 1H), 8.78 (s, 2H), 8.54 (s, 1H), 8.44 (t, J = 5.4Hz, 1H), 7.68 (s,1H),7.46(s,1H),4.21(d,J=5.4Hz,2H),2.32–2.24(m,1H),1.15–1.04(m,2H),0.97–0.90(m,2H).

[1126] Example 41

[1127] Compound 41: (E)-3-(3-cyclobutyloxy-6-trifluoromethylpyridin-4-yl)-1H-1,2,4-triazol-1-yl-2-pyrimidine-5-acrylamide

[1128]

[1129] Synthesis of compound 41

[1130]

[1131] Step S1: Synthesis of 2-cyclobutoxy-6-trifluoromethylpyridine

[1132] At room temperature, cyclobutanol (477 mg, 6.61 mmol) and tetrahydrofuran (6 mL) were added to a 50 mL round-bottom flask in sequence. The atmosphere was replaced with nitrogen, and potassium tert-butoxide (741.7...

Claims

1. A compound of formula (I) or its stereoisomers, tautomers, deuterated compounds, metabolites, pharmaceutically acceptable salts or prodrugs, wherein, A 1 、A 2 、A 3 Each independently is C or N; Ring B is C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl or heteroaryl composed of 5 to 12 atoms, and the said Ring B is optionally substituted by m Bn; m is 0, 1, 2 or 3; when m is 1, 2 or 3, Bn are the same or different; R 1 、R 2 、R 3 、R 4 、R 5 、Bn are each independently selected from hydrogen, deuterium, F, Cl, Br, I, -NO 2 、=O, N 3 、CN, -OH, -NH 2 、-C(=O)CH 2 CN, -NHC(=O)CH 2 CN, -N(CH 3 )C(=O)CH 2 CN, C 1 -C 12 alkyl, C 1 -C 12 haloalkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 - 12 atoms, C 6 -C 12 aryl, a heteroaryl composed of 5 - 12 atoms, -NR 10a R 10b 、-O-(C 0 -C 4 alkylene)-R 10c 、-O-(C 1 -C 4 alkylene)-OR 10c 、-O-(C 1 -C 4 alkylene)-NR 10a R 10b 、-C(=O)R 10d 、-N(R 10e )C(=O)R 10d 、-C(=O)NR 10a R 10b 、-N(R 10e )C(=O)NR 10a R 10b 、-N(R 10e )C(=O)OR 10a 、-C(=O)N(R 10e )C(=O)R 10d 、-S(=O) 2 R 10f 、-N(R 10e )S(=O) 2 R 10f or -S(=O) 2 NR 10a R 10b ,or R 1 and R 5 and together with the atoms attached thereto or R 1 and R 2 and together with the atoms attached thereto or R 2 and R 3 and together with the atoms attached thereto or R 3 and R 4 and together with the atoms attached thereto or R 4 and Bn and together with the atoms attached thereto or R 5 and Bn and together with the atoms attached thereto, form C 3 -C 12 a cycloalkyl or a heteroalkyl group consisting of 3 to 12 atoms; wherein each of said C 1 -C 12 alkyl, C 1 -C 12 haloalkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 3 -C 12 cycloalkyl, a heterocyclic group consisting of 3 to 12 atoms, C 6 -C 12 aryl, a heteroaryl consisting of 5 to 12 atoms and a heteroalkyl group consisting of 3 to 12 atoms are each independently optionally substituted by 1, 2, 3, 4 or 5 R 11 groups; R 8 is C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl or a heteroaryl group composed of 5 to 12 atoms, wherein each of the C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl, a heteroaryl group composed of 5 to 12 atoms is independently optionally substituted by 1, 2, 3, 4 or 5 R 10 groups; R 9 is -C(=O)NR 10a R 10b 、C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl or a heteroaryl group composed of 5 to 12 atoms, wherein each of the C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl, a heteroaryl group composed of 5 to 12 atoms is independently optionally substituted by 1, 2, 3, 4 or 5 R 10 groups; R 10 selected from hydrogen, deuterium, F, Cl, Br or I; R 10a 、R 10b 、R 10c 、R 10d 、R 10e 、R 10f are each independently H, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 3 -C 12 cycloalkyl, -(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), -(C 0 -C 4 alkylene)-(heterocyclic group composed of 3 to 12 atoms), -(C 0 -C 4 alkylene)-(C 6 -C 12 aryl) or -(C 0 -C 4 alkylene)-(heteroaryl composed of 5 to 12 atoms), or R 10a and R 10b together with the nitrogen atom to which they are attached form a heterocyclic group composed of 3 to 12 atoms, wherein each C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 3 -C 12 cycloalkyl, -(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), -(C 0 -C 4 alkylene)-(heterocyclic group composed of 3 to 12 atoms), -(C 0 -C 4 alkylene)-(C 6 -C 12 aryl), -(C 0 -C 4 (alkylene)-(heteroaryl consisting of 5 to 12 atoms) and the heterocyclic group consisting of 3 to 12 atoms are optionally substituted by 1, 2, 3 or 4 substituents independently selected from F, Cl, Br, CN, N 3 、-NO 2 、-OH、-NH 2 、C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl or C 1 -C 6 and are substituted by the substituents of alkylamino; Each R 11 is independently hydrogen, deuterium, F, Cl, Br, I, CN, -NO 2 , =O, N 3 , -OH, -NH 2 , C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 haloalkyl, C 3 -C 12 cycloalkyl, C 6 -C 12 aryl, a heterocyclic group composed of 3 - 12 atoms, a heteroaryl composed of 5 - 12 atoms, C 1 -C 12 aminoalkyl, C 1 -C 12 alkylamino, C 1 -C 12 alkoxy, C 1 -C 12 hydroxyalkyl, -NH(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), -NH(C 0 -C 4 alkylene)-(C 6 -C 12 aryl), -NH(C 0 -C 4 alkylene)-(a heterocyclic group composed of 3 - 12 atoms), -NH(C 0 -C 4 alkylene)-(a heteroaryl composed of 5 - 12 atoms), -N[(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl)] 2 , -N[(C 0 -C 4 alkylene)-(C 6 -C 12 aryl)] 2 , -N[(C 0 -C 4 alkylene)-(a heterocyclic group composed of 3 - 12 atoms)] 2 , -N[(C 0 -C 4 alkylene)-(a heteroaryl composed of 5 - 12 atoms)] 2 , -O-(C 0 -C 4 -alkylene)-(C 3 -C 12 -cycloalkyl), -O-(C 0 -C 4 -alkylene)-(C 6 -C 12 -aryl), -O-(C 0 -C 4 -alkylene)-(heterocyclic group composed of 3 to 12 atoms) or -O-(C 0 -C 4 -alkylene)-(heteroaryl composed of 5 to 12 atoms); and Provided that when R 9 is -C(=O)NH 2 , Bn is not simultaneously hydrogen or R 1 , R 3 is not simultaneously C 1 -C 12 haloalkyl or A 1 , A 2 , A 3 is not simultaneously C or R 10 and is not hydrogen.

2. The compound or its stereoisomers, tautomers, deuterated compounds, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 1, characterized in that, its structure is as shown in formula (II), Among them, B 1 , B 2 , B 3 , B 4 are each independently C or N, and B 5 is C, N or empty, and when B 5 is C or N, the said B 5 is optionally substituted by R 11 ; n is 1 or 2, and when n is 2, B 2 identical or different; B 2 optionally substituted by R 11 ; R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 are each independently selected from hydrogen, deuterium, F, Cl, Br, I, -NO 2 、=O、N 3 、CN、-OH、-NH 2 、-C(=O)CH 2 CN、-NHC(=O)CH 2 CN、-N(CH 3 )C(=O)CH 2 CN、C 1 -C 12 alkyl, C 1 -C 12 haloalkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 - 12 atoms, C 6 -C 12 aryl, a heteroaryl composed of 5 - 12 atoms, -NR 10a R 10b 、-O-(C 0 -C 4 alkylene)-R 10c 、-O-(C 1 -C 4 alkylene)-OR 10c 、-O-(C 1 -C 4 alkylene)-NR 10a R 10b 、-C(=O)R 10d 、-N(R 10e )C(=O)R 10d 、-C(=O)NR 10a R 10b 、-N(R 10e )C(=O)NR 10a R 10b 、-N(R 10e )C(=O)OR 10a 、-C(=O)N(R 10e )C(=O)R 10d 、-S(=O) 2 R 10f , -N(R 10e )S(=O) 2 R 10f or -S(=O) 2 NR 10a R 10b , or, R 1 and R 5 together with the atoms to which they are attached or R 1 and R 2 together with the atoms to which they are attached or R 2 and R 3 together with the atoms to which they are attached or R 3 and R 4 together with the atoms to which they are attached or R 4 and R 6 together with the atoms to which they are attached or R 5 and optionally B 5 substituent R 11 together with the atoms to which they are attached or R 5 and R 7 together with the atoms to which they are attached, form C 3 -C 12 cycloalkyl or a heteroalkyl group consisting of 3 - 12 atoms, wherein each C 1 -C 12 alkyl, C 1 -C 12 haloalkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 3 -C 12 cycloalkyl, a heterocyclic group consisting of 3 - 12 atoms, C 6 -C 12 aryl, a heteroaryl consisting of 5 - 12 atoms and a heteroalkyl group consisting of 3 - 12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 11 groups.

3. The compound or its stereoisomers, tautomers, deuterated compounds, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 2, characterized in that, its structure is as shown in formula (III), Among them, A is C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl or a heteroaryl group composed of 5 to 12 atoms, wherein each of the C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl, a heteroaryl group composed of 5 to 12 atoms is independently optionally substituted by 1, 2, 3, 4 or 5 R 11 groups.

4. The compound or its stereoisomers, tautomers, deuterated compounds, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 2, characterized in that, its structure is as shown in formula (IV), 5. The compound or its stereoisomers, tautomers, deuterated compounds, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 4, characterized in that, A 1 、A 3 is C; R 1 and R 3 are each independently selected from C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl; R 2 、R 4 、R 5 are H; B 1 and B 2 and B 3 and B 4 are each independently C or N, and B 5 is empty, and n is 1; R 6 and R 7 are each independently selected from hydrogen, deuterium, C 1 -C 6 alkyl, and the C 1 -C 6 alkyl is independently optionally substituted with 1, 2, 3, 4 or 5 R 11 groups, and each R 11 is independently hydrogen, deuterium, F, Cl, Br, I; R 8 a heteroaryl group composed of 5 to 12 atoms, wherein the heteroaryl group composed of 5 to 12 atoms is optionally substituted by 1, 2, 3, 4 or 5 R 10 groups; R 10 selected from hydrogen, deuterium; R 10a 、R 10b are each independently H, or R 10a and R 10b together with the nitrogen atom to which they are attached form a heterocyclic group consisting of 3 to 6 atoms, and the heterocyclic group consisting of 3 to 6 atoms is optionally substituted with 1, 2, 3 or 4 substituents independently selected from F, Cl, Br, -OH 6. The compound or its stereoisomers, tautomers, deuterated compounds, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 4, characterized in that, A 1 、A 2 、A 3 is C; R 1 、R 3 each independently selected from C 1 -C 3 haloalkyl; R 2 、R 4 、R 5 are H; B 1 、B 2 、B 3 、B 4 Each independently is C or N, and B 5 is empty, and n is 1; R 6 、R 7 each independently selected from hydrogen, C 1 -C 3 alkyl; R 8 selected from N-containing heteroaryl groups composed of 5 to 6 atoms; R 10 is hydrogen; R 10a 、R 10b are each independently H, or R 10a and R 10b together with the nitrogen atom to which they are attached form a heterocyclic group composed of 3 to 6 atoms, and the heterocyclic group composed of 3 to 6 atoms is substituted with 1, 2, 3 or 4 -OH substituents.

7. A compound of formula (I) or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs, wherein, A 1 、A 2 、A 3 Each independently is C or N; Ring B is C 3 -C 12 Cycloalkyl, a heterocyclic group composed of 3 - 12 atoms, C 6 -C 12 Aryl or heteroaryl composed of 5 - 12 atoms, and the said Ring B is optionally substituted by m Bn; m is 0, 1, 2 or 3; when m is 1, 2 or 3, Bn are the same or different; R 1 、R 2 、R 3 、R 4 、R 5 、Bn are each independently selected from hydrogen, deuterium, halogen, -NO 2 、=O, N 3 、CN, -OH, -NH 2 、-C(=O)CH 2 CN, -NHC(=O)CH 2 CN, -N(CH 3 )C(=O)CH 2 CN, -C(C 1-3 alkyl) 3 、C 1 -C 12 alkyl, C 1 -C 12 haloalkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 - 12 atoms, C 6 -C 12 aryl, a heteroaryl composed of 5 - 12 atoms, -C(C 1-3 alkyl) 2 -OH, -CH(C 1-3 alkyl)OH, -NR 10a R 10b 、-O-CH(C 1-3 alkyl) 2 、-O-(C 0 -C 4 alkylene)-R 10c 、-O-(C 1 -C 4 alkylene)-OR 10c 、-O-(C 1 -C 4 alkylene)-NR 10a R 10b 、-O-(C 3 -C 12 cycloalkyl), -O-(a heterocyclic group composed of 3 - 12 atoms), -C(=O)R 10d 、-N(R 10e )C(=O)R 10d 、-C(=O)NR 10a R 10b 、-N(R 10e )C(=O)NR 10a R 10b 、-N(R 10e )C(=O)OR 10a 、-C(=O)N(R 10e )C(=O)R 10d 、-S(=O) 2 R 10f 、-N(R 10e )S(=O) 2 R 10f 、-S(=O)(C 1-3 Alkyl)(=N)R 10f or -S(=O) 2 NR 10a R 10b , or, R 1 and R 5 Together with the atoms to which they are attached or R 1 and R 2 Together with the atoms to which they are attached or R 2 and R 3 Together with the atoms to which they are attached or R 3 and R 4 Together with the atoms to which they are attached or R 4 and Bn and the atoms to which they are attached or R 5 Together with Bn and the atoms to which they are attached, they form C 3 -C 12 Cycloalkyl or heterocyclic group composed of 3-12 atoms; wherein each C 1 -C 12 Alkyl, C 1 -C 12 Haloalkyl, C 2 -C 12 Alkenyl, C 2 -C 12 Alkynyl, C 1 -C 12 Alkoxy, C 3 -C 12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 6 -C 12 Aryl, heteroaryl of 5-12 atoms and heterocyclyl of 3-12 atoms are independently optionally substituted by 1, 2, 3, 4 or 5 R 11 substituted by a group; R 8 is an optionally substituted C 3 -C 12 cycloalkyl group, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl group or a heteroaryl group composed of 5 to 12 atoms; wherein each of the C 3 -C 12 cycloalkyl group, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl group, a heteroaryl group composed of 5 to 12 atoms is independently optionally substituted by 1, 2, 3, 4 or 5 R 16 groups; R 9 is hydrogen, -C(=O)NR 10a R 10b , -COR 13 , C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 - 12 atoms, C 6 -C 12 aryl or a heteroaryl composed of 5 - 12 atoms, wherein each of the C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 - 12 atoms, C 6 -C 12 aryl, a heteroaryl composed of 5 - 12 atoms is independently and optionally substituted by 1, 2, 3, 4 or 5 R 17 groups; or R 9 is absent, the group For wherein, X 1 and X 2 are each independently selected from C, N, O or S; R 10 selected from hydrogen, deuterium, F, Cl, Br or I; R 16 、R 17 are each independently selected from hydrogen, deuterium, halogen, =O, -CN, -OH, -NH 2 、-COOH, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3-6 cycloalkyl, -(C 1 -C 4 alkylene)COOH, -(C 1 -C 4 alkylene)N(C 1-3 alkyl) 2 、-(C 1 -C 4 alkylene)NH(C 1-3 alkyl)、-(C 1 -C 4 alkylene)OH、-(C 1 -C 4 alkylene)NH 2 、-CH(C 1 -C 6 alkyl)OH、-(C 1 -C 4 alkylene)OH、-(C 1 -C 4 alkylene)CH(C 1-3 alkyl)OH、-(C 0 -C 4 alkylene)CONH 2 、-(C 0 -C 4 alkylene)CF 3 、-O(C 1-3 alkyl)、-(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)O(C 1 -C 4 alkylene)OH、-(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)O(C 1 -C 4 alkylene)COOH、-(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)OH、-(C 1 -C 4 (Alkylene)CN, -(C 0 -C 4 (Alkylene)CONH(C 0 -C 4 (Alkylene)CN, -(C 0 -C 4 (Alkylene)SO 2 (C 1-3 Alkyl), -SO 2 (C 3 -C 12 (Cycloalkyl), -(C 0 -C 4 (Alkylene)O(C 1-3 (Alkyl), -(C 1 -C 4 (Alkylene)CHOH(C 1 -C 4 (Alkylene)OH, -(C 0 -C 4 (Alkylene)CH(NH 2 )COOH, -(C 0 -C 4 (Alkylene)CH(OH)COOH, -(C 0 -C 4 (Alkylene)-(C 3 -C 12 (Cycloalkyl), -(C 0 -C 4 (Alkylene)-(heterocyclic group composed of 3 - 6 atoms), -(C 0 -C 4 (Alkylene)-(C 6 -C 12 (Aryl) or -(C 0 -C 4 (Alkylene)-(heteroaryl composed of 5 - 12 atoms), wherein the alkylene, alkyl, aryl, cycloalkyl, heteroaryl, heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, -OCH 3 、-OH, -COOH, -NH 2 、-CN, -CH(CH 3 )OH; R 10a 、R 10b 、R 10c 、R 10d 、R 10e 、R 10f are each independently selected from hydrogen, deuterium, halogen, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 3 -C 12 cycloalkyl, -(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), -(C 0 -C 4 alkylene)-(heterocyclic group composed of 3-12 atoms), -(C 0 -C 4 alkylene)-(C 6 -C 12 aryl) or -(C 0 -C 4 alkylene)-(heteroaryl composed of 5-12 atoms), or R 10a and R 10b together with the nitrogen atom to which they are attached form a heterocyclic group composed of 3-12 atoms or a heteroaryl composed of 5-12 atoms, wherein each of the C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 alkoxy, C 3 -C 12 cycloalkyl, -(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), -(C 0 -C 4 alkylene)-(heterocyclic group composed of 3-12 atoms), -(C 0 -C 4 alkylene)-(C 6 -C 12 aryl), -(C 0 -C 4 (Alkylene)-(heteroaryl composed of 5 - 12 atoms) and heterocyclic group composed of 3 - 12 atoms and heteroaryl composed of 5 - 12 atoms are optionally substituted by 1, 2, 3 or 4 substituents independently selected from halogen, =O, -CN, -COOH, (C 1 -C 4 (Alkylene)CN, -N 3 -NO 2 -OH, -NH 2 -(C 1 -C 4 (Alkylene)NH 2 C 1 -C 6 Alkyl, C 1 -C 6 Halogenated alkyl, C 1 -C 6 Alkoxy, hydroxy C 1 -C 6 Alkyl, amino C 1 -C 6 Alkyl or C 1 -C 6 Alkylamino; Each R 11 is independently hydrogen, deuterium, halogen, CN, -NO 2 , =O, N 3 , -OH, -NH 2 , C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 12 haloalkyl, C 3 -C 12 cycloalkyl, C 6 -C 12 aryl, a heterocyclic group composed of 3 - 12 atoms, a heteroaryl group composed of 5 - 12 atoms, C 1 -C 12 aminoalkyl, C 1 -C 12 alkylamino, C 1 -C 12 alkoxy, C 1 -C 12 hydroxyalkyl, -NH(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl), -NH(C 0 -C 4 alkylene)-(C 6 -C 12 aryl), -NH(C 0 -C 4 alkylene)-(a heterocyclic group composed of 3 - 12 atoms), -NH(C 0 -C 4 alkylene)-(a heteroaryl group composed of 5 - 12 atoms), -N[(C 0 -C 4 alkylene)-(C 3 -C 12 cycloalkyl)] 2 , -N[(C 0 -C 4 alkylene)-(C 6 -C 12 aryl)] 2 , -N[(C 0 -C 4 alkylene)-(a heterocyclic group composed of 3 - 12 atoms)] 2 , -N[(C 0 -C 4 alkylene)-(a heteroaryl group composed of 5 - 12 atoms)] 2 , -O-(C 0 -C 4 -alkylene)-(C 3 -C 12 -cycloalkyl), -O-(C 0 -C 4 -alkylene)-(C 6 -C 12 -aryl), -O-(C 0 -C 4 -alkylene)-(heterocyclic group composed of 3 - 12 atoms) or -O-(C 0 -C 4 -alkylene)-(heteroaryl composed of 5 - 12 atoms); R 13 Selected from C 3-6 cycloalkyl, -NH(C 0 -C 4 -alkylene)CN, -NH(C 0 -C 4 -alkylene)CF 3 ; R 14 and R 15 are each independently selected from hydrogen, deuterium, halogen, ═O, -CN, -OH, -NH 2 , -COOH, C 1 -C 6 alkyl, C 3-6 cycloalkyl, -(C 1 -C 4 alkylene)COOH, -(C 1 -C 4 alkylene)N(C 1-3 alkyl) 2 , -(C 1 -C 4 alkylene)NH(C 1-3 alkyl), -(C 1 -C 4 alkylene)NH 2 , -(C 1 -C 4 alkylene)OH, -(C 1 -C 4 alkylene)CH(C 1-3 alkyl)OH, -(C 0 -C 4 alkylene)CONH 2 , -(C 0 -C 4 alkylene)CF 3 , -O(C 1-3 alkyl), -(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)O(C 1 -C 4 alkylene)OH, -(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)O(C 1 -C 4 alkylene)COOH, -(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)OH, -(C 1 -C 4 alkylene)CN, -(C 0 -C 4 alkylene)CONH(C 0 -C 4 alkylene)CN, -(C 0 -C 4 (Alkylene)SO 2 (C 1-3 Alkyl), -SO 2 (C 3 -C 12 (Cycloalkyl), -(C 0 -C 4 (Alkylene)O(C 1-3 (Alkylene), -(C 1 -C 4 (Alkylene)CHOH(C 1 -C 4 (Alkylene) OH, -(C 0 -C 4 (Alkylene)CH(NH 2 ))COOH, -(C 0 -C 4 (Alkylene)CH(OH)COOH, -(C 0 -C 4 (Alkylene)-(C 3 -C 12 (Cycloalkyl), -(C 0 -C 4 (Alkylene)-(heterocyclic group composed of 3 - 6 atoms), -(C 0 -C 4 (Alkylene)-(C 6 -C 12 (Aryl), -(C 0 -C 4 (Alkylene)-(heteroaryl composed of 5 - 12 atoms) or -(C 1 -C 4 (Alkylene)C(=O)-(heterocyclic group composed of 3 - 6 atoms), wherein the alkylene, alkyl, aryl, cycloalkyl, heteroaryl, heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, -OCH 3 , -OH, -COOH, -NH 2 , -CN, -CH(CH 3 )OH; and Provided that when R 9 is -C(=O)NH 2 , Bn is not simultaneously hydrogen or R 1 , R 3 is not simultaneously C 1 -C 12 haloalkyl or A 1 , A 2 , A 3 is not simultaneously C or R 10 is not hydrogen.

8. The compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 7, characterized in that, its structural formula is the compound of formula (V): Among them, B 1 , B 2 , B 3 , B 4 are each independently C or N; Among them, the group selected from one of the following formulas: Among them, ring A is selected from C 3 -C 12 cycloalkyl, heterocyclic group composed of 3 - 12 atoms, C 6 -C 12 aryl or heteroaryl composed of 5 - 12 atoms, wherein each C 3 -C 12 cycloalkyl, heterocyclic group composed of 3 - 12 atoms, C 6 -C 12 aryl or heteroaryl composed of 5 - 12 atoms is independently optionally substituted by 1, 2, 3, 4 or 5 R 16 groups; Ring C is selected from C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl or a heteroaryl group composed of 5 to 12 atoms, wherein each of the C 3 -C 12 cycloalkyl, a heterocyclic group composed of 3 to 12 atoms, C 6 -C 12 aryl or a heteroaryl group composed of 5 to 12 atoms is independently optionally substituted by 1, 2, 3, 4 or 5 R 17 groups; R 7 Selected from hydrogen, deuterium, halogen, C 1 -C 6 -alkyl, -NO 2 , =O, -CN, -OH or -C(=O)NH 2 ; Each R 11 is independently selected from hydrogen, deuterium, F, Cl, Br, I, -CN, -NO 2 , =O, N 3 , -OH, -NH 2 or C 1 -C 6 alkyl; Among them, when R 10a and R 10b are both hydrogen, R 7 is not hydrogen or A 2 is N.

9. The compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 8, characterized in that, Group selected from one of the structures shown below:

10. The compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 9, characterized in that, its structural formula is as shown in the following formula (VI), Wherein, R 1 and R 3 are each independently selected from halogen, -CF 3 , C 3 -C 6 cycloalkyl, a heterocyclic group composed of 3 to 6 atoms or a heteroaryl group composed of 5 to 6 atoms, -C(CH 3 ) 2 OH, -S(=O)(=NH)CH 3 , -S(=O)(=N)CH 3 Cl, -CF 2 CH 3 , -CF(CH 3 ) 2 , -CONH 2 , -C(C 1-3 alkyl) 3 , -O-CH(C 1-3 alkyl) 2 , -O-(C 3 -C 6 cycloalkyl), -O-(a heterocyclic group composed of 3 to 6 atoms); wherein the cycloalkyl, heteroaryl, and heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, =O, -OCH 3 , -OH, -COOH, -NH 2 , -CN, -CH(CH 3 )OH; R 2 、R 4 、R 5 are all hydrogen.

11. The compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 10, characterized in that, A 1 is C; R 1 、R 3 each independently selected from -CF 3 、C 3 -C 6 cycloalkyl; R 4 、R 5 is H; R 7 selected from hydrogen, deuterium, C 1 -C 6 alkyl; R 8 Selected from C 6 -C 12 aryl, heteroaryl composed of 5 - 12 atoms, wherein the C 6 -C 12 aryl, heteroaryl composed of 5 - 12 atoms is independently optionally substituted by 1 or 2 R 16 groups; R 9 is -C(=O)NR 10a R 10b ; R 16 Selected from hydrogen, deuterium, C 1 -C 6 alkoxy, -S(=O) 2 (C 3 -C 12 cycloalkyl); R 10a 、R 10b each independently selected from hydrogen or R 10a and R 10b together with the nitrogen atom to which they are attached form a heterocyclic group consisting of 3 to 12 atoms, wherein the heterocyclic group consisting of 3 to 12 atoms is optionally substituted by 1 or 2 -OH groups.

12. The compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 11, characterized in that, R 7 selected from hydrogen, C 1 -C 3 alkyl; R 8 Selected from C 6 -C 10 aryl, heteroaryl composed of 6-10 atoms, wherein the C 6 -C 10 aryl, heteroaryl composed of 6-10 atoms are each independently optionally substituted by one R 16 group; R 9 selected from -C(=O)NR 10a R 10b ; R 16 Selected from hydrogen, C 1 -C 6 alkoxy, -S(=O) 2 (C 3 -C 6 cycloalkyl); R 10a 、R 10b each independently selected from hydrogen or R 10a and R 10b together with the nitrogen atom to which they are attached form a heterocyclic group composed of 4 to 10 atoms, wherein the heterocyclic group composed of 4 to 10 atoms is optionally substituted by 1 -OH.

13. The compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs according to any one of claims 8 - 10, characterized in that, When A 2 is N, the group Among them, R 14 and R 15 are each independently selected from hydrogen, C 1 -C 3 alkyl, -(C 1 -C 4 alkylene)COOH, -(C 1 -C 4 alkylene)N(C 1-3 alkyl) 2 , -(C 1 -C 4 alkylene)OH, -(C 0 -C 4 alkylene)CONH 2 , -(C 0 -C 4 alkylene)CF 3 , -(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)OH, -(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)O(C 1 -C 4 alkylene)OH, -(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)O(C 1 -C 4 alkylene)COOH, -(C 1 -C 4 alkylene)CN, -(C 1 -C 4 alkylene)CH(C 1-3 alkyl)OH, -(C 0 -C 4 alkylene)SO 2 (C 1-3 alkyl), -(C 0 -C 4 alkylene)O(C 1-3 alkyl), -(C 1 -C 4 alkylene)CHOH(C 1 -C 4 alkylene)OH, -(C 0 -C 4 alkylene)CH(NH 2 )COOH, -CH 2 CONHCH 2 CN 14. The compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 13, characterized in that, its structural formula is as shown in the following formula (VII): Among them, R 1 and R 3 are each independently selected from -CF 3 , C 3 -C 6 cycloalkyl, heterocyclic group composed of 3 - 6 atoms or heteroaryl group composed of 5 - 6 atoms, -C(C 1-3 alkyl) 3 , -O-CH(C 1-3 alkyl) 2 , -O-(C 3 -C 6 cycloalkyl), -O-(heterocyclic group composed of 3 - 6 atoms); wherein the cycloalkyl, heteroaryl, and heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, -OCH 3 , -OH, -COOH, -NH 2 , -CN, -CH(CH 3 )OH.

15. The compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 8, characterized in that, When R 7 is not hydrogen, its structural formula is as shown in the following formula (VIII): Wherein, R 1 and R 3 are each independently selected from -CF 3 , C 3 -C 6 cycloalkyl, a heterocyclic group composed of 3 to 6 atoms or a heteroaryl group composed of 5 to 6 atoms, -C(C 1-3 alkyl) 3 , -O-CH(C 1-3 alkyl) 2 , -O-(C 3 -C 6 cycloalkyl), -O-(a heterocyclic group composed of 3 to 6 atoms); wherein the cycloalkyl, heteroaryl, and heterocyclic group may be further substituted by one or more of the following substituents: hydrogen, deuterium, halogen, -OCH 3 , -OH, -COOH, -NH 2 , -CN, -CH(CH 3 )OH.

16. The compound or its stereoisomers, tautomers, metabolites, pharmaceutically acceptable salts or prodrugs according to claim 8, It is characterized in that group Wherein X 1 and X 2 are both N, R 14 and R 15 each independently selected from hydrogen, C 1 -C 3 alkyl, -(C 1 -C 4 alkylene)COOH, -(C 1 -C 4 alkylene)N(C 1-3 alkyl) 2 、-(C 1 -C 4 alkylene)OH, -(C 0 -C 4 alkylene)CONH 2 、-(C 0 -C 4 alkylene)CF 3 、-(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)OH, -(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)O(C 1 -C 4 alkylene)OH, -(C 0 -C 4 alkylene)O(C 1 -C 4 alkylene)O(C 1 -C 4 alkylene)COOH, -(C 1 -C 4 alkylene)CN, -(C 1 -C 4 alkylene)CH(C 1-3 alkyl)OH, -(C 0 -C 4 alkylene)SO 2 (C 1-3 alkyl)、-(C 0 -C 4 alkylene)O(C 1-3 alkyl)、-(C 1 -C 4 alkylene)CHOH(C 1 -C 4 alkylene)OH, -(C 0 -C 4 alkylene)CH(NH 2 )COOH, -CH 2 CONHCH 2 CN, 17. The compound or its stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug according to claim 7 or 8, It is characterized in that -NR 10a R 10b selected from one of the following formulas: -NH 2 , 18. The compound or its stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug according to any one of claims 7-10, It is characterized in that R 1 、R 3 each independently selected from -CF 3 or C 3 -C 6 cycloalkyl group.

19. The compound or its stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug according to claim 8, It is characterized in that Ring A and ring C are each independently selected from 20. The compound or its stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug according to claim 8, It is characterized in that Group has the structure shown below:

21. A compound or its stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug, It is characterized in that The compound has one of the following structures:

22. The compound or its stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug according to claim 21, It is characterized in that The compound has one of the following structures:

23. A pharmaceutical composition comprising the compound or its stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug according to any one of claims 1-22.

24. The pharmaceutical composition according to claim 23, which further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, solvent or a combination thereof.

25. Use of the compound or its stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug according to any one of claims 1-22, or the pharmaceutical composition according to claim 23 or 24 in the preparation of a drug, wherein The drug is used to prevent, treat or alleviate diseases related to CRM1 disorders in mammals, Optionally, the mammal is a human.

26. The use according to claim 25, wherein The diseases related to CRM1 disorders include proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, polycythemia vera, essential thrombocythemia, myelofibrosis, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic obstructive pulmonary disease, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjogren's syndrome, psoriasis, type II diabetes, gout, post-traumatic stress disorder, respiratory allergic diseases, sinusitis, eczema, measles, food allergy, insect venom allergy, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, organ transplant rejection, tissue transplant rejection, cell transplant rejection, viral infection, ophthalmic disorders, neurodegenerative disorders, abnormal tissue growth disorders or coronavirus disease 2019.

27. The use according to claim 26, wherein The cancer includes at least one of prostate cancer, colon cancer, lymphoma, myeloma, gastric cancer, lung cancer, breast cancer, pancreatic cancer, liver cancer and kidney cancer. Use of a compound according to any one of claims 1-22, or a stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition according to claim 23 or 24, for the manufacture of a medicament, wherein, the medicament is for selectively antagonizing Crm1.

Citation Information

Cited By

  • Synthesis method of 3, 5-dibromo-4-methylpyridine

    CN122608545A